Diseases and Medical Conditions: Causes, Symptoms, Prevention & Treatment
Diseases and Medical Conditions: Causes, Symptoms, Prevention & Treatment
| # | Disease | Cause / Organism | Vector | Transmission | Main symptoms | Prevention | Treatment |
| 1 | Malaria | Plasmodium spp. | Female Anopheles | Mosquito bite | Fever, chills, sweating | Nets, repellents, vector control | Antimalarial drugs |
| 2 | Dengue | Dengue virus | Aedes | Mosquito bite | Fever, headache, muscle/joint pain | Remove standing water, repellents | Supportive care; severe cases need hospital care |
| 3 | Chikungunya | Chikungunya virus | Aedes | Mosquito bite | Fever, severe joint pain | Mosquito control | Supportive care |
| 4 | Zika | Zika virus | Aedes | Mosquito bite; also sexual transmission | Fever, rash, joint pain | Mosquito/sexual precautions | Supportive care |
| 5 | Yellow fever | Yellow fever virus | Mosquitoes | Mosquito bite | Fever, jaundice, headache | Vaccination, mosquito control | Supportive/hospital care |
| 6 | Japanese encephalitis | JE virus | Culex | Mosquito bite | Fever, confusion, seizures | Vaccination, mosquito control | Supportive hospital care |
| 7 | West Nile disease | West Nile virus | Culex | Mosquito bite | Fever; sometimes encephalitis | Mosquito control | Supportive care |
| 8 | Lymphatic filariasis | Filarial worms | Mosquitoes | Mosquito bite | Limb/genital swelling | Mosquito control, mass drug programs | Antifilarial medicines; supportive care |
| 9 | Rift Valley fever | RVF virus | Mosquitoes | Mosquito bite; infected animals | Fever, weakness | Mosquito/vector control | Supportive care |
| 10 | Rabies | Rabies virus | — | Bite/saliva of infected animal | Fever, neurological symptoms | Vaccination, avoid animal bites | Immediate post-exposure treatment; once symptoms appear, usually fatal |
| 11 | Tuberculosis | Mycobacterium tuberculosis | — | Airborne | Cough, fever, weight loss | Vaccination where recommended, ventilation | Combination antibiotics |
| 12 | Cholera | Vibrio cholerae | — | Contaminated food/water | Profuse watery diarrhea | Safe water, sanitation | Rehydration; antibiotics in selected cases |
| 13 | Typhoid fever | Salmonella Typhi | — | Contaminated food/water | Prolonged fever, abdominal symptoms | Safe food/water, vaccination | Antibiotics guided by resistance |
| 14 | Paratyphoid fever | Salmonella Paratyphi | — | Food/water | Fever, abdominal symptoms | Food/water hygiene | Antibiotics |
| 15 | Diphtheria | Corynebacterium diphtheriae | — | Respiratory droplets/contact | Sore throat, membrane, breathing difficulty | Vaccination | Antitoxin + antibiotics |
| 16 | Tetanus | Clostridium tetani | — | Spores entering wounds | Muscle stiffness, spasms | Vaccination, wound care | Antitoxin + antibiotics/supportive care |
| 17 | Pertussis | Bordetella pertussis | — | Respiratory droplets | Severe coughing fits | Vaccination | Antibiotics + supportive care |
| 18 | Pneumococcal disease | Streptococcus pneumoniae | — | Respiratory droplets | Pneumonia, meningitis, ear infection | Vaccination | Antibiotics |
| 19 | Meningococcal disease | Neisseria meningitidis | — | Respiratory secretions | Fever, meningitis, rash | Vaccination | Urgent antibiotics |
| 20 | Leprosy | Mycobacterium leprae | — | Prolonged close contact; respiratory route likely | Skin lesions, numbness, nerve damage | Early diagnosis and treatment | Multidrug therapy |
| 21 | Gonorrhea | Neisseria gonorrhoeae | — | Sexual contact | Discharge, painful urination; may be asymptomatic | Condoms, testing | Antibiotics |
| 22 | Syphilis | Treponema pallidum | — | Sexual/vertical transmission | Sores, rash; later organ damage | Safer sex, testing | Penicillin-based treatment |
| 23 | Chlamydia | Chlamydia trachomatis | — | Sexual contact | Often asymptomatic; discharge/pelvic pain | Condoms, testing | Antibiotics |
| 24 | Lyme disease | Borrelia spp. | Ticks | Tick bite | Rash, fever, joint/nerve problems | Tick avoidance | Antibiotics |
| 25 | Plague | Yersinia pestis | Fleas | Flea bites; infected animals | Fever, swollen lymph nodes | Rodent/flea control | Urgent antibiotics |
| 26 | Scrub typhus | Orientia tsutsugamushi | Chiggers/mites | Mite bite | Fever, headache, rash | Avoid mite exposure | Antibiotics |
| 27 | Typhus | Rickettsia spp. | Lice/fleas/mites depending on type | Arthropod bites | Fever, headache, rash | Hygiene/vector control | Antibiotics |
| 28 | Rocky Mountain spotted fever | Rickettsia rickettsii | Ticks | Tick bite | Fever, headache, rash | Tick avoidance | Doxycycline |
| 29 | Brucellosis | Brucella spp. | — | Unpasteurized dairy/animal contact | Fever, sweating, joint pain | Pasteurization, animal precautions | Combination antibiotics |
| 30 | Anthrax | Bacillus anthracis | — | Animal products/spores | Skin lesion or severe systemic disease | Occupational precautions, vaccination for selected groups | Antibiotics |
| 31 | Botulism | Clostridium botulinum toxin | — | Contaminated food; wounds; infants | Paralysis, difficulty breathing | Safe food preservation | Antitoxin + intensive care |
| 32 | Salmonellosis | Salmonella spp. | — | Contaminated food/water | Diarrhea, fever, cramps | Food safety | Fluids; antibiotics for selected severe cases |
| 33 | Shigellosis | Shigella spp. | — | Fecal-oral | Bloody diarrhea, fever | Handwashing, sanitation | Fluids; antibiotics in selected cases |
| 34 | Campylobacteriosis | Campylobacter spp. | — | Undercooked food/contamination | Diarrhea, fever, cramps | Food hygiene | Fluids; antibiotics in selected cases |
| 35 | Listeriosis | Listeria monocytogenes | — | Contaminated food | Fever; severe disease in pregnancy/newborns | Food safety | Antibiotics |
| 36 | Hepatitis A | HAV | — | Food/water; close contact | Fever, nausea, jaundice | Vaccine, sanitation | Supportive care |
| 37 | Hepatitis B | HBV | — | Blood, sexual, mother-to-child | Liver inflammation; chronic disease possible | Vaccination, safe blood/sex practices | Antiviral treatment for selected chronic cases |
| 38 | Hepatitis C | HCV | — | Blood exposure | Often silent; chronic liver disease | Safe injections/blood | Direct-acting antivirals can cure most infections |
| 39 | Hepatitis E | HEV | — | Mainly contaminated water/food | Hepatitis, jaundice | Safe water/food | Usually supportive care |
| 40 | HIV infection/AIDS | HIV | — | Sexual, blood, mother-to-child | Immune-system damage; opportunistic infections | Prevention, testing, PrEP/PEP where appropriate | Lifelong antiretroviral therapy |
| 41 | COVID-19 | SARS-CoV-2 | — | Respiratory particles | Fever, cough, sore throat; severe respiratory disease possible | Vaccination, ventilation, infection-control measures | Supportive care; antivirals for eligible high-risk patients |
| 42 | Influenza | Influenza viruses | — | Respiratory droplets/aerosols | Fever, cough, body aches | Annual vaccination, hygiene | Supportive care; antivirals for selected patients |
| 43 | Measles | Measles virus | — | Airborne | Fever, cough, rash | MMR vaccination | Supportive care; vitamin A in children where recommended |
| 44 | Mumps | Mumps virus | — | Respiratory droplets | Swollen salivary glands, fever | MMR vaccination | Supportive care |
| 45 | Rubella | Rubella virus | — | Respiratory droplets | Mild fever, rash | MMR vaccination | Supportive care |
| 46 | Chickenpox | Varicella-zoster virus | — | Airborne/contact | Itchy blistering rash, fever | Vaccination | Supportive care; antivirals for selected patients |
| 47 | Shingles | Varicella-zoster virus reactivation | — | Contact with blister fluid can transmit chickenpox | Painful localized rash | Shingles vaccine | Antivirals, pain management |
| 48 | Polio | Poliovirus | — | Fecal-oral | Fever; sometimes paralysis | Polio vaccination, sanitation | Supportive care |
| 49 | Hepatitis D | HDV | — | Blood/body fluids; requires HBV | Hepatitis | Hepatitis B vaccination | Specialist antiviral management |
| 50 | Respiratory syncytial virus disease | RSV | — | Respiratory secretions | Cold-like illness; bronchiolitis | Hygiene; vaccines/prevention for eligible groups | Supportive care |
| 51 | Ebola disease | Ebola virus | — | Body fluids/contact | Fever, vomiting, diarrhea, bleeding | Infection control | Specialized supportive care and approved therapies |
| 52 | Marburg virus disease | Marburg virus | — | Body fluids/contact | Fever, severe systemic illness | Infection control | Supportive care |
| 53 | Lassa fever | Lassa virus | Rodent reservoir | Rodent exposure/body fluids | Fever, weakness; severe disease possible | Rodent control, infection control | Supportive care; selected antiviral use |
| 54 | Mpox | Mpox virus | — | Skin-to-skin/contact, respiratory exposure | Rash, fever, swollen lymph nodes | Vaccination for eligible groups, contact precautions | Supportive care; specific treatment for selected severe cases |
| 55 | Dengue hemorrhagic/severe dengue | Dengue virus | Aedes | Mosquito bite | Bleeding, plasma leakage, shock | Mosquito control | Urgent supportive hospital care |
| 56 | Hand-foot-and-mouth disease | Enteroviruses | — | Respiratory/fecal-oral/contact | Mouth sores, hand/foot rash | Hand hygiene | Supportive care |
| 57 | Rotavirus gastroenteritis | Rotavirus | — | Fecal-oral | Severe diarrhea/vomiting in children | Vaccination, hygiene | Rehydration |
| 58 | Norovirus gastroenteritis | Norovirus | — | Food, water, person-to-person | Vomiting, diarrhea | Hygiene, food safety | Rehydration |
| 59 | Viral gastroenteritis | Various viruses | — | Fecal-oral/contact | Diarrhea, vomiting | Hygiene, safe food/water | Fluids/electrolytes |
| 60 | Infectious mononucleosis | Epstein-Barr virus | — | Saliva | Fever, sore throat, swollen nodes | Avoid sharing saliva | Supportive care |
| 61 | Amoebiasis | Entamoeba histolytica | — | Fecal-oral food/water | Diarrhea, abdominal pain | Safe water/food | Antiprotozoal medicines |
| 62 | Giardiasis | Giardia duodenalis | — | Contaminated water/food | Diarrhea, bloating | Safe water | Antiprotozoal medicines |
| 63 | Cryptosporidiosis | Cryptosporidium | — | Contaminated water/food | Watery diarrhea | Safe water, hygiene | Rehydration; selected therapy |
| 64 | Toxoplasmosis | Toxoplasma gondii | — | Undercooked meat, cat feces, congenital | Often mild; severe fetal/immune disease | Food/cat-litter precautions | Antiparasitic therapy for selected cases |
| 65 | Trichomoniasis | Trichomonas vaginalis | — | Sexual contact | Genital irritation/discharge | Condoms, testing | Metronidazole/tinidazole |
| 66 | Leishmaniasis | Leishmania spp. | Sandflies | Sandfly bite | Skin ulcers or systemic disease | Sandfly/vector control | Antileishmanial drugs |
| 67 | African trypanosomiasis | Trypanosoma brucei | Tsetse fly | Fly bite | Fever, sleep disturbance, neurological disease | Tsetse control | Stage-specific medicines |
| 68 | Chagas disease | Trypanosoma cruzi | Triatomine bug | Bug feces; also food/congenital/transfusion | Fever; later heart/digestive disease | Vector control, safe food/blood | Antiparasitic drugs |
| 69 | Schistosomiasis | Schistosoma spp. | Freshwater snails | Skin contact with contaminated freshwater | Abdominal/urinary symptoms | Safe water, sanitation | Praziquantel |
| 70 | Ascariasis | Ascaris lumbricoides | — | Ingesting eggs from contaminated soil/food | Abdominal symptoms; worms | Sanitation, hygiene | Anthelmintic drugs |
| 71 | Hookworm disease | Ancylostoma/Necator | — | Larvae penetrate skin from soil | Anemia, abdominal symptoms | Footwear, sanitation | Anthelmintic drugs + iron when needed |
| 72 | Enterobiasis | Enterobius vermicularis | — | Ingesting eggs | Night-time anal itching | Hygiene, washing bedding | Anthelmintic treatment |
| 73 | Taeniasis | Taenia spp. | — | Undercooked infected meat | Abdominal symptoms or none | Cook meat thoroughly | Anthelmintic drugs |
| 74 | Cysticercosis | Taenia solium larvae | — | Ingesting eggs | Seizures/neurological disease possible | Sanitation, food hygiene | Antiparasitic + symptom-specific treatment |
| 75 | Strongyloidiasis | Strongyloides stercoralis | — | Larvae penetrate skin | Rash, abdominal symptoms | Footwear/sanitation | Ivermectin |
| 76 | Trichuriasis | Trichuris trichiura | — | Ingesting eggs | Abdominal symptoms, anemia | Sanitation | Anthelmintic drugs |
| 77 | Ringworm | Dermatophyte fungi | — | Skin contact/fomites | Ring-shaped itchy rash | Hygiene, avoid sharing items | Antifungal medicines |
| 78 | Candidiasis | Candida spp. | — | Usually overgrowth of normal flora | Thrush, genital or invasive infection | Risk-factor control | Antifungal medicines |
| 79 | Aspergillosis | Aspergillus spp. | — | Inhalation of spores | Lung disease; invasive disease in high-risk people | Reduce exposure in high-risk settings | Antifungal medicines |
| 80 | Histoplasmosis | Histoplasma spp. | — | Inhalation of spores | Lung disease, sometimes disseminated | Avoid heavy exposure to contaminated soil/bird/bat droppings | Antifungal medicines |
| 81 | Cryptococcosis | Cryptococcus spp. | — | Inhalation of environmental yeast | Pneumonia, meningitis | Mainly risk reduction in immunocompromised people | Antifungal therapy |
| 82 | Scabies | Sarcoptes scabiei mite | — | Prolonged skin contact | Severe itching, burrows | Treat contacts, wash bedding/clothes | Permethrin/other scabicides |
| 83 | Trachoma | Chlamydia trachomatis | — | Contact/flies; poor sanitation | Eye inflammation, scarring | Facial cleanliness, sanitation | Antibiotics; surgery for advanced disease |
| 84 | Conjunctivitis | Viruses/bacteria | — | Contact/respiratory secretions | Red, watery/discharging eye | Hand hygiene | Depends on cause |
| 85 | Scarlet fever | Group A Streptococcus | — | Respiratory droplets/contact | Sore throat, characteristic rash | Hygiene, early diagnosis | Antibiotics |
| 86 | Strep throat | Group A Streptococcus | — | Respiratory droplets | Sore throat, fever | Hygiene | Antibiotics when confirmed |
| 87 | Rheumatic fever | Immune complication of Group A strep | — | Follows untreated strep infection | Fever, joint/heart inflammation | Prompt treatment of strep | Antibiotics + anti-inflammatory/supportive treatment |
| 88 | Acute bacterial meningitis | Several bacteria | — | Respiratory/contact depending on organism | Fever, headache, stiff neck | Vaccination where available | Emergency antibiotics |
| 89 | Pneumonia | Bacteria/viruses/fungi | — | Respiratory exposure or aspiration | Cough, fever, breathing difficulty | Vaccines, hygiene | Depends on cause |
| 90 | Otitis media | Usually bacterial/viral | — | Often follows respiratory infection | Ear pain, fever | Vaccination, smoke avoidance | Observation or antibiotics depending on case |
| 91 | Gastroenteritis | Viruses/bacteria/parasites | — | Food, water, contact | Diarrhea, vomiting | Food/water hygiene | Rehydration; cause-specific treatment |
| 92 | Pelvic inflammatory disease | Usually sexually transmitted bacteria | — | Ascending genital infection | Pelvic pain, discharge, fever | STI prevention/testing | Combination antibiotics |
| 93 | Genital herpes | HSV-1/HSV-2 | — | Skin-to-skin/sexual contact | Painful blisters/ulcers | Condoms, avoid contact during outbreaks | Antiviral medicines |
| 94 | HPV infection | Human papillomavirus | — | Skin-to-skin/sexual contact | Often asymptomatic; warts; some cancers | HPV vaccination, screening | No treatment for virus itself; treat lesions/cancers |
| 95 | Cervical cancer | High-risk HPV infection | — | HPV acquired mainly through sexual contact | Often no early symptoms | HPV vaccine, cervical screening | Surgery/radiotherapy/chemotherapy depending on stage |
| 96 | Viral encephalitis | Several viruses | Sometimes mosquitoes/ticks | Vector bites or other routes | Fever, confusion, seizures | Vaccines/vector control where applicable | Supportive/ICU care; cause-specific therapy |
| 97 | Hantavirus disease | Hantaviruses | Rodents are reservoir | Inhalation/contact with rodent excreta | Fever; severe lung or kidney disease | Rodent control, safe cleaning | Supportive hospital care |
| 98 | Nipah virus infection | Nipah virus | — | Fruit bats/animals; person-to-person | Fever, encephalitis, breathing problems | Avoid exposure to infected animals/secretions | Intensive supportive care |
| 99 | Crimean-Congo hemorrhagic fever | CCHF virus | Ticks | Tick bite/contact with infected blood | Fever, bleeding, severe illness | Tick precautions, infection control | Intensive supportive care |
| 100 | Yellow fever | Yellow fever virus | Mosquitoes | Mosquito bite | Fever, jaundice, severe systemic disease | Vaccination + mosquito control | Supportive hospital care |
| # | Disease | Cause / Organism | Vector | Transmission | Main symptoms | Prevention | Treatment |
| 101 | O’nyong’nyong fever | O’nyong’nyong virus | Anopheles mosquitoes | Mosquito bite | Fever, rash, joint pain | Mosquito control | Supportive care |
| 102 | Oropouche fever | Oropouche virus | Culicoides midges; mosquitoes may contribute | Vector bite | Fever, headache, muscle/joint pain | Vector avoidance | Supportive care |
| 103 | Tick-borne encephalitis | TBE virus | Ticks | Tick bite; rarely unpasteurized dairy | Fever, headache, encephalitis | Tick avoidance, vaccination where recommended | Supportive care |
| 104 | Onchocerciasis | Onchocerca volvulus | Blackflies | Blackfly bite | Itching, skin changes, eye disease | Vector control, mass treatment | Ivermectin |
| 105 | Dracunculiasis | Dracunculus medinensis | — | Drinking water containing infected copepods | Painful emerging worm | Safe drinking water | Slow extraction of worm, wound care |
| 106 | Echinococcosis | Echinococcus spp. | — | Ingesting parasite eggs | Cysts in organs | Dog/food hygiene | Surgery and/or antiparasitic drugs |
| 107 | Foodborne trematodiasis | Liver/lung flukes | Snails involved in life cycle | Raw/undercooked aquatic food | Abdominal/liver/lung disease | Cook food thoroughly | Praziquantel or other specific drugs |
| 108 | Yaws | Treponema pallidum pertenue | — | Skin-to-skin contact | Skin lesions, bone disease | Hygiene, early treatment | Azithromycin or penicillin |
| 109 | Buruli ulcer | Mycobacterium ulcerans | Not established | Environmental exposure suspected | Large painless skin ulcers | Wound/environmental precautions | Antibiotics; wound/surgical care |
| 110 | Mycetoma | Various fungi/bacteria | — | Organisms enter skin through injury | Swelling, nodules, draining sinuses | Protective footwear | Long-term antimicrobial treatment; surgery sometimes |
| 111 | Chromoblastomycosis | Dematiaceous fungi | — | Traumatic implantation into skin | Chronic wart-like skin lesions | Protective footwear | Long-term antifungals ± surgery |
| 112 | Noma | Polymicrobial infection associated with severe malnutrition | — | Not established as simple person-to-person disease | Rapid facial tissue destruction | Nutrition, oral hygiene, early infection care | Antibiotics, nutrition, surgery |
| 113 | Podoconiosis | Mineral particles + susceptibility | — | Environmental exposure through bare feet | Chronic leg swelling | Footwear, hygiene | Foot care, compression, surgery in selected cases |
| 114 | Tungiasis | Tunga penetrans flea | Flea | Flea penetrates skin | Painful itchy skin lesions | Shoes, environmental control | Removal + wound care |
| 115 | Snakebite envenoming | Snake venom | Snake | Snakebite | Pain, swelling, bleeding/paralysis | Avoid snake exposure | Appropriate antivenom + emergency care |
| 116 | Rat-bite fever | Streptobacillus / Spirillum | — | Rat bite/scratch or contaminated food | Fever, rash, joint pain | Rodent control | Antibiotics |
| 117 | Q fever | Coxiella burnetii | — | Inhalation of contaminated animal material | Fever, headache; pneumonia/hepatitis possible | Animal/workplace precautions | Doxycycline |
| 118 | Tularemia | Francisella tularensis | Ticks, deer flies | Vector bite, animals, inhalation | Fever, ulcers, swollen nodes | Tick protection | Antibiotics |
| 119 | Melioidosis | Burkholderia pseudomallei | — | Soil/water exposure | Fever, pneumonia, abscesses | Avoid contaminated soil/water when risk is high | Prolonged antibiotics |
| 120 | Glanders | Burkholderia mallei | — | Infected animals/body fluids | Fever, skin/lung disease | Animal-control precautions | Antibiotics |
| 121 | Legionnaires’ disease | Legionella spp. | — | Inhaled contaminated water aerosols | Pneumonia, fever | Water-system management | Antibiotics |
| 122 | Mycoplasma pneumonia | Mycoplasma pneumoniae | — | Respiratory droplets | Cough, fever, sore throat | Hygiene | Antibiotics when indicated |
| 123 | Psittacosis | Chlamydia psittaci | — | Inhalation from infected birds | Fever, pneumonia | Bird-handling precautions | Antibiotics |
| 124 | Q fever pneumonia | Coxiella burnetii | — | Inhalation from infected animals | Fever, pneumonia | Animal-product precautions | Doxycycline |
| 125 | Actinomycosis | Actinomyces spp. | — | Normal flora; tissue invasion after disruption | Abscesses, jaw/neck swelling | Oral hygiene | Long-term antibiotics |
| 126 | Nocardiosis | Nocardia spp. | — | Inhalation/soil wound contamination | Lung/brain/skin disease | Risk reduction in vulnerable people | Prolonged antibiotics |
| 127 | Erysipelas | Group A Streptococcus | — | Bacteria enter damaged skin | Red, painful swollen skin | Skin/wound care | Antibiotics |
| 128 | Cellulitis | Usually streptococci/staphylococci | — | Bacteria enter broken skin | Redness, warmth, swelling | Wound care | Antibiotics |
| 129 | Impetigo | S. aureus / Group A strep | — | Direct contact | Superficial sores/crusts | Hygiene | Topical/systemic antibiotics |
| 130 | Necrotizing fasciitis | Various bacteria | — | Infection through wound | Severe pain, swelling, tissue destruction | Wound care | Emergency surgery + antibiotics |
| 131 | Toxic shock syndrome | Bacterial toxins | — | Usually S. aureus or Group A strep | Fever, rash, low blood pressure | Wound/tampon/device safety | Emergency antibiotics + source control |
| 132 | Gas gangrene | Clostridium spp. | — | Wound contamination | Severe pain, swelling, gas in tissues | Prompt wound care | Emergency surgery + antibiotics |
| 133 | H. pylori infection | Helicobacter pylori | — | Likely oral/fecal-oral routes | Gastritis, ulcers | Hygiene/food safety | Combination eradication therapy |
| 134 | Bacillary dysentery | Shigella spp. | — | Fecal-oral | Bloody diarrhea, fever | Sanitation | Rehydration ± antibiotics |
| 135 | Yersiniosis | Yersinia enterocolitica | — | Contaminated food | Diarrhea, abdominal pain | Food safety | Supportive; antibiotics in severe cases |
| 136 | Vibrio gastroenteritis | Non-cholera Vibrio spp. | — | Seafood/water | Diarrhea, abdominal pain | Cook seafood | Supportive; antibiotics in selected cases |
| 137 | Hepatitis-associated liver infection | Hepatitis viruses | — | Depends on virus | Fatigue, nausea, jaundice | Vaccines/safe food and blood | Virus-specific/supportive |
| 138 | Adenovirus infection | Adenoviruses | — | Respiratory/fecal-oral/contact | Fever, sore throat, diarrhea | Hygiene | Supportive care |
| 139 | Parainfluenza infection | Human parainfluenza viruses | — | Respiratory secretions | Croup, cough, fever | Hygiene | Supportive care |
| 140 | Human metapneumovirus infection | hMPV | — | Respiratory secretions | Cough, fever, bronchiolitis | Hygiene | Supportive care |
| 141 | Parvovirus B19 infection | Parvovirus B19 | — | Respiratory; blood; pregnancy transmission | Rash, joint pain, anemia | Hygiene | Supportive care; special care for severe anemia |
| 142 | Roseola | HHV-6/HHV-7 | — | Saliva/contact | High fever followed by rash | Hygiene | Supportive care |
| 143 | Cytomegalovirus infection | CMV | — | Body fluids/congenital | Often mild; congenital disease possible | Hygiene, precautions in pregnancy | Usually supportive; antivirals for selected severe cases |
| 144 | Herpes simplex infection | HSV-1/HSV-2 | — | Skin/mucosal contact | Blisters/ulcers | Avoid contact during lesions | Antiviral medicines |
| 145 | Molluscum contagiosum | Molluscum contagiosum virus | — | Skin contact/fomites | Small raised skin bumps | Avoid direct contact/sharing items | Often resolves; lesion treatment if needed |
| 146 | Warts | Human papillomaviruses | — | Direct skin contact | Skin growths | Avoid direct contact | Destruction/topical treatments |
| 147 | Hand, foot and mouth disease | Enteroviruses | — | Contact, respiratory/fecal-oral | Fever, mouth sores, rash | Hand hygiene | Supportive care |
| 148 | Viral croup | Parainfluenza and other viruses | — | Respiratory droplets | Barking cough, noisy breathing | Hygiene | Steroids; emergency airway care if severe |
| 149 | Viral bronchiolitis | RSV and other viruses | — | Respiratory secretions | Wheezing, breathing difficulty | Hygiene, immunization/prevention where available | Supportive care |
| 150 | Acute viral hepatitis | HAV/HBV/HCV/HDV/HEV | — | Depends on virus | Fatigue, nausea, jaundice | Vaccination and route-specific prevention | Virus-specific or supportive |
| 151 | Avian influenza | Influenza A viruses | — | Infected birds/animals; limited human transmission | Fever, respiratory symptoms | Avoid infected animals, food safety | Antivirals + supportive care |
| 152 | Swine influenza | Influenza A viruses | — | Respiratory exposure | Fever, cough, body aches | Vaccination where applicable, hygiene | Antivirals/supportive care |
| 153 | MERS | MERS-CoV | — | Camel exposure; person-to-person | Fever, pneumonia | Infection control, avoid exposure | Supportive hospital care |
| 154 | SARS | SARS-CoV | — | Respiratory/contact | Fever, cough, pneumonia | Infection control | Supportive care |
| 155 | Hantavirus pulmonary syndrome | Hantaviruses | Rodents are reservoir | Inhalation of rodent excreta | Fever, rapidly worsening breathing | Rodent control | Intensive supportive care |
| 156 | Severe fever with thrombocytopenia syndrome | SFTS virus | Ticks | Tick bite/contact | Fever, low platelets, GI symptoms | Tick avoidance | Supportive care |
| 157 | Omsk hemorrhagic fever | Omsk hemorrhagic fever virus | Ticks | Tick bite; animal exposure | Fever, bleeding | Tick precautions | Supportive care |
| 158 | Kyasanur Forest disease | KFD virus | Ticks | Tick bite | Fever, headache, bleeding | Tick control/protection | Supportive care |
| 159 | Colorado tick fever | Colorado tick fever virus | Ticks | Tick bite | Fever, headache, muscle pain | Tick avoidance | Supportive care |
| 160 | Powassan disease | Powassan virus | Ticks | Tick bite | Fever, encephalitis | Tick avoidance | Supportive care |
| 161 | Jamestown Canyon virus disease | Jamestown Canyon virus | Mosquitoes | Mosquito bite | Fever, headache; encephalitis sometimes | Mosquito protection | Supportive care |
| 162 | La Crosse encephalitis | La Crosse virus | Aedes mosquitoes | Mosquito bite | Fever, seizures, encephalitis | Mosquito control | Supportive care |
| 163 | Eastern equine encephalitis | EEE virus | Mosquitoes | Mosquito bite | Fever, encephalitis | Mosquito protection | Supportive care |
| 164 | Western equine encephalitis | WEE virus | Mosquitoes | Mosquito bite | Fever, encephalitis | Mosquito control | Supportive care |
| 165 | St. Louis encephalitis | SLE virus | Culex mosquitoes | Mosquito bite | Fever, encephalitis | Mosquito control | Supportive care |
| 166 | Venezuelan equine encephalitis | VEE virus | Mosquitoes | Mosquito bite | Fever, neurological disease | Mosquito control | Supportive care |
| 167 | Mayaro fever | Mayaro virus | Haemagogus mosquitoes | Mosquito bite | Fever, severe joint pain | Mosquito protection | Supportive care |
| 168 | Ross River virus disease | Ross River virus | Mosquitoes | Mosquito bite | Fever, rash, joint pain | Mosquito control | Supportive care |
| 169 | Barmah Forest virus disease | Barmah Forest virus | Mosquitoes | Mosquito bite | Fever, rash, joint pain | Mosquito protection | Supportive care |
| 170 | Murray Valley encephalitis | MVE virus | Culex mosquitoes | Mosquito bite | Fever, encephalitis | Mosquito control | Supportive care |
| 171 | Toscana virus infection | Toscana virus | Sandflies | Sandfly bite | Fever, headache, meningitis | Sandfly protection | Supportive care |
| 172 | Sandfly fever | Phleboviruses | Sandflies | Sandfly bite | Sudden fever, headache, muscle pain | Sandfly control | Supportive care |
| 173 | Rift Valley fever | RVF virus | Mosquitoes | Mosquito bite/animal contact | Fever; severe eye/brain/bleeding disease possible | Mosquito/animal control | Supportive care |
| 174 | Crimean-Congo hemorrhagic fever | CCHF virus | Ticks | Tick/animal blood exposure | Fever, bleeding | Tick protection, infection control | Intensive supportive care |
| 175 | Relapsing fever | Borrelia spp. | Ticks or body lice | Vector bite | Recurrent fever, headache | Vector control | Antibiotics |
| 176 | Murine typhus | Rickettsia typhi | Fleas | Flea exposure | Fever, headache, rash | Flea/rodent control | Doxycycline |
| 177 | Scrub typhus | Orientia tsutsugamushi | Chiggers | Mite bite | Fever, rash, eschar | Avoid mite exposure | Doxycycline |
| 178 | Anaplasmosis | Anaplasma phagocytophilum | Ticks | Tick bite | Fever, headache, muscle aches | Tick prevention | Doxycycline |
| 179 | Ehrlichiosis | Ehrlichia spp. | Ticks | Tick bite | Fever, headache, muscle aches | Tick prevention | Doxycycline |
| 180 | Babesiosis | Babesia spp. | Ticks | Tick bite; blood transfusion | Fever, anemia, fatigue | Tick prevention | Antiparasitic combination therapy |
| 181 | Anisakiasis | Anisakis larvae | — | Raw/undercooked marine fish | Abdominal pain, nausea | Properly cook/freeze fish | Endoscopic removal/supportive care |
| 182 | Angiostrongyliasis | Angiostrongylus spp. | Snails/slugs | Raw/undercooked intermediate hosts | Meningitis, headache | Food hygiene | Supportive; specialist antiparasitic treatment |
| 183 | Fascioliasis | Fasciola spp. | Freshwater snails | Raw aquatic plants/water | Liver/biliary disease | Safe food/water | Triclabendazole |
| 184 | Clonorchiasis | Clonorchis sinensis | Freshwater snails/fish | Raw freshwater fish | Biliary disease | Cook fish | Praziquantel |
| 185 | Opisthorchiasis | Opisthorchis spp. | Snails/fish | Raw freshwater fish | Biliary disease | Cook fish | Praziquantel |
| 186 | Paragonimiasis | Paragonimus spp. | Snails/crabs | Raw/undercooked crustaceans | Cough, chest pain | Cook crustaceans | Praziquantel |
| 187 | Dientamoebiasis | Dientamoeba fragilis | — | Fecal-oral suspected | Diarrhea, abdominal pain | Hygiene | Treatment when clinically indicated |
| 188 | Blastocystis infection | Blastocystis spp. | — | Fecal-oral | Sometimes diarrhea/abdominal symptoms | Safe food/water | Treatment depends on clinical assessment |
| 189 | Balantidiasis | Balantidium coli | — | Fecal-oral | Diarrhea, colitis | Sanitation | Tetracycline/metronidazole alternatives |
| 190 | Babesiosis | Babesia spp. | Ticks | Tick/blood exposure | Fever, hemolytic anemia | Tick prevention | Antiparasitic therapy |
| 191 | Cryptosporidiosis | Cryptosporidium | — | Fecal-oral/water | Watery diarrhea | Safe water | Rehydration; nitazoxanide in selected patients |
| 192 | Microsporidiosis | Microsporidia | — | Environmental/food/water exposure | Diarrhea or organ disease | Hygiene/safe water | Organism- and immune-status-specific treatment |
| 193 | Acanthamoeba keratitis | Acanthamoeba | — | Contaminated water/contact lenses | Severe eye pain, redness, vision loss | Proper contact-lens hygiene | Prolonged topical antiamoebic therapy |
| 194 | Naegleria fowleri infection | Naegleria fowleri | — | Contaminated water entering nose | Rapid meningitis/encephalitis | Avoid forcing warm freshwater into nose | Emergency specialist treatment |
| 195 | Primary amoebic meningoencephalitis | Naegleria fowleri | — | Water entering nose | Severe headache, fever, neurological symptoms | Water precautions | Intensive specialist treatment |
| 196 | Pneumocystis pneumonia | Pneumocystis jirovecii | — | Opportunistic infection | Dry cough, fever, breathing difficulty | HIV care/prophylaxis in eligible people | TMP-SMX and supportive care |
| 197 | Talaromycosis | Talaromyces marneffei | — | Environmental exposure | Fever, skin/lung/systemic disease | Risk reduction in endemic areas | Antifungal therapy |
| 198 | Sporotrichosis | Sporothrix spp. | — | Skin inoculation; occasionally animal transmission | Nodules along lymph vessels | Gloves/protective clothing | Itraconazole or other antifungals |
| 199 | Mucormycosis | Mucorales fungi | — | Inhalation/inoculation | Sinus, lung, skin or systemic disease | Control underlying risks | Urgent antifungal therapy + surgery when needed |
| 200 | Pneumocystis infection | Pneumocystis jirovecii | — | Likely person-to-person/environmental | Pneumonia in immunocompromised people | Preventive therapy for eligible high-risk patients | TMP-SMX |
| # | Disease | Cause / Organism | Vector | Transmission / Origin | Main symptoms | Prevention | Treatment |
| 201 | Actinomycosis | Actinomyces bacteria | — | Normal flora becoming invasive | Abscesses, swelling | Oral hygiene | Long-term antibiotics |
| 202 | Acanthosis nigricans | Metabolic/hormonal factors | — | Noninfectious | Dark, thick skin | Healthy weight/metabolic control | Treat underlying cause |
| 203 | Addison disease | Adrenal insufficiency | — | Autoimmune/other causes | Weakness, low BP, pigmentation | Cause-specific | Hormone replacement |
| 204 | Adrenal insufficiency | Low cortisol | — | Autoimmune, adrenal/pituitary disease | Fatigue, low BP | Depends on cause | Corticosteroid replacement |
| 205 | Amyloidosis | Abnormal amyloid protein deposits | — | Usually acquired/genetic | Organ dysfunction | Depends on type | Treat underlying protein disorder |
| 206 | Amyotrophic lateral sclerosis | Motor-neuron degeneration | — | Usually sporadic; some genetic | Progressive muscle weakness | No established prevention | Disease-modifying/supportive care |
| 207 | Alzheimer’s disease | Neurodegenerative processes | — | Multifactorial/genetic risk | Progressive memory/cognitive decline | Risk-factor management | Symptom/disease-modifying treatments for selected patients |
| 208 | Parkinson disease | Neurodegeneration | — | Multifactorial | Tremor, rigidity, slow movement | No proven prevention | Medicines, exercise, surgery in selected cases |
| 209 | Huntington disease | HTT gene mutation | — | Autosomal dominant inheritance | Movement, psychiatric and cognitive changes | Genetic counseling | Symptom management |
| 210 | Multiple sclerosis | Immune-mediated CNS demyelination | — | Autoimmune/multifactorial | Vision, weakness, sensory problems | No established prevention | Disease-modifying therapies |
| 211 | Epilepsy | Abnormal brain electrical activity | — | Genetic, structural, metabolic or unknown | Recurrent seizures | Treat causes/injury prevention | Antiseizure medicines; surgery in selected cases |
| 212 | Migraine | Neurological disorder | — | Genetic/environmental triggers | Headache, nausea, light sensitivity | Trigger management | Acute and preventive medicines |
| 213 | Meningitis | Bacteria, viruses, fungi or parasites | — | Depends on organism | Fever, headache, stiff neck | Vaccination/hygiene | Cause-specific emergency treatment |
| 214 | Encephalitis | Viruses, autoimmune causes, others | Sometimes mosquitoes/ticks | Depends on cause | Fever, confusion, seizures | Vaccination/vector control | Cause-specific treatment |
| 215 | Guillain-Barré syndrome | Immune-mediated nerve damage | — | Often follows infection | Weakness, paralysis | No reliable prevention | IVIG/plasma exchange |
| 216 | Myasthenia gravis | Autoimmune neuromuscular disorder | — | Autoimmune | Muscle weakness, drooping eyelids | Trigger management | Immunotherapy and symptomatic treatment |
| 217 | Bell’s palsy | Facial nerve dysfunction | — | Often associated with viral reactivation | One-sided facial weakness | Not established | Corticosteroids ± antivirals |
| 218 | Trigeminal neuralgia | Trigeminal nerve disorder | — | Usually nerve compression | Severe facial pain | — | Medicines; procedures/surgery |
| 219 | Huntington-like neurodegeneration | Various genetic disorders | — | Genetic | Movement/cognitive symptoms | Genetic counseling | Supportive/symptomatic |
| 220 | Narcolepsy | Hypocretin dysfunction | — | Autoimmune/genetic factors | Excessive daytime sleepiness, cataplexy | — | Wake-promoting medicines |
| 221 | Insomnia disorder | Multiple biological/psychological factors | — | Noninfectious | Difficulty sleeping | Sleep hygiene | CBT-I ± medication |
| 222 | Sleep apnea | Airway obstruction/central breathing disorder | — | Structural/metabolic/neurological | Snoring, pauses in breathing, daytime sleepiness | Weight management where relevant | CPAP/oral devices/surgery |
| 223 | Restless legs syndrome | Neurological/genetic factors | — | Multifactorial | Urge to move legs, discomfort | Correct iron deficiency | Iron treatment/medicines |
| 224 | Autism spectrum disorder | Neurodevelopmental/genetic factors | — | Developmental | Communication/social and behavioral differences | No proven prevention | Educational/behavioral support |
| 225 | ADHD | Neurodevelopmental/genetic factors | — | Developmental | Inattention, hyperactivity, impulsivity | — | Behavioral therapy/medication |
| 226 | Down syndrome | Trisomy 21 | — | Chromosomal | Developmental/intellectual differences | Risk counseling | Supportive and medical management |
| 227 | Turner syndrome | Monosomy X | — | Chromosomal | Short stature, ovarian insufficiency | — | Growth hormone/hormone replacement |
| 228 | Klinefelter syndrome | XXY chromosome pattern | — | Chromosomal | Small testes, infertility, low testosterone | — | Testosterone/supportive care |
| 229 | Fragile X syndrome | FMR1 gene expansion | — | X-linked genetic | Developmental disability, behavioral features | Genetic counseling | Supportive treatment |
| 230 | Phenylketonuria | PAH gene deficiency | — | Autosomal recessive | Developmental damage if untreated | Newborn screening | Phenylalanine-restricted diet |
| 231 | Cystic fibrosis | CFTR mutations | — | Genetic | Lung infections, digestive problems | Genetic counseling/screening | CFTR modulators, airway/digestive treatment |
| 232 | Sickle cell disease | Hemoglobin S mutation | — | Genetic | Anemia, pain crises | Genetic counseling | Hydroxyurea, transfusion, transplantation in selected cases |
| 233 | Thalassemia | Globin gene mutations | — | Genetic | Severe anemia | Screening/genetic counseling | Transfusions, chelation, transplantation in selected cases |
| 234 | Hemophilia A | Factor VIII deficiency | — | X-linked genetic | Excessive bleeding | Genetic counseling | Factor replacement/non-factor therapies |
| 235 | Hemophilia B | Factor IX deficiency | — | X-linked genetic | Bleeding | Genetic counseling | Factor IX replacement |
| 236 | Von Willebrand disease | Von Willebrand factor disorder | — | Usually inherited | Easy bleeding | Avoid unnecessary bleeding risks | Desmopressin/factor therapy depending on type |
| 237 | Marfan syndrome | FBN1 mutation | — | Autosomal dominant | Tall stature, eye/aortic problems | Genetic counseling | Cardiovascular/eye monitoring and treatment |
| 238 | Ehlers-Danlos syndromes | Connective-tissue gene disorders | — | Genetic | Joint hypermobility, fragile tissues | Injury prevention/genetic counseling | Supportive care |
| 239 | Achondroplasia | FGFR3 mutation | — | Genetic | Short-limb dwarfism | Genetic counseling | Supportive/specialist treatment |
| 240 | Albinism | Melanin-production gene variants | — | Genetic | Low pigmentation, vision problems | Sun protection | Vision and skin protection |
| 241 | Duchenne muscular dystrophy | DMD mutation | — | X-linked genetic | Progressive muscle weakness | Genetic counseling | Steroids, mutation-specific therapies/support |
| 242 | Spinal muscular atrophy | SMN1 mutation | — | Autosomal recessive | Progressive muscle weakness | Genetic screening | Disease-modifying therapy |
| 243 | Rett syndrome | MECP2 mutation | — | Usually de novo X-linked | Developmental regression, hand movements | — | Supportive care |
| 244 | Neurofibromatosis type 1 | NF1 mutation | — | Autosomal dominant | Café-au-lait spots, nerve tumors | Genetic counseling | Monitoring/surgery/targeted treatment |
| 245 | Tuberous sclerosis | TSC1/TSC2 mutations | — | Genetic | Tumors in multiple organs, seizures | Genetic counseling | Antiseizure/targeted therapies |
| 246 | Gaucher disease | Glucocerebrosidase deficiency | — | Genetic | Enlarged liver/spleen, anemia, bone disease | Genetic counseling | Enzyme replacement/substrate reduction |
| 247 | Wilson disease | Copper metabolism disorder | — | ATP7B mutation | Liver/neurological disease | Genetic testing | Copper chelation/zinc |
| 248 | Hemochromatosis | Excess iron absorption | — | Genetic or acquired | Liver disease, diabetes, fatigue | Screening in high-risk families | Phlebotomy/chelation |
| 249 | G6PD deficiency | G6PD gene variant | — | Genetic | Hemolytic anemia after triggers | Avoid triggering drugs/foods | Supportive care/transfusion if needed |
| 250 | Hereditary spherocytosis | RBC membrane defects | — | Genetic | Anemia, jaundice | Genetic counseling | Folic acid; splenectomy in selected cases |
| 251 | Osteogenesis imperfecta | Collagen gene defects | — | Genetic | Fragile bones | Injury prevention | Bisphosphonates/supportive orthopedic care |
| 252 | Osteoporosis | Low bone density | — | Aging, hormones, medications etc. | Fragility fractures | Calcium/vitamin D, exercise | Osteoporosis medicines |
| 253 | Osteoarthritis | Joint cartilage degeneration | — | Degenerative | Joint pain/stiffness | Weight management, injury prevention | Exercise, pain treatment, joint replacement |
| 254 | Rheumatoid arthritis | Autoimmune disease | — | Immune-mediated | Joint inflammation, pain | No proven prevention | DMARDs/biologics |
| 255 | Gout | Uric acid crystal deposition | — | Metabolic | Sudden painful swollen joint | Weight/diet/medication management | NSAIDs/colchicine; urate-lowering therapy |
| 256 | Systemic lupus erythematosus | Autoimmune disease | — | Immune-mediated | Rash, joint pain, organ inflammation | Sun protection/medical monitoring | Immunomodulating medicines |
| 257 | Sjögren syndrome | Autoimmune disease | — | Immune-mediated | Dry eyes, dry mouth | Dental/eye care | Lubricants/immunotherapy |
| 258 | Systemic sclerosis | Autoimmune connective-tissue disease | — | Immune-mediated | Skin tightening, vascular/organ disease | — | Organ-specific/immunosuppressive treatment |
| 259 | Vasculitis | Blood-vessel inflammation | — | Autoimmune/infectious/other | Fever, rash, organ dysfunction | Cause-specific | Immunosuppression/cause-specific treatment |
| 260 | Psoriasis | Immune-mediated skin disease | — | Multifactorial | Scaly skin plaques | Trigger management | Topical/systemic/biologic therapy |
| 261 | Atopic dermatitis | Immune/skin-barrier disorder | — | Multifactorial | Itchy eczema | Skin moisturization, trigger control | Topical/systemic therapy |
| 262 | Vitiligo | Autoimmune melanocyte destruction | — | Noninfectious | Depigmented patches | Sun protection | Topical therapy/phototherapy |
| 263 | Alopecia areata | Autoimmune hair loss | — | Immune-mediated | Patchy hair loss | — | Steroids/other immune treatments |
| 264 | Acne vulgaris | Follicular inflammation | — | Noninfectious | Pimples, blackheads | Skin care | Topical/oral medicines |
| 265 | Rosacea | Chronic inflammatory skin disorder | — | Multifactorial | Facial redness, bumps | Trigger avoidance | Topical/oral therapy |
| 266 | Hidradenitis suppurativa | Chronic follicular inflammation | — | Noninfectious | Painful nodules/abscesses | Weight/smoking management | Antibiotics/biologics/surgery |
| 267 | Seborrheic dermatitis | Inflammatory skin disorder | — | Associated with Malassezia | Scaly oily skin | Skin care | Antifungal/topical anti-inflammatory |
| 268 | Contact dermatitis | Irritant/allergic reaction | — | Skin exposure | Itching, rash | Avoid trigger | Topical corticosteroids/avoidance |
| 269 | Urticaria | Mast-cell mediated reaction | — | Allergic/nonallergic | Itchy raised wheals | Avoid triggers | Antihistamines |
| 270 | Anaphylaxis | Severe systemic allergic reaction | — | Allergen exposure | Breathing difficulty, low BP, swelling | Allergen avoidance | Immediate epinephrine + emergency care |
| 271 | Asthma | Chronic airway inflammation | — | Allergens/irritants/genetic factors | Wheezing, cough, breathlessness | Trigger control | Inhaled medications |
| 272 | COPD | Smoking/air pollution and other exposures | — | Noninfectious | Chronic cough, breathlessness | Stop smoking, clean air | Inhalers, rehabilitation, oxygen when indicated |
| 273 | Emphysema | Alveolar destruction | — | Smoking/other exposures | Breathlessness | Avoid smoking | Inhalers/supportive care |
| 274 | Chronic bronchitis | Chronic airway inflammation | — | Smoking/irritants | Productive cough | Avoid tobacco | Inhalers/supportive care |
| 275 | Pulmonary fibrosis | Lung scarring | — | Autoimmune/drug/environmental/unknown | Progressive breathlessness | Avoid known exposures | Antifibrotic therapy for selected forms |
| 276 | Sarcoidosis | Granulomatous inflammatory disease | — | Unknown/immune | Lung/skin/other organ disease | — | Observation, steroids/immunosuppression |
| 277 | Pulmonary hypertension | High pulmonary arterial pressure | — | Multiple causes | Breathlessness, fatigue | Treat underlying causes | Cause-specific medicines |
| 278 | Coronary artery disease | Atherosclerosis | — | Noninfectious | Chest pain, heart attack | Control BP/lipids, no smoking | Medicines/interventions |
| 279 | Myocardial infarction | Blocked coronary artery | — | Atherosclerotic plaque rupture | Chest pain, sweating, breathlessness | Cardiovascular risk reduction | Emergency reperfusion + medicines |
| 280 | Heart failure | Impaired heart pumping/filling | — | Many heart diseases | Breathlessness, swelling, fatigue | Control cardiovascular risks | Guideline-directed medicines/devices |
| 281 | Hypertension | Persistently high blood pressure | — | Multifactorial | Often asymptomatic | Healthy diet, exercise, monitoring | Antihypertensive medicines |
| 282 | Atrial fibrillation | Abnormal atrial rhythm | — | Age/heart disease/genetic factors | Irregular heartbeat, palpitations | Cardiovascular risk control | Rate/rhythm control, anticoagulation when indicated |
| 283 | Stroke | Blocked or ruptured brain blood vessel | — | Vascular disease | Sudden weakness/speech problems | Control BP, diabetes, cholesterol | Emergency reperfusion or bleeding management |
| 284 | Peripheral artery disease | Arterial atherosclerosis | — | Noninfectious | Leg pain when walking | No smoking, cardiovascular risk control | Medicines/exercise/revascularization |
| 285 | Aortic aneurysm | Aortic wall weakening | — | Genetic/atherosclerotic factors | Often asymptomatic; rupture causes severe pain | BP/smoking control | Monitoring or surgery |
| 286 | Rheumatic heart disease | Heart damage after rheumatic fever | — | Post-strep immune complication | Valve disease, breathlessness | Treat strep infections | Antibiotic prophylaxis + valve treatment |
| 287 | Cardiomyopathy | Heart muscle disease | — | Genetic, infectious, metabolic etc. | Heart failure/arrhythmia | Cause-specific | Medicines/devices/surgery |
| 288 | Endocarditis | Infection of heart lining/valves | — | Bloodstream infection | Fever, murmur, embolic symptoms | Dental/infection care; prophylaxis for selected people | Prolonged antibiotics ± surgery |
| 289 | Pericarditis | Pericardial inflammation | — | Viral, autoimmune, other | Sharp chest pain | Cause-specific | Anti-inflammatory therapy |
| 290 | Deep vein thrombosis | Blood clot in vein | — | Immobility, cancer, hormones etc. | Leg swelling/pain | Mobility, risk management | Anticoagulants |
| 291 | Pulmonary embolism | Blood clot blocking lung artery | — | Usually DVT migration | Sudden breathlessness/chest pain | DVT prevention | Anticoagulation/emergency therapy |
| 292 | Varicose veins | Abnormal venous valves | — | Venous disease | Enlarged twisted veins | Exercise/compression | Compression, procedures |
| 293 | Anemia | Many causes | — | Nutritional/genetic/chronic blood loss | Fatigue, pallor, weakness | Balanced diet/screening | Treat underlying cause |
| 294 | Iron-deficiency anemia | Iron deficiency | — | Poor intake/blood loss/malabsorption | Fatigue, pallor | Iron-rich diet | Iron replacement + cause treatment |
| 295 | Vitamin B12 deficiency | B12 deficiency | — | Diet/malabsorption | Anemia, neurological symptoms | Adequate B12 | B12 replacement |
| 296 | Folate deficiency | Folate deficiency | — | Poor intake/malabsorption | Megaloblastic anemia | Adequate folate | Folate replacement |
| 297 | Obesity | Excess body fat | — | Energy imbalance + biology/environment | Increased metabolic risk | Diet, activity, healthy environment | Lifestyle + medicines/surgery when appropriate |
| 298 | Type 1 diabetes | Autoimmune beta-cell destruction | — | Autoimmune/genetic | Excess thirst/urination, weight loss | No established prevention | Lifelong insulin |
| 299 | Type 2 diabetes | Insulin resistance/beta-cell dysfunction | — | Genetic/metabolic/environmental | Thirst, urination; often silent | Healthy lifestyle/risk reduction | Lifestyle + glucose-lowering medicines |
| 300 | Gestational diabetes | Diabetes during pregnancy | — | Pregnancy-related metabolic changes | Often asymptomatic | Prenatal screening/risk management | Diet/activity + medicines when needed |
| # | Disease | Cause / Organism | Vector | Transmission / Origin | Main symptoms | Prevention | Treatment |
| 301 | Type 1 diabetes complications | Chronic hyperglycemia | — | Metabolic | Kidney/eye/nerve damage | Glucose/BP control | Diabetes management |
| 302 | Diabetic ketoacidosis | Severe insulin deficiency | — | Diabetes complication | Vomiting, dehydration, rapid breathing | Diabetes control | Emergency insulin/fluids/electrolytes |
| 303 | Hypothyroidism | Low thyroid hormone | — | Autoimmune/iodine/other | Fatigue, cold intolerance, weight gain | Adequate iodine | Levothyroxine |
| 304 | Hyperthyroidism | Excess thyroid hormone | — | Graves disease/nodules | Weight loss, tremor, fast heartbeat | Cause-specific | Antithyroid drugs/radioiodine/surgery |
| 305 | Graves disease | Autoimmune thyroid stimulation | — | Autoimmune | Hyperthyroidism, eye symptoms | — | Antithyroid therapy/radioiodine/surgery |
| 306 | Hashimoto thyroiditis | Autoimmune thyroid destruction | — | Autoimmune | Hypothyroidism, enlarged thyroid | — | Thyroid hormone |
| 307 | Goiter | Enlarged thyroid | — | Iodine deficiency/thyroid disease | Neck swelling | Adequate iodine | Cause-specific |
| 308 | Cushing syndrome | Excess cortisol | — | Steroid drugs/tumors | Weight gain, weakness, skin changes | Safe steroid use | Treat cause |
| 309 | Primary hyperaldosteronism | Excess aldosterone | — | Adrenal disease | Hypertension, low potassium | — | Medicines/surgery |
| 310 | Polycystic ovary syndrome | Hormonal/metabolic disorder | — | Multifactorial | Irregular periods, acne, excess hair | Healthy lifestyle | Lifestyle/hormonal/metabolic treatment |
| 311 | Endometriosis | Endometrial-like tissue | — | Noninfectious | Pelvic pain, infertility | — | Pain/hormonal therapy; surgery |
| 312 | Uterine fibroids | Benign smooth-muscle tumors | — | Hormonal/genetic | Heavy bleeding, pelvic pressure | — | Medicines/procedures/surgery |
| 313 | Premenstrual syndrome | Hormonal cycle-related disorder | — | Menstrual cycle | Mood/physical symptoms | Exercise, symptom tracking | Lifestyle/medicines |
| 314 | Preeclampsia | Pregnancy-associated hypertension | — | Pregnancy complication | High BP, proteinuria/organ problems | Prenatal care | Monitoring, medicines, delivery when necessary |
| 315 | Ectopic pregnancy | Pregnancy outside uterus | — | Pregnancy complication | Pain, bleeding | STI prevention/tubal health | Medicines or surgery |
| 316 | Peptic ulcer disease | H. pylori/NSAIDs | — | Infection/medication | Abdominal pain, bleeding | Treat H. pylori; safe NSAID use | Acid suppression + eradication therapy |
| 317 | GERD | Acid reflux | — | Functional/anatomical | Heartburn, regurgitation | Weight management, trigger control | Acid suppression |
| 318 | Celiac disease | Immune reaction to gluten | — | Genetic/immune | Diarrhea, weight loss, anemia | Gluten avoidance after diagnosis | Strict gluten-free diet |
| 319 | Crohn disease | Immune-mediated intestinal disease | — | Multifactorial | Diarrhea, abdominal pain, weight loss | — | Immunotherapy/biologics/surgery |
| 320 | Ulcerative colitis | Immune-mediated colon inflammation | — | Multifactorial | Bloody diarrhea, abdominal pain | — | Anti-inflammatory/immunosuppressive therapy |
| 321 | Irritable bowel syndrome | Gut-brain interaction disorder | — | Multifactorial | Abdominal pain, altered bowel habits | Diet/stress management | Dietary/medication management |
| 322 | Diverticular disease | Intestinal diverticula | — | Age/diet/genetic factors | Abdominal pain or bleeding | Fiber/healthy lifestyle | Dietary/medical/surgical treatment |
| 323 | Appendicitis | Inflamed appendix | — | Usually obstruction | Right-lower abdominal pain, fever | — | Appendectomy ± antibiotics |
| 324 | Pancreatitis | Pancreatic inflammation | — | Gallstones/alcohol/other | Severe upper abdominal pain | Limit alcohol, gallstone management | Hospital supportive care |
| 325 | Cirrhosis | Chronic liver damage | — | Alcohol, viral hepatitis, metabolic disease | Liver failure, swelling, jaundice | Vaccination/alcohol-risk reduction | Cause treatment; transplant in advanced cases |
| 326 | Fatty liver disease | Metabolic dysfunction | — | Metabolic | Often asymptomatic | Weight/metabolic management | Lifestyle; selected medicines |
| 327 | Alcohol-associated liver disease | Chronic alcohol exposure | — | Alcohol | Fatty liver, hepatitis, cirrhosis | Reduce/avoid alcohol | Abstinence/supportive and liver care |
| 328 | Gallstones | Crystals in gallbladder | — | Metabolic/genetic factors | Biliary pain, nausea | Healthy weight | Observation, medicines or surgery |
| 329 | Cholecystitis | Inflamed gallbladder | — | Usually gallstone obstruction | Right-upper abdominal pain, fever | Gallstone management | Antibiotics + often surgery |
| 330 | Hepatic encephalopathy | Toxin accumulation from liver failure | — | Liver disease complication | Confusion, altered consciousness | Treat liver disease/triggers | Lactulose/rifaximin and cause treatment |
| 331 | Acute kidney injury | Sudden kidney dysfunction | — | Dehydration, drugs, illness | Low urine, swelling, abnormal labs | Avoid kidney toxins/dehydration | Treat cause/supportive care |
| 332 | Chronic kidney disease | Progressive kidney damage | — | Diabetes, hypertension, kidney disease | Often silent; fatigue/swelling later | Control diabetes/BP | Cause control, medicines, dialysis/transplant |
| 333 | Kidney stones | Mineral crystals | — | Metabolic/dehydration | Severe flank pain, blood in urine | Hydration/diet | Pain relief, stone removal/medicines |
| 334 | Glomerulonephritis | Kidney glomerular inflammation | — | Immune/infectious | Blood/protein in urine, swelling | Treat causes | Cause-specific therapy |
| 335 | Nephrotic syndrome | Glomerular protein leakage | — | Kidney disease | Heavy proteinuria, edema | Treat underlying disease | Cause-specific + edema/protein management |
| 336 | Urinary tract infection | Usually E. coli | — | Bacteria enter urinary tract | Burning urination, frequency | Hydration/hygiene | Antibiotics |
| 337 | Pyelonephritis | Kidney infection | — | Ascending urinary infection | Fever, flank pain | Prompt UTI treatment | Antibiotics |
| 338 | Benign prostatic hyperplasia | Prostate enlargement | — | Age-related | Weak urine stream, frequency | — | Medicines/procedures |
| 339 | Prostatitis | Prostate inflammation/infection | — | Bacterial/nonbacterial | Pelvic pain, urinary symptoms | — | Antibiotics for bacterial forms |
| 340 | Erectile dysfunction | Vascular/neurological/hormonal causes | — | Noninfectious | Difficulty maintaining erection | Cardiovascular risk control | Lifestyle, PDE5 inhibitors and other treatments |
| 341 | Glaucoma | Optic nerve damage | — | Often high/abnormal eye pressure | Peripheral vision loss | Eye screening | Pressure-lowering drops/laser/surgery |
| 342 | Cataract | Lens clouding | — | Aging, diabetes, trauma | Blurred vision | UV protection/risk control | Cataract surgery |
| 343 | Macular degeneration | Retinal degeneration | — | Age/genetic factors | Central vision loss | Smoking cessation/eye care | Anti-VEGF or other treatment depending on type |
| 344 | Diabetic retinopathy | Diabetes-related retinal damage | — | Chronic hyperglycemia | Vision changes or none early | Glucose/BP control | Laser/anti-VEGF/surgery |
| 345 | Retinal detachment | Retina separates | — | Aging/trauma/eye disease | Flashes, floaters, curtain-like vision loss | Eye protection | Urgent surgery |
| 346 | Otosclerosis | Abnormal bone growth in middle ear | — | Genetic factors | Conductive hearing loss | — | Hearing aids/surgery |
| 347 | Ménière disease | Inner-ear fluid disorder | — | Multifactorial | Vertigo, hearing loss, tinnitus | Trigger management | Diet/medicines; procedures in severe cases |
| 348 | Tinnitus | Auditory system dysfunction | — | Noise/age/ear disease | Ringing or buzzing | Hearing protection | Cause-specific management |
| 349 | Hearing loss | Genetic/age/noise/infection causes | — | Multiple | Reduced hearing | Vaccination/noise protection | Hearing aids/cochlear implant depending on type |
| 350 | Otitis externa | Bacteria/fungi | — | Water/trauma | Ear canal pain/itching | Keep ears dry, avoid trauma | Ear drops |
| 351 | Sinusitis | Viral/bacterial/inflammatory | — | Respiratory infection | Facial pressure, nasal congestion | Hygiene | Supportive; antibiotics in selected bacterial cases |
| 352 | Allergic rhinitis | IgE-mediated allergy | — | Allergens | Sneezing, runny nose | Allergen avoidance | Antihistamines/nasal steroids |
| 353 | Nasal polyps | Chronic inflammatory disease | — | Noninfectious | Nasal blockage, reduced smell | Control inflammation | Steroid sprays/surgery |
| 354 | Tonsillitis | Viral/bacterial infection | — | Respiratory/contact | Sore throat, fever | Hygiene | Supportive; antibiotics for bacterial causes |
| 355 | Oral candidiasis | Candida | — | Overgrowth | White mouth patches | Oral hygiene | Antifungal |
| 356 | Periodontitis | Oral bacteria | — | Plaque-associated | Gum bleeding, tooth loss | Brushing/dental care | Professional cleaning + treatment |
| 357 | Dental caries | Acid-producing oral bacteria | — | Oral bacteria + sugars | Tooth pain/cavities | Fluoride/oral hygiene | Fillings/restoration |
| 358 | Gingivitis | Plaque bacteria | — | Plaque accumulation | Red/bleeding gums | Oral hygiene | Dental cleaning |
| 359 | Oral cancer | Tobacco, alcohol, HPV and other risks | — | Noninfectious risk factors | Mouth ulcer/lump | Tobacco avoidance, HPV prevention | Surgery/radiation/systemic therapy |
| 360 | Lung cancer | Smoking and other carcinogens | — | Environmental/genetic | Cough, weight loss, breathlessness | No smoking | Surgery/systemic therapy/radiation |
| 361 | Breast cancer | Genetic/hormonal/environmental factors | — | Noninfectious | Lump, skin/nipple changes | Screening/risk reduction | Surgery/systemic therapy/radiation |
| 362 | Colorectal cancer | Genetic/environmental factors | — | Noninfectious | Bleeding, bowel changes | Screening, lifestyle | Surgery/chemotherapy/radiation/targeted therapy |
| 363 | Prostate cancer | Genetic/age-related factors | — | Noninfectious | Often silent early; urinary symptoms later | Screening discussion | Surveillance/surgery/radiation/systemic therapy |
| 364 | Cervical cancer | High-risk HPV | — | Sexual acquisition of HPV | Abnormal bleeding | HPV vaccine/screening | Surgery/radiation/systemic therapy |
| 365 | Ovarian cancer | Genetic/other factors | — | Noninfectious | Bloating, pelvic symptoms | Genetic counseling where indicated | Surgery/chemotherapy/targeted therapy |
| 366 | Endometrial cancer | Endometrial cell mutations/hormonal factors | — | Noninfectious | Abnormal uterine bleeding | Risk-factor management | Surgery ± systemic/radiation treatment |
| 367 | Leukemia | Abnormal blood-forming cells | — | Genetic mutations | Fatigue, infections, bleeding | Limited prevention | Chemotherapy/targeted therapy/transplant depending on type |
| 368 | Lymphoma | Abnormal lymphocytes | — | Genetic/immune/infectious factors | Enlarged lymph nodes, fever, weight loss | Cause-specific | Chemotherapy/immunotherapy/radiation |
| 369 | Multiple myeloma | Abnormal plasma cells | — | Genetic changes | Bone pain, anemia, kidney problems | — | Targeted therapy/immunotherapy/transplant in selected cases |
| 370 | Melanoma | Malignant melanocytes | — | UV/genetic factors | Changing pigmented lesion | Sun protection | Surgery ± systemic therapy |
| 371 | Basal cell carcinoma | Skin basal cells, UV exposure | — | Noninfectious | Pearly skin lesion | Sun protection | Excision/topical/other treatment |
| 372 | Squamous cell skin cancer | Keratinocytes, UV/other risks | — | Noninfectious | Scaly/ulcerated lesion | Sun protection | Excision/other therapy |
| 373 | Thyroid cancer | Genetic/environmental factors | — | Noninfectious | Thyroid nodule | Appropriate evaluation | Surgery ± radioiodine/systemic therapy |
| 374 | Pancreatic cancer | Genetic/environmental factors | — | Noninfectious | Weight loss, abdominal pain, jaundice | No established prevention | Surgery/systemic therapy |
| 375 | Liver cancer | HBV/HCV/cirrhosis and other factors | — | Chronic liver disease | Weight loss, abdominal pain | Hepatitis prevention/treatment | Surgery/ablation/systemic therapy |
| 376 | Kidney cancer | Genetic/environmental factors | — | Noninfectious | Blood in urine, pain, mass | Smoking/BP control | Surgery/systemic therapy |
| 377 | Bladder cancer | Tobacco/chemical exposure | — | Noninfectious | Blood in urine | Smoking cessation | Surgery/chemotherapy/immunotherapy |
| 378 | Brain tumors | Genetic/cellular mutations | — | Noninfectious | Headache, seizures, neurological deficits | Limited prevention | Surgery/radiation/systemic therapy |
| 379 | Bone cancer | Genetic/cellular mutations | — | Noninfectious | Bone pain/swelling | — | Surgery/chemotherapy/radiation |
| 380 | Testicular cancer | Germ-cell abnormalities | — | Genetic/developmental | Testicular lump/swelling | — | Surgery ± chemotherapy/radiation |
| 381 | Hodgkin lymphoma | Malignant lymphocytes | — | Multifactorial; EBV association | Enlarged lymph nodes, fever | — | Chemotherapy/radiation/immunotherapy |
| 382 | Non-Hodgkin lymphoma | Malignant lymphocytes | — | Many genetic/immune factors | Nodes, fever, weight loss | Cause/risk management | Type-specific systemic therapy |
| 383 | Acute lymphoblastic leukemia | Abnormal lymphoid precursors | — | Genetic mutations | Fever, anemia, bleeding | — | Multi-agent chemotherapy ± targeted therapy |
| 384 | Acute myeloid leukemia | Abnormal myeloid precursors | — | Genetic mutations | Anemia, infections, bleeding | — | Chemotherapy/targeted therapy/transplant |
| 385 | Chronic lymphocytic leukemia | Abnormal B lymphocytes | — | Genetic changes | Often asymptomatic; nodes/infections | — | Observation or systemic therapy |
| 386 | Chronic myeloid leukemia | BCR-ABL mutation | — | Acquired genetic change | Fatigue, enlarged spleen | — | Tyrosine kinase inhibitors |
| 387 | Sepsis | Dysregulated response to infection | — | Complication of infection | Fever/low temperature, organ failure | Infection prevention | Emergency antibiotics/supportive care |
| 388 | Septic shock | Severe sepsis with circulatory failure | — | Infection | Very low BP, organ failure | Infection prevention | ICU fluids, antibiotics, vasopressors |
| 389 | Osteomyelitis | Bacteria/fungi | — | Bloodstream/wound spread | Bone pain, fever | Wound care | Prolonged antimicrobials ± surgery |
| 390 | Septic arthritis | Joint infection | — | Bloodstream/direct introduction | Hot swollen painful joint | Infection prevention | Urgent drainage + antibiotics |
| 391 | Discitis | Infection/inflammation of spinal disc | — | Bloodstream/contiguous spread | Back pain, fever | Infection control | Antibiotics |
| 392 | Meningococcemia | N. meningitidis bloodstream infection | — | Respiratory contact | Fever, rash, shock | Vaccination | Emergency antibiotics |
| 393 | Gas gangrene | Clostridium species | — | Contaminated wound | Severe tissue destruction | Wound care | Surgery + antibiotics |
| 394 | Wound botulism | C. botulinum toxin | — | Contaminated wound | Paralysis | Wound/drug safety | Antitoxin + wound care |
| 395 | Necrotizing enterocolitis | Intestinal inflammation in premature infants | — | Multifactorial | Abdominal swelling, feeding intolerance | Neonatal preventive care | Stop feeds, antibiotics, surgery if needed |
| 396 | Kawasaki disease | Immune-mediated childhood disease | — | Unknown | Fever, rash, mucosal changes | — | IVIG + aspirin under specialist care |
| 397 | Henoch-Schönlein purpura | IgA vasculitis | — | Immune-mediated | Purpura, abdominal/joint pain | — | Supportive/steroids for severe disease |
| 398 | Kawasaki-like multisystem inflammatory syndrome | Immune response after infection | — | Post-infectious | Fever, inflammation, organ involvement | Infection prevention | Hospital immunomodulatory care |
| 399 | Kawasaki disease with coronary complications | Kawasaki disease | — | Immune-mediated | Fever/coronary artery disease | Early treatment | IVIG + specialist cardiac care |
| 400 | Rheumatic fever | Group A strep immune reaction | — | After throat/skin infection | Migratory arthritis, carditis | Treat strep infection | Antibiotics + anti-inflammatory therapy |
| # | Disease | Cause / Organism | Vector | Transmission / Origin | Main symptoms | Prevention | Treatment |
| 401 | Acute rheumatic fever | Group A Streptococcus | — | Post-strep immune reaction | Fever, joint inflammation | Treat strep | Antibiotics/anti-inflammatory |
| 402 | Chronic rheumatic heart disease | Prior rheumatic fever | — | Immune-mediated | Valve damage | Secondary antibiotic prevention | Valve/heart-failure treatment |
| 403 | Kawasaki disease | Unknown immune trigger | — | Noninfectious | Prolonged fever, rash, mucosal changes | — | IVIG + aspirin |
| 404 | Kawasaki-associated coronary aneurysm | Kawasaki inflammation | — | Complication | Heart/vascular complications | Early Kawasaki treatment | Cardiology-directed therapy |
| 405 | Takayasu arteritis | Autoimmune vasculitis | — | Immune-mediated | Artery narrowing, weak pulses | — | Immunosuppression |
| 406 | Giant cell arteritis | Autoimmune vasculitis | — | Immune-mediated | Headache, jaw pain, vision risk | — | Urgent corticosteroids |
| 407 | Polyarteritis nodosa | Necrotizing vasculitis | — | Immune/infectious associations | Fever, pain, organ ischemia | Cause-specific | Immunosuppression |
| 408 | Granulomatosis with polyangiitis | Autoimmune vasculitis | — | Immune-mediated | Sinus/lung/kidney disease | — | Immunosuppressive therapy |
| 409 | Microscopic polyangiitis | Autoimmune vasculitis | — | Immune-mediated | Kidney/lung disease | — | Immunosuppression |
| 410 | Behçet disease | Inflammatory vasculitis | — | Genetic/environmental | Mouth/genital ulcers, eye inflammation | — | Immunosuppression |
| 411 | Antiphospholipid syndrome | Autoimmune clotting disorder | — | Autoimmune | Clots, pregnancy complications | Risk-factor management | Anticoagulation |
| 412 | Dermatomyositis | Autoimmune muscle/skin disease | — | Immune-mediated | Muscle weakness, rash | — | Steroids/immunosuppressants |
| 413 | Polymyositis | Immune-mediated muscle disease | — | Autoimmune | Muscle weakness | — | Immunosuppression |
| 414 | Polymyalgia rheumatica | Inflammatory disorder | — | Immune-mediated | Shoulder/hip stiffness and pain | — | Corticosteroids |
| 415 | Mixed connective tissue disease | Autoimmune overlap syndrome | — | Immune-mediated | Joint, skin, muscle, organ symptoms | — | Immunosuppression |
| 416 | Autoimmune hepatitis | Immune liver disease | — | Autoimmune | Hepatitis, fatigue, jaundice | — | Corticosteroids/immunosuppression |
| 417 | Primary biliary cholangitis | Autoimmune bile-duct disease | — | Autoimmune | Itching, fatigue, liver disease | — | Ursodeoxycholic acid/other therapy |
| 418 | Primary sclerosing cholangitis | Bile-duct inflammation/scarring | — | Immune-associated | Itching, jaundice, liver disease | — | Monitoring, treatment of complications/transplant |
| 419 | Addison disease | Adrenal insufficiency | — | Usually autoimmune | Fatigue, low BP | Medical monitoring | Cortisol/mineralocorticoid replacement |
| 420 | Multiple endocrine neoplasia | MEN gene mutations | — | Genetic | Multiple endocrine tumors | Genetic testing/surveillance | Surgery/medical treatment |
| 421 | Pheochromocytoma | Catecholamine-producing tumor | — | Usually adrenal tumor | High BP, sweating, palpitations | Genetic screening when indicated | Surgery + alpha blockade |
| 422 | Acromegaly | Excess growth hormone | — | Pituitary adenoma | Enlarged hands/face, metabolic effects | — | Surgery/medicines/radiation |
| 423 | Pituitary gigantism | Excess growth hormone in childhood | — | Pituitary disorder | Excessive height growth | — | Surgery/medicines |
| 424 | Diabetes insipidus | ADH deficiency/resistance | — | Pituitary/kidney causes | Excess urination/thirst | Cause-specific | Desmopressin or other therapy |
| 425 | Hyperparathyroidism | Excess PTH | — | Parathyroid disease | High calcium, stones/bone symptoms | — | Surgery/medical therapy |
| 426 | Hypoparathyroidism | Low PTH | — | Autoimmune/surgical/genetic | Low calcium, muscle spasms | — | Calcium/vitamin D |
| 427 | Primary hyperparathyroidism | Parathyroid adenoma/hyperplasia | — | Endocrine disorder | High calcium | — | Surgery/medical therapy |
| 428 | Rickets | Vitamin D/calcium/phosphate deficiency | — | Nutritional/metabolic | Bone deformities, poor growth | Vitamin D/calcium | Supplements |
| 429 | Osteomalacia | Poor bone mineralization | — | Vitamin D/metabolic | Bone pain, weakness | Vitamin D/calcium | Correct deficiency |
| 430 | Scurvy | Vitamin C deficiency | — | Nutritional | Bleeding gums, poor wound healing | Fruits/vegetables | Vitamin C |
| 431 | Beriberi | Vitamin B1 deficiency | — | Nutritional | Neurological/heart disease | Adequate thiamine | Thiamine |
| 432 | Pellagra | Niacin deficiency | — | Nutritional | Dermatitis, diarrhea, dementia | Balanced diet | Niacin |
| 433 | Kwashiorkor | Severe protein deficiency | — | Malnutrition | Edema, growth failure | Adequate nutrition | Therapeutic nutrition |
| 434 | Marasmus | Severe calorie deficiency | — | Malnutrition | Severe wasting | Adequate nutrition | Therapeutic nutrition |
| 435 | Obsessive-compulsive disorder | Neuropsychiatric disorder | — | Multifactorial | Intrusive thoughts/compulsions | — | CBT/medicines |
| 436 | Panic disorder | Anxiety disorder | — | Multifactorial | Recurrent panic attacks | — | CBT/medicines |
| 437 | Generalized anxiety disorder | Anxiety disorder | — | Multifactorial | Persistent excessive worry | — | CBT/medicines |
| 438 | Major depressive disorder | Mood disorder | — | Biological/psychological/social factors | Persistent low mood/loss of interest | Mental-health support | Psychotherapy/medicines |
| 439 | Bipolar disorder | Mood disorder | — | Genetic/environmental | Mania/depression | — | Mood stabilizers/psychotherapy |
| 440 | Schizophrenia | Neuropsychiatric disorder | — | Genetic/environmental | Psychosis, functional impairment | — | Antipsychotic treatment/support |
| 441 | Anorexia nervosa | Eating disorder | — | Multifactorial | Restrictive eating, low weight | Early recognition | Nutritional/psychological/medical care |
| 442 | Bulimia nervosa | Eating disorder | — | Multifactorial | Binge eating and compensatory behaviors | Early recognition | Psychotherapy/medicines/nutrition |
| 443 | Binge-eating disorder | Eating disorder | — | Multifactorial | Recurrent binge eating | — | CBT/medical management |
| 444 | Post-traumatic stress disorder | Trauma-related disorder | — | Traumatic exposure | Intrusive memories, avoidance, hyperarousal | Trauma-informed support | Trauma-focused psychotherapy/medicines |
| 445 | Tourette syndrome | Neurodevelopmental disorder | — | Genetic/environmental | Motor and vocal tics | — | Behavioral therapy/medicines |
| 446 | Cerebral palsy | Developing-brain injury/disorder | — | Prenatal/perinatal/postnatal causes | Movement/posture problems | Prenatal/perinatal care | Rehabilitation/supportive treatment |
| 447 | Hydrocephalus | Abnormal CSF accumulation | — | Congenital, tumor, bleeding, infection | Headache, vomiting, neurological changes | Cause prevention | Neurosurgical CSF diversion |
| 448 | Spina bifida | Neural-tube defect | — | Genetic/environmental | Weakness, bladder/bowel problems | Folic acid before pregnancy | Surgery/supportive care |
| 449 | Bell’s palsy | Facial nerve palsy | — | Often post-viral | Facial weakness | — | Steroids ± antivirals |
| 450 | Cluster headache | Trigeminal autonomic headache | — | Neurological | Severe one-sided eye pain | Avoid triggers | Oxygen/triptans; prevention |
| 451 | Tension-type headache | Headache disorder | — | Multifactorial | Band-like headache | Sleep/stress management | Analgesics/preventive medicines |
| 452 | Multiple system atrophy | Neurodegenerative disorder | — | Sporadic | Movement/autonomic problems | — | Supportive treatment |
| 453 | ALS | Motor-neuron degeneration | — | Usually sporadic/genetic | Progressive weakness | — | Disease-modifying/supportive |
| 454 | Creutzfeldt-Jakob disease | Prion | — | Usually sporadic | Rapid dementia, movement abnormalities | Avoid contaminated tissue exposure | Supportive care |
| 455 | Fatal familial insomnia | Prion disease | — | Genetic | Progressive insomnia, autonomic/neurological symptoms | Genetic counseling | Supportive |
| 456 | Kuru | Prion | — | Historically ritual exposure | Progressive neurological disease | Avoid exposure | Supportive |
| 457 | Niemann-Pick disease | Lipid-storage disorders | — | Genetic | Liver/spleen/neurological disease | Genetic counseling | Type-specific therapy/supportive |
| 458 | Tay-Sachs disease | HEXA deficiency | — | Autosomal recessive | Progressive neurological deterioration | Carrier screening | Supportive care |
| 459 | Pompe disease | Acid alpha-glucosidase deficiency | — | Genetic | Muscle/heart weakness | Screening/genetic counseling | Enzyme replacement |
| 460 | Fabry disease | Alpha-galactosidase A deficiency | — | X-linked | Kidney, heart, nerve symptoms | Genetic counseling | Enzyme/chaperone therapy |
| 461 | McArdle disease | Muscle glycogen phosphorylase deficiency | — | Genetic | Exercise intolerance, muscle cramps | Activity planning | Supportive/metabolic management |
| 462 | Acute intermittent porphyria | Heme synthesis disorder | — | Genetic | Abdominal pain, neurological symptoms | Trigger avoidance | Hemin/glucose/supportive treatment |
| 463 | Familial Mediterranean fever | MEFV mutation | — | Genetic | Recurrent fever, abdominal/joint pain | — | Colchicine |
| 464 | Alpha-1 antitrypsin deficiency | SERPINA1 mutation | — | Genetic | Lung/liver disease | No smoking | Lung/liver management |
| 465 | Hereditary angioedema | C1 inhibitor deficiency/dysfunction | — | Genetic | Recurrent swelling | Trigger planning | C1 inhibitor/bradykinin-targeted therapy |
| 466 | Duchenne muscular dystrophy | DMD mutation | — | X-linked | Progressive weakness | Genetic counseling | Steroids/gene-targeted options/support |
| 467 | Becker muscular dystrophy | DMD mutation | — | X-linked | Progressive muscle weakness | Genetic counseling | Supportive/disease-modifying therapy |
| 468 | Friedreich ataxia | FXN mutation | — | Autosomal recessive | Ataxia, weakness, heart disease | Genetic counseling | Supportive/targeted therapy where available |
| 469 | Huntington disease | HTT CAG expansion | — | Autosomal dominant | Movement/cognitive/psychiatric changes | Genetic counseling | Symptomatic care |
| 470 | Rett syndrome | MECP2 mutation | — | Genetic | Developmental regression | — | Supportive |
| 471 | Prader-Willi syndrome | Chromosome 15 imprinting disorder | — | Genetic | Hypotonia, hyperphagia, developmental issues | Genetic counseling | Nutritional/endocrine management |
| 472 | Angelman syndrome | Chromosome 15 imprinting/UBE3A | — | Genetic | Developmental delay, seizures | Genetic counseling | Supportive/antiseizure |
| 473 | Cri-du-chat syndrome | Chromosome 5 deletion | — | Chromosomal | Developmental delay, characteristic cry | Genetic | Supportive |
| 474 | Edwards syndrome | Trisomy 18 | — | Chromosomal | Severe developmental/congenital abnormalities | Prenatal screening | Supportive/specialist care |
| 475 | Patau syndrome | Trisomy 13 | — | Chromosomal | Severe congenital abnormalities | Prenatal screening | Supportive/specialist care |
| 476 | Rett-like disorders | Various genes | — | Genetic | Developmental regression | Genetic testing | Supportive |
| 477 | Fragile X syndrome | FMR1 expansion | — | X-linked | Intellectual/developmental differences | Genetic counseling | Supportive |
| 478 | Neurofibromatosis type 2 | NF2 mutation | — | Genetic | Schwannomas, hearing loss | Genetic counseling | Monitoring/surgery/radiation |
| 479 | Von Hippel-Lindau disease | VHL mutation | — | Genetic | Kidney/brain/retinal tumors | Genetic surveillance | Surgery/targeted treatment |
| 480 | Li-Fraumeni syndrome | TP53 mutation | — | Genetic | Multiple cancer risks | Genetic surveillance | Cancer-specific |
| 481 | Lynch syndrome | DNA mismatch-repair mutations | — | Genetic | Increased colorectal/endometrial cancer risk | Genetic testing/surveillance | Cancer prevention/treatment |
| 482 | Familial adenomatous polyposis | APC mutation | — | Genetic | Numerous colon polyps | Genetic screening | Surveillance/colectomy |
| 483 | BRCA-associated cancer syndrome | BRCA1/2 mutations | — | Genetic | Breast/ovarian/prostate/pancreatic cancer risk | Genetic counseling/screening | Risk-reducing/cancer-specific treatment |
| 484 | Retinitis pigmentosa | Retinal gene disorders | — | Genetic | Night blindness, peripheral vision loss | Genetic counseling | Low-vision support; gene-specific therapy in selected cases |
| 485 | Leber congenital amaurosis | Retinal gene disorders | — | Genetic | Severe childhood visual impairment | Genetic counseling | Gene-specific therapy for eligible mutations |
| 486 | Stargardt disease | ABCA4 mutations | — | Genetic | Juvenile central vision loss | Genetic counseling | Low-vision support |
| 487 | Achromatopsia | Cone-photoreceptor gene disorders | — | Genetic | Color blindness, light sensitivity | Eye protection | Supportive |
| 488 | Retinoblastoma | RB1 mutation | — | Genetic/sporadic | Childhood eye tumor | Genetic screening | Chemotherapy/local therapy/surgery |
| 489 | Alport syndrome | Collagen IV mutations | — | Genetic | Kidney disease, hearing/eye abnormalities | Genetic counseling | Kidney/BP management |
| 490 | Polycystic kidney disease | PKD mutations | — | Genetic | Enlarged kidneys, hypertension | Genetic counseling | BP/kidney management |
| 491 | Bartter syndrome | Renal salt-transport defects | — | Genetic | Low potassium, dehydration | Genetic | Electrolyte replacement |
| 492 | Gitelman syndrome | Renal electrolyte transport defect | — | Genetic | Low potassium/magnesium | Genetic | Electrolyte replacement |
| 493 | Fabry disease | Alpha-galactosidase A deficiency | — | Genetic | Kidney/heart/nerve symptoms | Genetic counseling | Enzyme/chaperone therapy |
| 494 | Alport syndrome | COL4A mutations | — | Genetic | Hematuria, kidney failure, hearing loss | Genetic counseling | Kidney/BP management |
| 495 | Goodpasture disease | Autoimmune basement-membrane disease | — | Autoimmune | Lung bleeding, kidney failure | — | Immunosuppression/plasma exchange |
| 496 | Minimal change disease | Kidney immune disorder | — | Immune-mediated | Nephrotic syndrome | — | Corticosteroids |
| 497 | IgA nephropathy | IgA immune deposits | — | Immune-mediated | Blood/protein in urine | BP control | Supportive/immunosuppressive therapy |
| 498 | Polycystic liver disease | Genetic cystic disease | — | Genetic | Enlarged liver, cysts | Genetic counseling | Symptom/surgical management |
| 499 | Primary hyperoxaluria | Oxalate metabolism defect | — | Genetic | Kidney stones/kidney failure | Genetic | Diet, medicines, transplant in severe cases |
| 500 | Cystinuria | Amino-acid transport defect | — | Genetic | Recurrent kidney stones | Genetic | High fluids, alkalinization, medicines |
| # | Disease | Cause / Organism | Vector | Transmission / Origin | Main symptoms | Prevention | Treatment |
| 501 | Phenylketonuria | PAH deficiency | — | Genetic | Intellectual disability if untreated | Newborn screening | Phenylalanine-restricted diet |
| 502 | Maple syrup urine disease | Branched-chain amino-acid metabolism defect | — | Genetic | Neurological illness, characteristic urine odor | Newborn screening | Special diet; metabolic emergency care |
| 503 | Homocystinuria | Metabolic enzyme defects | — | Genetic | Eye, skeletal, vascular, neurological problems | Screening | Vitamin/diet/metabolic therapy |
| 504 | Galactosemia | Galactose metabolism defect | — | Genetic | Liver failure, infection, developmental problems | Newborn screening | Avoid galactose/lactose |
| 505 | Hereditary fructose intolerance | Aldolase B deficiency | — | Genetic | Vomiting, hypoglycemia after fructose | Avoid fructose/sucrose | Dietary avoidance |
| 506 | Glycogen storage disease | Glycogen metabolism defects | — | Genetic | Hypoglycemia, enlarged liver/muscle problems | Genetic counseling | Diet/metabolic therapy |
| 507 | Medium-chain acyl-CoA dehydrogenase deficiency | Fatty-acid oxidation defect | — | Genetic | Hypoglycemia during fasting | Newborn screening | Avoid fasting; emergency glucose |
| 508 | Ornithine transcarbamylase deficiency | Urea-cycle defect | — | X-linked genetic | Hyperammonemia, neurological symptoms | Genetic counseling | Protein management/ammonia-lowering treatment |
| 509 | Maple syrup urine disease | BCKD deficiency | — | Genetic | Neurological/metabolic crisis | Screening | Dietary/metabolic treatment |
| 510 | Congenital adrenal hyperplasia | Steroid synthesis enzyme defects | — | Genetic | Hormonal abnormalities | Newborn screening | Hormone replacement |
| 511 | Congenital hypothyroidism | Thyroid-development/hormone defects | — | Genetic/developmental | Poor growth, developmental impairment | Newborn screening | Thyroid hormone |
| 512 | Turner syndrome | Monosomy X | — | Chromosomal | Short stature, ovarian insufficiency | — | Growth hormone/hormone replacement |
| 513 | Klinefelter syndrome | XXY | — | Chromosomal | Hypogonadism, infertility | — | Testosterone/support |
| 514 | Rett syndrome | MECP2 mutation | — | Genetic | Developmental regression | — | Supportive |
| 515 | Prader-Willi syndrome | Chromosome 15 imprinting disorder | — | Genetic | Hyperphagia, developmental problems | Nutritional supervision | Hormonal/nutritional management |
| 516 | Angelman syndrome | UBE3A-related disorder | — | Genetic | Developmental delay, seizures | — | Supportive |
| 517 | Noonan syndrome | RAS/MAPK pathway mutations | — | Genetic | Short stature, heart defects | Genetic counseling | Cardiac/endocrine management |
| 518 | Rett syndrome | MECP2 | — | Genetic | Regression, seizures | — | Supportive |
| 519 | Williams syndrome | 7q11.23 deletion | — | Genetic | Characteristic features, heart disease | Genetic counseling | Cardiac/developmental management |
| 520 | DiGeorge syndrome | 22q11.2 deletion | — | Genetic | Immune, heart, calcium abnormalities | Genetic testing | Immune/cardiac/endocrine treatment |
| 521 | Common variable immunodeficiency | Immune deficiency | — | Genetic/immune | Recurrent infections | Infection prevention | Immunoglobulin replacement |
| 522 | Severe combined immunodeficiency | Multiple genetic defects | — | Genetic | Severe recurrent infections | Newborn screening | Stem-cell transplant/gene therapy |
| 523 | Chronic granulomatous disease | Phagocyte dysfunction | — | Genetic | Recurrent bacterial/fungal infections | Infection prophylaxis | Antimicrobials ± stem-cell transplant |
| 524 | Wiskott-Aldrich syndrome | WAS mutation | — | X-linked | Infections, eczema, bleeding | Genetic counseling | Stem-cell transplant/support |
| 525 | Selective IgA deficiency | Low IgA | — | Immune/genetic | Recurrent respiratory/GI infections | Infection precautions | Treat infections |
| 526 | Hereditary angioedema | C1 inhibitor disorder | — | Genetic | Recurrent swelling | Trigger planning | Targeted acute/preventive therapy |
| 527 | Ataxia-telangiectasia | ATM mutation | — | Genetic | Ataxia, telangiectasia, immune deficiency | Genetic counseling | Supportive |
| 528 | Diabetic nephropathy | Diabetes-related kidney damage | — | Chronic diabetes | Proteinuria, kidney decline | Glucose/BP control | Kidney-protective therapy |
| 529 | Diabetic neuropathy | Diabetes-related nerve damage | — | Chronic diabetes | Numbness, pain | Glucose control/foot care | Pain medicines/risk management |
| 530 | Diabetic foot disease | Diabetes + neuropathy/vascular disease | — | Complication | Ulcers, infection | Foot care | Wound care, antibiotics/surgery when needed |
| 531 | Hyperlipidemia | High blood lipids | — | Genetic/diet/metabolic | Usually asymptomatic | Diet/exercise | Lipid-lowering medicines |
| 532 | Familial hypercholesterolemia | LDL-receptor pathway mutations | — | Genetic | Very high LDL, premature cardiovascular disease | Family screening | Statins/other lipid therapy |
| 533 | Metabolic syndrome | Central obesity, insulin resistance, etc. | — | Metabolic | High BP, high glucose/lipids | Exercise/healthy diet | Risk-factor treatment |
| 534 | Hyperuricemia | High uric acid | — | Metabolic/genetic | Often asymptomatic; gout risk | Diet/weight management | Urate-lowering treatment when indicated |
| 535 | Hypoglycemia | Low blood glucose | — | Diabetes drugs, endocrine disease, fasting | Sweating, confusion, weakness | Medication/meal planning | Glucose |
| 536 | Hypercalcemia | High blood calcium | — | Cancer, parathyroid, drugs | Weakness, stones, confusion | Cause-specific | Fluids/cause-specific therapy |
| 537 | Hyponatremia | Low blood sodium | — | Medications, fluid disorders, disease | Confusion, seizures | Cause management | Controlled sodium/fluid treatment |
| 538 | Hyperkalemia | High blood potassium | — | Kidney disease/drugs | Weakness, dangerous arrhythmia | Kidney/drug monitoring | Emergency potassium-lowering treatment |
| 539 | Hypokalemia | Low potassium | — | Diuretics/GI losses | Weakness, arrhythmia | Electrolyte management | Potassium replacement |
| 540 | Metabolic acidosis | Excess acid/low bicarbonate | — | Kidney failure, diabetes, toxins | Rapid breathing, confusion | Treat causes | Cause-specific emergency treatment |
| 541 | Respiratory failure | Inadequate gas exchange | — | Lung/heart/neurological causes | Severe breathlessness, low oxygen | Treat underlying disease | Oxygen/ventilation |
| 542 | Acute respiratory distress syndrome | Severe inflammatory lung injury | — | Infection, trauma, sepsis etc. | Severe breathing failure | Prevent/treat causes | ICU ventilation/support |
| 543 | Pleural effusion | Fluid around lungs | — | Heart/liver/cancer/infection etc. | Breathlessness, chest pain | Treat underlying cause | Drainage/cause treatment |
| 544 | Pneumothorax | Collapsed lung | — | Trauma/spontaneous/lung disease | Sudden chest pain, breathlessness | Avoid smoking/trauma risks | Observation, aspiration/chest tube |
| 545 | Empyema | Pus in pleural space | — | Bacterial infection | Fever, chest pain, breathlessness | Treat pneumonia | Antibiotics + drainage |
| 546 | Tuberculosis meningitis | M. tuberculosis | — | Spread from TB infection | Headache, fever, neurological signs | TB control | Prolonged anti-TB therapy + steroids |
| 547 | Tuberculous pleuritis | M. tuberculosis | — | Airborne TB infection | Chest pain, fever, fluid | TB prevention | Anti-TB therapy |
| 548 | Tuberculous lymphadenitis | M. tuberculosis | — | TB infection | Enlarged lymph nodes | TB control | Anti-TB therapy |
| 549 | Extrapulmonary tuberculosis | M. tuberculosis | — | Airborne infection followed by spread | Organ-specific symptoms | TB prevention | Multi-drug therapy |
| 550 | Drug-resistant tuberculosis | Drug-resistant M. tuberculosis | — | Airborne | Persistent TB symptoms | Adherence/infection control | Specialized multidrug regimen |
| 551 | Multidrug-resistant TB | Resistant TB bacteria | — | Airborne | TB symptoms | Infection control/adherence | Second-line regimen |
| 552 | Extensively drug-resistant TB | Highly resistant TB | — | Airborne | TB symptoms | Infection control | Specialized regimen |
| 553 | Non-tuberculous mycobacterial disease | NTM bacteria | — | Environmental exposure | Lung/skin disease | Risk reduction | Prolonged combination antibiotics |
| 554 | MAC infection | Mycobacterium avium complex | — | Environmental | Lung/systemic disease | Risk reduction | Combination antimicrobials |
| 555 | Leprosy reaction | Immune reaction in leprosy | — | Complication | Nerve pain/inflammation | Early leprosy treatment | Steroids/immune therapy |
| 556 | Pott disease | Spinal tuberculosis | — | TB spread | Back pain, neurological deficits | TB control | Anti-TB therapy ± surgery |
| 557 | Miliary tuberculosis | Disseminated TB | — | Bloodstream spread of TB | Fever, weight loss, multi-organ disease | TB prevention | Multi-drug TB therapy |
| 558 | Tuberculous pericarditis | TB infection | — | Spread of TB | Chest pain, fluid, heart failure | TB control | Anti-TB therapy + steroids in selected cases |
| 559 | Tuberculous osteomyelitis | TB bacteria | — | Bloodstream/contiguous spread | Bone pain/swelling | TB control | Anti-TB therapy |
| 560 | Tuberculous abdominal disease | TB bacteria | — | Spread of TB | Abdominal pain, weight loss | TB control | Anti-TB therapy |
| 561 | Infective endocarditis | Bacteria/fungi | — | Bloodstream infection | Fever, murmur, emboli | Dental/medical precautions | IV antimicrobials ± surgery |
| 562 | Prosthetic-valve endocarditis | Bacteria/fungi | — | Bloodstream infection | Fever, valve dysfunction | Infection prevention | Prolonged antimicrobials ± surgery |
| 563 | Myocarditis | Viral/immune/toxic causes | — | Infection or immune reaction | Chest pain, arrhythmia, heart failure | Infection prevention | Supportive/cause-specific |
| 564 | Dilated cardiomyopathy | Genetic/toxic/infectious causes | — | Noninfectious | Heart failure | Avoid cardiotoxins | Heart-failure therapy |
| 565 | Hypertrophic cardiomyopathy | Sarcomere mutations | — | Genetic | Breathlessness, chest pain, arrhythmia | Family screening | Medicines/procedures |
| 566 | Restrictive cardiomyopathy | Infiltrative/storage disease | — | Multiple | Heart failure | Treat underlying disease | Cause-specific |
| 567 | Congenital heart disease | Developmental/genetic factors | — | Congenital | Murmur, cyanosis, heart failure | Prenatal care | Medicines/catheter/surgery |
| 568 | Atrial septal defect | Congenital heart defect | — | Congenital | Often asymptomatic, murmur | — | Observation/device/surgery |
| 569 | Ventricular septal defect | Congenital heart defect | — | Congenital | Murmur, heart failure if large | — | Observation/closure |
| 570 | Tetralogy of Fallot | Congenital heart defect | — | Congenital | Cyanosis, breathlessness | — | Surgical repair |
| 571 | Coarctation of aorta | Congenital narrowing | — | Congenital | High BP, weak legs | — | Surgery/catheter intervention |
| 572 | Rheumatic mitral stenosis | Rheumatic heart disease | — | Post-strep immune damage | Breathlessness, fatigue | Strep prevention | Medicines/valve intervention |
| 573 | Mitral valve prolapse | Valve structural abnormality | — | Genetic/degenerative | Palpitations, often none | — | Observation/medicines/surgery |
| 574 | Aortic stenosis | Valve calcification/congenital/rheumatic | — | Degenerative/congenital | Chest pain, fainting, breathlessness | Cardiovascular risk control | Valve replacement/intervention |
| 575 | Aortic regurgitation | Aortic valve leakage | — | Degenerative/infectious/congenital | Breathlessness, palpitations | Cause-specific | Monitoring/surgery |
| 576 | Mitral regurgitation | Mitral valve leakage | — | Degenerative/ischemic/rheumatic | Breathlessness | Cause-specific | Medicines/surgery |
| 577 | Deep vein thrombosis | Venous clot | — | Immobility/cancer/hormones | Leg swelling/pain | Mobility/anticoagulation prevention | Anticoagulants |
| 578 | Pulmonary embolism | Clot in pulmonary artery | — | Usually DVT | Breathlessness/chest pain | DVT prevention | Anticoagulation/emergency therapy |
| 579 | Chronic venous insufficiency | Venous valve dysfunction | — | Venous disease | Leg swelling/skin changes | Exercise/compression | Compression/wound care/procedures |
| 580 | Lymphedema | Lymphatic dysfunction | — | Congenital/cancer/surgery/infection | Limb swelling | Skin care/compression | Compression/physical therapy |
| 581 | Varicose veins | Venous valve failure | — | Chronic venous disease | Enlarged superficial veins | Exercise/compression | Procedures if symptomatic |
| 582 | Raynaud phenomenon | Abnormal vascular response | — | Cold/stress/autoimmune | Fingers change color, pain | Keep warm | Trigger avoidance/vasodilators |
| 583 | Buerger disease | Tobacco-associated vascular inflammation | — | Smoking | Limb pain/ischemia | Stop tobacco | Smoking cessation/supportive/vascular care |
| 584 | Atherosclerosis | Arterial plaque | — | Lipid/inflammatory disease | Depends on affected artery | No smoking, lipid/BP control | Statins/risk reduction/intervention |
| 585 | Abdominal aortic aneurysm | Aortic wall degeneration | — | Age/smoking/genetics | Often silent; rupture severe | Smoking cessation/screening in selected groups | Monitoring/surgery |
| 586 | Subarachnoid hemorrhage | Ruptured cerebral aneurysm/other vessel | — | Noninfectious | Sudden severe headache | BP/smoking control | Emergency neurosurgery/intervention |
| 587 | Intracerebral hemorrhage | Brain vessel rupture | — | Hypertension/vascular disorders | Sudden neurological deficits | BP control | Emergency stroke care |
| 588 | Transient ischemic attack | Temporary brain ischemia | — | Vascular disease | Temporary stroke-like symptoms | Vascular risk reduction | Urgent stroke prevention |
| 589 | Cerebral aneurysm | Weak cerebral artery wall | — | Genetic/acquired | Often silent; rupture causes hemorrhage | BP/smoking control | Monitoring/coiling/clipping |
| 590 | Multiple sclerosis | Immune CNS demyelination | — | Autoimmune/multifactorial | Vision, sensory/motor problems | — | Disease-modifying therapy |
| 591 | Neuromyelitis optica | AQP4/MOG-associated immune disease | — | Autoimmune | Optic neuritis, spinal cord attacks | — | Immunotherapy |
| 592 | Transverse myelitis | Spinal cord inflammation | — | Immune/infectious | Weakness, sensory/bladder problems | — | Steroids/plasma exchange |
| 593 | Optic neuritis | Optic nerve inflammation | — | Immune/infectious | Painful vision loss | — | Cause-specific/steroids |
| 594 | Peripheral neuropathy | Nerve damage | — | Diabetes, toxins, deficiency etc. | Numbness, pain, weakness | Control causes | Cause treatment/pain management |
| 595 | Carpal tunnel syndrome | Median nerve compression | — | Repetitive/structural factors | Hand numbness/weakness | Ergonomics | Splint/injection/surgery |
| 596 | Sciatica | Nerve-root compression | — | Disc degeneration/herniation | Radiating leg pain | Exercise/ergonomics | Conservative care; surgery selected |
| 597 | Parkinsonism | Multiple causes | — | Neurodegenerative/drug/vascular | Slowness, rigidity, tremor | Cause-specific | Levodopa/cause-specific therapy |
| 598 | Essential tremor | Neurological movement disorder | — | Often genetic | Action/postural tremor | — | Medicines/deep brain stimulation selected |
| 599 | Dystonia | Abnormal muscle contractions | — | Genetic/neurological | Sustained twisting movements | — | Botulinum toxin/medicines |
| 600 | Restless legs syndrome | Neurological disorder | — | Genetic/iron deficiency/other | Urge to move legs, evening discomfort | Correct iron deficiency | Iron or neurological medicines |
| # | Disease | Cause / Organism | Vector | Transmission / Origin | Main symptoms | Prevention | Treatment |
| 601 | Common cold | Rhinoviruses, other viruses | — | Respiratory droplets/contact | Runny nose, cough | Hand hygiene | Rest, fluids |
| 602 | Influenza | Influenza viruses | — | Respiratory droplets/aerosols | Fever, cough, body aches | Flu vaccine | Antivirals/supportive care |
| 603 | COVID-19 | SARS-CoV-2 | — | Respiratory aerosols/droplets | Fever, cough, fatigue | Vaccination, ventilation | Supportive/antiviral treatment |
| 604 | Respiratory syncytial virus infection | RSV | — | Respiratory secretions | Cough, wheezing | Immunization for eligible groups | Supportive care |
| 605 | Human metapneumovirus infection | hMPV | — | Respiratory secretions | Cough, fever, wheezing | Hygiene | Supportive care |
| 606 | Parainfluenza infection | Parainfluenza viruses | — | Respiratory droplets | Croup, cough | Hygiene | Supportive care |
| 607 | Croup | Parainfluenza and other viruses | — | Respiratory | Barking cough, stridor | Hygiene | Steroids; emergency airway care if severe |
| 608 | Bronchiolitis | Usually RSV | — | Respiratory | Wheezing, rapid breathing | Hygiene/immunization | Supportive care |
| 609 | Whooping cough | Bordetella pertussis | — | Respiratory droplets | Severe coughing fits | Vaccination | Antibiotics/support |
| 610 | Diphtheria | Corynebacterium diphtheriae | — | Respiratory/contact | Sore throat, membrane, toxicity | Vaccination | Antitoxin + antibiotics |
| 611 | Scarlet fever | Group A Streptococcus | — | Respiratory/contact | Fever, sore throat, rash | Hygiene | Antibiotics |
| 612 | Strep throat | Group A Streptococcus | — | Respiratory droplets | Sore throat, fever | Hygiene | Antibiotics when confirmed |
| 613 | Epiglottitis | Usually bacterial, including H. influenzae | — | Respiratory | Airway obstruction, drooling | Vaccination | Emergency airway + antibiotics |
| 614 | Legionnaires’ disease | Legionella | — | Inhalation of contaminated water aerosols | Pneumonia, fever | Water-system control | Antibiotics |
| 615 | Pontiac fever | Legionella | — | Contaminated water aerosols | Fever, flu-like illness | Water-system control | Usually supportive |
| 616 | Mycoplasma pneumonia | Mycoplasma pneumoniae | — | Respiratory droplets | Dry cough, fever | Hygiene | Antibiotics when indicated |
| 617 | Chlamydial pneumonia | Chlamydia pneumoniae | — | Respiratory droplets | Cough, fever | Hygiene | Antibiotics |
| 618 | Psittacosis | Chlamydia psittaci | — | Bird droppings/secretions | Fever, pneumonia | Bird-exposure precautions | Antibiotics |
| 619 | Q fever | Coxiella burnetii | — | Livestock aerosols/products | Fever, hepatitis/pneumonia | Occupational precautions | Antibiotics |
| 620 | Hantavirus pulmonary syndrome | Hantaviruses | — | Rodent urine/droppings aerosols | Fever, severe respiratory failure | Rodent control | Intensive supportive care |
| 621 | Hantavirus hemorrhagic fever with renal syndrome | Hantaviruses | — | Rodent exposure | Fever, kidney failure, bleeding | Rodent control | Supportive care |
| 622 | Avian influenza | Influenza A viruses | — | Infected birds/animals; some human transmission | Fever, respiratory disease | Avoid infected animals | Antivirals/support |
| 623 | Swine influenza | Influenza A viruses | — | Respiratory; pigs/humans | Flu symptoms | Hygiene/vaccination | Antivirals/support |
| 624 | Middle East respiratory syndrome | MERS-CoV | — | Camel exposure/person-to-person | Severe respiratory disease | Infection control | Supportive |
| 625 | SARS | SARS-CoV | — | Respiratory | Severe pneumonia | Infection control | Supportive |
| 626 | Adenovirus infection | Adenoviruses | — | Respiratory/contact/fecal-oral | Fever, conjunctivitis, diarrhea | Hygiene | Supportive |
| 627 | Rhinovirus infection | Rhinoviruses | — | Respiratory/contact | Cold symptoms | Hand hygiene | Supportive |
| 628 | Enterovirus infection | Enteroviruses | — | Fecal-oral/respiratory | Fever, rash, neurological disease | Hygiene | Supportive |
| 629 | Hand-foot-and-mouth disease | Enteroviruses | — | Fecal-oral/contact | Mouth ulcers, hand/foot rash | Hygiene | Supportive |
| 630 | Herpangina | Enteroviruses | — | Fecal-oral/respiratory | Fever, throat blisters | Hygiene | Supportive |
| 631 | Poliomyelitis | Poliovirus | — | Fecal-oral | Paralysis, meningitis | Vaccination | Supportive/rehabilitation |
| 632 | Viral meningitis | Enteroviruses and others | — | Depends on virus | Headache, fever, neck stiffness | Vaccination/hygiene | Supportive/cause-specific |
| 633 | Viral encephalitis | Several viruses | Sometimes mosquitoes/ticks | Vector or other routes | Fever, seizures, confusion | Vaccination/vector control | Antivirals when available/support |
| 634 | Herpes simplex encephalitis | HSV-1/HSV-2 | — | Herpesvirus infection/reactivation | Fever, seizures, altered behavior | Safer sex; hygiene | IV acyclovir |
| 635 | Varicella | Varicella-zoster virus | — | Airborne/droplets/contact | Itchy vesicular rash | Vaccination | Supportive/antiviral |
| 636 | Herpes zoster | Varicella-zoster virus | — | Reactivation of latent virus | Painful unilateral rash | Shingles vaccine | Antivirals/pain treatment |
| 637 | Infectious mononucleosis | Epstein-Barr virus | — | Saliva | Fever, sore throat, lymph nodes | Avoid saliva sharing | Supportive |
| 638 | Cytomegalovirus infection | CMV | — | Body fluids/congenital/blood | Often mild; congenital disease | Hygiene | Usually supportive; antivirals in severe cases |
| 639 | Roseola | HHV-6/HHV-7 | — | Respiratory/saliva | High fever followed by rash | Hygiene | Supportive |
| 640 | Molluscum contagiosum | Molluscum contagiosum virus | — | Skin contact | Small umbilicated bumps | Avoid direct contact | Often resolves; removal if needed |
| 641 | Warts | Human papillomaviruses | — | Skin contact | Rough skin growths | HPV prevention/hygiene | Cryotherapy/topical therapy |
| 642 | Genital warts | Low-risk HPV | — | Sexual contact | Genital growths | HPV vaccination/condoms | Topical or procedural treatment |
| 643 | Herpes genitalis | HSV-1/HSV-2 | — | Sexual/skin contact | Painful blisters/ulcers | Condoms, testing | Antivirals |
| 644 | Herpes labialis | HSV-1 | — | Oral/skin contact | Cold sores | Avoid contact during outbreaks | Antivirals |
| 645 | Mpox | Monkeypox virus | — | Close contact/animal exposure | Fever, lymph nodes, lesions | Vaccination for eligible risk groups | Supportive; antivirals in selected cases |
| 646 | Measles | Measles virus | — | Airborne | Fever, cough, rash | MMR vaccine | Supportive, vitamin A in children where indicated |
| 647 | Mumps | Mumps virus | — | Respiratory droplets | Parotid swelling, fever | MMR vaccine | Supportive |
| 648 | Rubella | Rubella virus | — | Respiratory droplets | Mild fever, rash | MMR vaccine | Supportive |
| 649 | Rotavirus gastroenteritis | Rotavirus | — | Fecal-oral | Severe diarrhea/vomiting | Vaccination, hygiene | Rehydration |
| 650 | Norovirus gastroenteritis | Norovirus | — | Fecal-oral/food/contact | Vomiting, diarrhea | Hand hygiene/food safety | Rehydration |
| 651 | Hepatitis A | HAV | — | Fecal-oral | Jaundice, fatigue | Vaccine, sanitation | Supportive |
| 652 | Hepatitis B | HBV | — | Blood/sex/perinatal | Hepatitis, chronic liver disease | Vaccine, safe blood/sex | Antivirals for chronic disease |
| 653 | Hepatitis C | HCV | — | Blood exposure | Often silent; liver disease | Blood safety, avoid needle sharing | Direct-acting antivirals |
| 654 | Hepatitis D | HDV | — | Blood/body fluids; requires HBV | Severe hepatitis | Hepatitis B vaccination | Antiviral/specialist care |
| 655 | Hepatitis E | HEV | — | Fecal-oral, contaminated food/water | Acute hepatitis | Safe water/food | Supportive |
| 656 | HIV infection | Human immunodeficiency virus | — | Sexual, blood, perinatal | Immune deficiency if untreated | PrEP, condoms, safe blood | Combination antiretroviral therapy |
| 657 | AIDS | Advanced HIV infection | — | HIV infection | Opportunistic infections, cancers | HIV prevention/testing | ART + opportunistic infection treatment |
| 658 | Dengue | Dengue virus | Aedes mosquito | Mosquito bite | Fever, severe aches, bleeding in severe disease | Mosquito control | Fluids/supportive; avoid certain NSAIDs |
| 659 | Chikungunya | Chikungunya virus | Aedes mosquito | Mosquito bite | Fever, severe joint pain | Mosquito control | Supportive/pain treatment |
| 660 | Zika disease | Zika virus | Aedes mosquito | Mosquito, sexual, congenital | Fever, rash, joint pain | Mosquito/sexual precautions | Supportive |
| 661 | Yellow fever | Yellow fever virus | Aedes/Haemagogus mosquitoes | Mosquito bite | Fever, jaundice, bleeding | Vaccination/vector control | Supportive |
| 662 | West Nile fever | West Nile virus | Culex mosquito | Mosquito bite | Fever; neurological disease in some | Mosquito control | Supportive |
| 663 | Japanese encephalitis | Japanese encephalitis virus | Culex mosquitoes | Mosquito bite | Encephalitis, seizures | Vaccination/vector control | Supportive |
| 664 | St. Louis encephalitis | St. Louis encephalitis virus | Culex mosquito | Mosquito bite | Fever, encephalitis | Mosquito control | Supportive |
| 665 | La Crosse encephalitis | La Crosse virus | Mosquitoes | Mosquito bite | Fever, seizures, encephalitis | Mosquito control | Supportive |
| 666 | Eastern equine encephalitis | EEE virus | Mosquitoes | Mosquito bite | Severe encephalitis | Mosquito control | Supportive |
| 667 | Western equine encephalitis | WEE virus | Mosquitoes | Mosquito bite | Encephalitis | Mosquito control | Supportive |
| 668 | Venezuelan equine encephalitis | VEE virus | Mosquitoes | Mosquito bite | Fever, encephalitis | Mosquito control | Supportive |
| 669 | Rift Valley fever | RVF virus | Mosquitoes | Mosquito/animal exposure | Fever, hepatitis, eye disease | Vector/animal control | Supportive |
| 670 | Crimean-Congo hemorrhagic fever | CCHF virus | Ticks | Tick/animal/blood exposure | Fever, bleeding | Tick avoidance/infection control | Supportive/specialist care |
| 671 | Oropouche fever | Oropouche virus | Biting midges/mosquitoes | Vector bite | Fever, headache, muscle pain | Vector control | Supportive |
| 672 | Mayaro fever | Mayaro virus | Mosquitoes | Mosquito bite | Fever, joint pain | Vector control | Supportive |
| 673 | Chagas disease | Trypanosoma cruzi | Triatomine bug | Bug feces, food, congenital/blood | Fever; later heart/GI disease | Housing/vector control | Benznidazole/nifurtimox |
| 674 | African trypanosomiasis | Trypanosoma brucei | Tsetse fly | Fly bite | Fever, sleep disturbance, neurological disease | Tsetse control | Stage-specific medicines |
| 675 | Leishmaniasis | Leishmania spp. | Sandfly | Sandfly bite | Skin ulcers or visceral disease | Sandfly control | Species/form-specific treatment |
| 676 | Malaria | Plasmodium spp. | Anopheles mosquito | Mosquito bite | Fever, chills, anemia | Nets, repellents, preventive medicines | Antimalarial drugs |
| 677 | Babesiosis | Babesia spp. | Ticks | Tick bite/blood | Fever, hemolytic anemia | Tick avoidance | Antimicrobials |
| 678 | Lyme disease | Borrelia spp. | Ixodes tick | Tick bite | Rash, fever, joint/neurological disease | Tick avoidance | Antibiotics |
| 679 | Rocky Mountain spotted fever | Rickettsia rickettsii | Ticks | Tick bite | Fever, rash, headache | Tick avoidance | Doxycycline |
| 680 | Scrub typhus | Orientia tsutsugamushi | Chiggers | Mite bite | Fever, rash, eschar | Mite avoidance | Doxycycline/appropriate antibiotic |
| 681 | Epidemic typhus | Rickettsia prowazekii | Body louse | Louse feces | Fever, headache, rash | Louse control | Doxycycline |
| 682 | Murine typhus | Rickettsia typhi | Fleas | Flea exposure | Fever, headache | Flea/rodent control | Doxycycline |
| 683 | Trench fever | Bartonella quintana | Body louse | Louse exposure | Recurrent fever, bone pain | Louse control | Antibiotics |
| 684 | Cat-scratch disease | Bartonella henselae | Fleas | Cat scratch/bite | Lymph-node swelling | Flea control, wound care | Usually supportive; antibiotics selected cases |
| 685 | Tularemia | Francisella tularensis | Ticks/other routes | Tick, animal, aerosol | Fever, ulcers, lymph nodes | Tick/animal precautions | Antibiotics |
| 686 | Brucellosis | Brucella spp. | — | Unpasteurized dairy/animals | Fever, sweats, joint pain | Pasteurization/animal control | Combination antibiotics |
| 687 | Anthrax | Bacillus anthracis | — | Animal products/spores | Skin, lung or GI disease | Occupational protection/vaccine for selected groups | Antibiotics ± antitoxin |
| 688 | Plague | Yersinia pestis | Fleas | Flea/animal; respiratory in pneumonic form | Fever, lymph nodes, pneumonia | Flea/rodent control | Antibiotics |
| 689 | Leptospirosis | Leptospira | — | Animal urine/water/soil | Fever, muscle pain, jaundice | Avoid contaminated water | Antibiotics/support |
| 690 | Tetanus | Clostridium tetani | — | Spores enter wounds | Muscle rigidity/spasms | Vaccination/wound care | Antitoxin + antibiotics/support |
| 691 | Botulism | Clostridium botulinum toxin | — | Food/wound/infant intestinal colonization | Flaccid paralysis | Food safety | Antitoxin/supportive ventilation |
| 692 | Gas gangrene | Clostridium spp. | — | Contaminated wound | Severe tissue destruction | Wound care | Surgery + antibiotics |
| 693 | Foodborne salmonellosis | Salmonella | — | Contaminated food/water | Diarrhea, fever | Food hygiene | Fluids; antibiotics selected cases |
| 694 | Shigellosis | Shigella | — | Fecal-oral | Bloody diarrhea, fever | Sanitation | Fluids ± antibiotics |
| 695 | Campylobacteriosis | Campylobacter | — | Undercooked poultry/contaminated food | Diarrhea, abdominal pain | Food safety | Supportive ± antibiotics |
| 696 | Cholera | Vibrio cholerae | — | Contaminated water/food | Profuse watery diarrhea | Safe water/sanitation | Immediate rehydration + antibiotics in selected cases |
| 697 | Yersiniosis | Yersinia enterocolitica | — | Contaminated food | Diarrhea, abdominal pain | Food safety | Supportive/antibiotics selected cases |
| 698 | Listeriosis | Listeria monocytogenes | — | Contaminated food | Fever, meningitis, pregnancy complications | Food safety | Antibiotics |
| 699 | E. coli diarrheal disease | Diarrheagenic E. coli | — | Contaminated food/water | Diarrhea | Food/water hygiene | Rehydration; type-specific treatment |
| 700 | Hemolytic uremic syndrome | Shiga-toxin-producing bacteria | — | Often contaminated food | Bloody diarrhea, kidney injury | Food safety | Supportive care |
| # | Disease | Cause / Organism | Vector | Transmission / Origin | Main symptoms | Prevention | Treatment |
| 701 | Typhoid fever | Salmonella Typhi | — | Fecal-oral | Prolonged fever, abdominal symptoms | Vaccine/sanitation | Antibiotics |
| 702 | Paratyphoid fever | Salmonella Paratyphi | — | Fecal-oral | Fever, abdominal symptoms | Food/water hygiene | Antibiotics |
| 703 | Amoebiasis | Entamoeba histolytica | — | Fecal-oral | Dysentery, liver abscess | Sanitation | Metronidazole + luminal agent |
| 704 | Giardiasis | Giardia duodenalis | — | Fecal-oral/water | Foul diarrhea, bloating | Safe water | Antiprotozoal therapy |
| 705 | Cryptosporidiosis | Cryptosporidium | — | Fecal-oral/water | Watery diarrhea | Safe water | Rehydration; immune restoration |
| 706 | Cyclosporiasis | Cyclospora cayetanensis | — | Contaminated food/water | Prolonged watery diarrhea | Food/water hygiene | TMP-SMX |
| 707 | Cystoisosporiasis | Cystoisospora belli | — | Fecal-oral | Watery diarrhea | Sanitation | TMP-SMX |
| 708 | Balantidiasis | Balantidium coli | — | Fecal-oral | Diarrhea/dysentery | Sanitation | Tetracycline/metronidazole |
| 709 | Toxoplasmosis | Toxoplasma gondii | — | Undercooked meat/cat feces/congenital | Often mild; fetal/brain disease | Food/cat precautions | Pyrimethamine-based therapy in selected cases |
| 710 | Trichomoniasis | Trichomonas vaginalis | — | Sexual contact | Genital discharge/irritation | Condoms/testing | Metronidazole/tinidazole |
| 711 | Cryptococcosis | Cryptococcus spp. | — | Environmental inhalation | Lung/meningitis disease | — | Antifungal therapy |
| 712 | Histoplasmosis | Histoplasma | — | Inhaled environmental spores | Lung/systemic disease | Avoid heavy exposure | Antifungals |
| 713 | Blastomycosis | Blastomyces | — | Inhaled spores | Lung/skin/bone disease | Exposure precautions | Antifungals |
| 714 | Coccidioidomycosis | Coccidioides | — | Inhaled desert soil spores | Pneumonia, disseminated disease | Dust avoidance | Antifungals when indicated |
| 715 | Sporotrichosis | Sporothrix | — | Skin inoculation/plant exposure | Nodular skin/lymphatic lesions | Gloves/plant precautions | Itraconazole |
| 716 | Aspergillosis | Aspergillus | — | Inhaled spores | Allergy, lung disease, invasive infection | Avoid high-risk exposures | Antifungals |
| 717 | Mucormycosis | Mucorales fungi | — | Inhaled/inoculated spores | Severe sinus/lung/skin disease | Diabetes control | Urgent antifungal + surgery |
| 718 | Candidiasis | Candida spp. | — | Overgrowth/opportunistic infection | Oral, genital or systemic disease | Risk-factor control | Antifungals |
| 719 | Pneumocystis pneumonia | Pneumocystis jirovecii | — | Opportunistic/reactivation | Breathlessness, dry cough | HIV prophylaxis where indicated | TMP-SMX |
| 720 | Talaromycosis | Talaromyces marneffei | — | Environmental exposure | Disseminated disease | HIV care | Antifungals |
| 721 | Chromoblastomycosis | Dematiaceous fungi | — | Traumatic skin implantation | Chronic verrucous lesions | Protective footwear | Antifungals/surgery |
| 722 | Mycetoma | Bacteria or fungi | — | Traumatic implantation | Swelling, draining sinuses | Foot protection | Long-term antimicrobial/surgical therapy |
| 723 | Onychomycosis | Dermatophytes/yeasts | — | Direct contact/environment | Thick discolored nails | Foot hygiene | Topical/oral antifungals |
| 724 | Tinea corporis | Dermatophytes | — | Skin contact/animals | Ring-shaped rash | Hygiene | Topical antifungal |
| 725 | Tinea capitis | Dermatophytes | — | Contact | Scalp scaling/hair loss | Avoid sharing combs | Oral antifungal |
| 726 | Tinea pedis | Dermatophytes | — | Moist surfaces/contact | Athlete’s foot | Dry feet/footwear hygiene | Antifungal |
| 727 | Tinea cruris | Dermatophytes | — | Contact/moisture | Groin rash | Keep area dry | Antifungal |
| 728 | Scabies | Sarcoptes scabiei | — | Prolonged skin contact | Severe itching, burrows | Treat close contacts | Permethrin/ivermectin |
| 729 | Pediculosis capitis | Head louse | — | Head-to-head contact | Scalp itching | Avoid sharing personal items | Permethrin/other pediculicides |
| 730 | Pediculosis corporis | Body louse | — | Clothing/body contact | Itching, rash | Hygiene/laundering | Delousing |
| 731 | Pubic lice | Pthirus pubis | — | Sexual/close contact | Genital itching | Treat partners | Pediculicide |
| 732 | Trachoma | Chlamydia trachomatis | Mechanical flies possible | Eye contact/fomites | Chronic conjunctivitis/scarring | Facial cleanliness/sanitation | Antibiotics/surgery |
| 733 | Bacterial conjunctivitis | Various bacteria | — | Contact | Red eye, discharge | Hygiene | Antibiotic drops when indicated |
| 734 | Viral conjunctivitis | Adenovirus/other viruses | — | Contact | Red watery eyes | Hand hygiene | Supportive |
| 735 | Keratitis | Bacteria/fungi/viruses/parasites | — | Eye injury/contact lenses | Eye pain, vision loss | Contact-lens hygiene | Cause-specific urgent therapy |
| 736 | Acanthamoeba keratitis | Acanthamoeba | — | Contaminated water/contact lenses | Severe eye pain | Proper lens hygiene | Prolonged antiamoebic treatment |
| 737 | Dacryocystitis | Bacterial infection | — | Tear-duct obstruction | Pain/swelling near eye | Treat obstruction | Antibiotics/drainage |
| 738 | Cellulitis | Bacteria | — | Skin breach | Red, warm, swollen skin | Wound care | Antibiotics |
| 739 | Erysipelas | Usually streptococci | — | Skin infection | Raised red painful plaque | Skin care | Antibiotics |
| 740 | Impetigo | S. aureus/S. pyogenes | — | Skin contact | Honey-colored crusts | Hygiene | Topical/oral antibiotics |
| 741 | Folliculitis | Bacteria/fungi/irritation | — | Follicular infection | Small pustules | Skin hygiene | Topical/systemic treatment |
| 742 | Furunculosis | Usually S. aureus | — | Skin contact/self-inoculation | Boils | Hygiene | Drainage ± antibiotics |
| 743 | Erysipeloid | Erysipelothrix rhusiopathiae | — | Animal/fish handling | Painful skin lesion | Gloves | Antibiotics |
| 744 | Pitted keratolysis | Skin bacteria | — | Moist footwear | Foot odor/pits | Keep feet dry | Topical antimicrobials |
| 745 | Pinta | Treponema carateum | — | Skin contact | Pigmented skin lesions | Hygiene | Penicillin |
| 746 | Yaws | Treponema pallidum pertenue | — | Skin contact | Skin/bone lesions | Hygiene | Azithromycin/penicillin |
| 747 | Bejel | Treponema pallidum endemicum | — | Nonsexual close contact | Skin/bone disease | Hygiene | Penicillin |
| 748 | Syphilis | Treponema pallidum | — | Sexual/congenital | Ulcers, rash, neurological disease | Safer sex/testing | Penicillin |
| 749 | Gonorrhea | Neisseria gonorrhoeae | — | Sexual/perinatal | Discharge, pelvic/testicular infection | Condoms/testing | Ceftriaxone-based treatment |
| 750 | Chlamydia infection | Chlamydia trachomatis | — | Sexual/perinatal | Discharge, pelvic disease | Condoms/testing | Antibiotics |
| 751 | Lymphogranuloma venereum | Specific C. trachomatis strains | — | Sexual | Genital lesion, lymph nodes | Safer sex | Doxycycline |
| 752 | Chancroid | Haemophilus ducreyi | — | Sexual | Painful genital ulcers | Safer sex | Antibiotics |
| 753 | Donovanosis | Klebsiella granulomatis | — | Sexual/close contact | Painless genital ulcers | Safer sex | Antibiotics |
| 754 | Pelvic inflammatory disease | Usually ascending STI bacteria | — | Sexual infection | Pelvic pain, fever | STI prevention | Combination antibiotics |
| 755 | Epididymitis | STI or urinary bacteria | — | Sexual/urinary | Scrotal pain/swelling | STI prevention | Antibiotics |
| 756 | Orchitis | Viral/bacterial | — | Infection | Testicular swelling/pain | Vaccination | Cause-specific |
| 757 | Vaginitis | Candida, bacteria, protozoa | — | Microbiome imbalance/infection | Discharge/itching | Hygiene/safe sex | Cause-specific |
| 758 | Bacterial vaginosis | Vaginal bacterial imbalance | — | Non-classic STI association | Discharge/odor | Avoid douching | Metronidazole/clindamycin |
| 759 | Pelvic actinomycosis | Actinomyces | — | Usually endogenous; IUD association | Pelvic mass/inflammation | Appropriate IUD care | Long-term antibiotics |
| 760 | Congenital syphilis | Treponema pallidum | — | Mother-to-child | Rash, bone/organ disease | Prenatal screening/treatment | Penicillin |
| 761 | Congenital toxoplasmosis | Toxoplasma gondii | — | Mother-to-child | Eye/brain disease | Food/cat precautions | Pyrimethamine-based regimen |
| 762 | Congenital CMV | CMV | — | Mother-to-child | Hearing loss, developmental disease | Hygiene during pregnancy | Specialist antiviral therapy |
| 763 | Congenital rubella syndrome | Rubella virus | — | Mother-to-child | Deafness, heart/eye disease | MMR vaccination | Supportive |
| 764 | Neonatal herpes | HSV | — | During birth/close contact | Skin/brain/disseminated disease | Maternal management | IV acyclovir |
| 765 | Neonatal sepsis | Bacteria/fungi | — | Maternal or hospital/community exposure | Fever/low temperature, lethargy | Prenatal/neonatal infection prevention | Emergency antibiotics/support |
| 766 | Group B strep neonatal disease | Streptococcus agalactiae | — | Mother-to-child during birth | Sepsis/meningitis | Maternal screening/prophylaxis | Antibiotics |
| 767 | Necrotizing fasciitis | Aggressive bacteria | — | Wound/soft-tissue infection | Severe pain, tissue destruction | Wound care | Emergency surgery + antibiotics |
| 768 | Toxic shock syndrome | S. aureus/S. pyogenes toxins | — | Infection/toxin production | Fever, shock, rash | Wound/tampon safety | Antibiotics, source control, ICU |
| 769 | Rheumatic fever | Group A strep | — | Post-infectious | Fever, migratory arthritis | Strep treatment | Antibiotics/anti-inflammatory |
| 770 | Post-streptococcal glomerulonephritis | Group A strep | — | Immune complication | Blood/protein urine, swelling | Treat infections | Supportive |
| 771 | Kawasaki disease | Immune-mediated | — | Childhood inflammatory disease | Fever, rash, mucosal changes | — | IVIG |
| 772 | MIS-C | Post-SARS-CoV-2 inflammatory syndrome | — | Post-infectious | Fever, inflammation, organ involvement | Infection prevention | Hospital immunomodulatory care |
| 773 | MIS-A | Post-SARS-CoV-2 inflammatory syndrome | — | Post-infectious | Fever, organ dysfunction | Infection prevention | Hospital care |
| 774 | Reye syndrome | Associated with viral illness + aspirin in children | — | Drug/viral association | Brain/liver dysfunction | Avoid aspirin in children with viral illness | ICU supportive |
| 775 | Kawasaki coronary aneurysm | Kawasaki complication | — | Inflammatory complication | Coronary artery disease | Early treatment | Cardiac specialist care |
| 776 | Heatstroke | Extreme heat | — | Environmental | High temperature, confusion | Hydration/cooling | Emergency rapid cooling |
| 777 | Heat exhaustion | Heat exposure | — | Environmental | Sweating, weakness, dizziness | Cooling/hydration | Cooling/fluids |
| 778 | Hypothermia | Cold exposure | — | Environmental | Low temperature, confusion | Warm clothing | Rewarming |
| 779 | Frostbite | Freezing tissue injury | — | Cold exposure | Numb/pale frozen tissue | Cold protection | Controlled rewarming/specialist care |
| 780 | Decompression sickness | Nitrogen bubbles | — | Rapid pressure reduction | Joint pain, neurological symptoms | Proper diving procedures | Recompression + oxygen |
| 781 | Carbon monoxide poisoning | CO gas | — | Inhalation | Headache, confusion, unconsciousness | Ventilation/detectors | Fresh air + oxygen |
| 782 | Lead poisoning | Lead | — | Environmental/occupational ingestion/inhalation | Abdominal pain, anemia, neurological effects | Remove exposure | Chelation when indicated |
| 783 | Mercury poisoning | Mercury | — | Food/occupational/environmental | Neurological/kidney symptoms | Exposure control | Remove exposure ± chelation |
| 784 | Arsenic poisoning | Arsenic | — | Contaminated water/industry | GI, neurological, skin effects | Safe water | Chelation/supportive |
| 785 | Methanol poisoning | Methanol | — | Toxic ingestion | Visual impairment, acidosis | Safe chemical/food handling | Fomepizole ± dialysis |
| 786 | Ethylene glycol poisoning | Antifreeze chemical | — | Toxic ingestion | Acidosis, kidney failure | Secure storage | Fomepizole ± dialysis |
| 787 | Organophosphate poisoning | Pesticide chemicals | — | Inhalation/ingestion/skin | Salivation, sweating, breathing problems | PPE/safe handling | Atropine + pralidoxime |
| 788 | Cyanide poisoning | Cyanide compounds | — | Inhalation/ingestion | Rapid collapse, tissue hypoxia | Industrial safety | Specific antidotes/support |
| 789 | Acetaminophen poisoning | Drug overdose | — | Ingestion | Liver injury | Safe dosing | N-acetylcysteine |
| 790 | Salicylate poisoning | Aspirin overdose | — | Ingestion | Ringing ears, acidosis, rapid breathing | Safe dosing | Alkalinization/support |
| 791 | Radiation sickness | Ionizing radiation | — | High-dose radiation | Nausea, marrow failure, burns | Radiation protection | Supportive/specialist treatment |
| 792 | Silicosis | Silica dust | — | Occupational inhalation | Chronic cough, breathlessness | Respiratory PPE/exposure control | Supportive; TB screening |
| 793 | Asbestosis | Asbestos fibers | — | Occupational inhalation | Fibrosis, breathlessness | Exposure control | Supportive |
| 794 | Coal workers’ pneumoconiosis | Coal dust | — | Occupational inhalation | Lung fibrosis/cough | Dust control | Supportive |
| 795 | Byssinosis | Cotton/flax/hemp dust | — | Textile occupational exposure | Chest tightness, cough | Dust control | Exposure reduction/support |
| 796 | Occupational asthma | Workplace allergens/irritants | — | Inhalation at work | Wheeze/cough | Workplace exposure control | Asthma treatment |
| 797 | Asbestosis-related mesothelioma | Asbestos-associated cancer | — | Occupational/environmental exposure | Chest pain, breathlessness | Avoid asbestos | Cancer therapy |
| 798 | Silica-associated lung cancer | Carcinogenic silica exposure | — | Occupational | Cancer symptoms | Exposure control | Cancer-specific |
| 799 | Noise-induced hearing loss | Chronic loud noise | — | Occupational/environmental | Permanent hearing loss | Hearing protection | Hearing rehabilitation |
| 800 | Vibration white finger | Hand-arm vibration | — | Occupational vibration | Finger color changes/numbness | Reduce vibration exposure | Exposure reduction/vascular treatment |
| # | Disease | Cause / Organism | Vector | Transmission / Origin | Main symptoms | Prevention | Treatment |
| 801 | Pneumoconiosis | Mineral dust | — | Occupational inhalation | Cough, fibrosis | Dust control | Supportive |
| 802 | Hypersensitivity pneumonitis | Inhaled antigens | — | Environmental/occupational | Cough, breathlessness | Avoid antigen | Steroids when indicated |
| 803 | Farmer’s lung | Moldy hay antigens | — | Occupational inhalation | Fever, cough, breathlessness | Avoid dusty mold exposure | Antigen avoidance/steroids |
| 804 | Bird fancier’s lung | Bird proteins | — | Inhalation | Breathlessness/cough | Avoid exposure | Antigen avoidance/steroids |
| 805 | Asbestos pleural disease | Asbestos fibers | — | Inhalation | Pleural plaques/thickening | Exposure prevention | Monitoring/supportive |
| 806 | Occupational dermatitis | Workplace irritants/allergens | — | Skin exposure | Rash/itching | PPE/avoidance | Topical treatment |
| 807 | Occupational contact urticaria | Workplace allergens | — | Skin/inhalation | Hives | Exposure avoidance | Antihistamines |
| 808 | Farmer’s occupational asthma | Agricultural allergens | — | Inhalation | Wheezing | Exposure control | Asthma treatment |
| 809 | Chronic beryllium disease | Beryllium | — | Occupational inhalation | Lung inflammation/fibrosis | Exposure control | Corticosteroids |
| 810 | Hard-metal lung disease | Cobalt/tungsten compounds | — | Occupational | Lung inflammation | PPE | Exposure removal/steroids |
| 811 | Byssinosis | Textile dust | — | Occupational | Chest tightness | Dust control | Exposure reduction |
| 812 | Bagassosis | Sugarcane bagasse mold | — | Occupational inhalation | Hypersensitivity lung disease | Dust control | Exposure avoidance/steroids |
| 813 | Farmer’s lung | Thermophilic actinomycetes | — | Moldy agricultural material | Cough, fever | Dust control | Antigen avoidance |
| 814 | Monday fever | Organic dust exposure | — | Occupational | Fever/chills after work exposure | Workplace control | Exposure reduction |
| 815 | Minamata disease | Methylmercury | — | Contaminated seafood | Neurological disease | Pollution control | Supportive |
| 816 | Itai-itai disease | Cadmium | — | Contaminated food/water | Bone/kidney disease | Pollution control | Supportive/exposure removal |
| 817 | Fluorosis | Excess fluoride | — | Water/food exposure | Dental/bone changes | Safe fluoride levels | Exposure reduction |
| 818 | Iodine deficiency disorders | Iodine deficiency | — | Nutritional | Goiter, developmental problems | Iodized salt | Iodine |
| 819 | Vitamin A deficiency | Vitamin A deficiency | — | Nutritional | Night blindness, eye disease | Adequate diet | Vitamin A |
| 820 | Vitamin D deficiency | Vitamin D deficiency | — | Nutritional/sunlight | Bone weakness | Nutrition/sun exposure | Vitamin D |
| 821 | Vitamin K deficiency | Vitamin K deficiency | — | Nutritional/malabsorption | Bleeding | Adequate nutrition | Vitamin K |
| 822 | Protein-energy malnutrition | Nutritional deficiency | — | Inadequate food intake | Wasting/growth failure | Food security | Therapeutic nutrition |
| 823 | Beriberi | Thiamine deficiency | — | Nutritional | Neurological/cardiac disease | Balanced diet | Thiamine |
| 824 | Pellagra | Niacin deficiency | — | Nutritional | Dermatitis/diarrhea/cognitive changes | Balanced diet | Niacin |
| 825 | Scurvy | Vitamin C deficiency | — | Nutritional | Bleeding gums, poor healing | Fruit/vegetables | Vitamin C |
| 826 | Megaloblastic anemia | B12/folate deficiency | — | Nutritional/malabsorption | Fatigue, anemia | Balanced diet | B12/folate |
| 827 | Pernicious anemia | Autoimmune B12 malabsorption | — | Autoimmune | Anemia, neurological signs | Monitoring | B12 replacement |
| 828 | Aplastic anemia | Bone marrow failure | — | Immune/drugs/chemicals/genetic | Anemia, infection, bleeding | Avoid causative exposures | Immunosuppression/transplant |
| 829 | Hemolytic anemia | RBC destruction | — | Autoimmune/genetic/drug/infection | Jaundice, fatigue | Cause-specific | Cause-specific |
| 830 | Autoimmune hemolytic anemia | Autoantibodies against RBCs | — | Autoimmune | Anemia, jaundice | — | Steroids/immunotherapy |
| 831 | Thrombotic thrombocytopenic purpura | ADAMTS13 deficiency/inhibition | — | Autoimmune/genetic | Low platelets, anemia, neurological/renal disease | — | Plasma exchange + immunotherapy |
| 832 | Immune thrombocytopenic purpura | Autoimmune platelet destruction | — | Autoimmune | Bruising, bleeding | — | Steroids/IVIG/other |
| 833 | Disseminated intravascular coagulation | Systemic coagulation activation | — | Sepsis/trauma/cancer etc. | Bleeding/clotting | Treat cause | Treat underlying cause/support |
| 834 | Hemophilia A | Factor VIII deficiency | — | X-linked | Bleeding | Genetic counseling | Factor VIII/non-factor therapy |
| 835 | Hemophilia B | Factor IX deficiency | — | X-linked | Bleeding | Genetic counseling | Factor IX |
| 836 | Von Willebrand disease | VWF abnormality | — | Genetic | Mucosal bleeding | Avoid unnecessary bleeding risks | Desmopressin/factor therapy |
| 837 | Factor V Leiden thrombophilia | Factor V mutation | — | Genetic | Venous thrombosis | Risk management | Anticoagulation when indicated |
| 838 | Protein C deficiency | Natural anticoagulant deficiency | — | Genetic | Thrombosis | Risk management | Anticoagulation |
| 839 | Protein S deficiency | Natural anticoagulant deficiency | — | Genetic | Thrombosis | Risk management | Anticoagulation |
| 840 | Antithrombin deficiency | Natural anticoagulant deficiency | — | Genetic | Thrombosis | Risk management | Anticoagulation |
| 841 | Hereditary hemochromatosis | Iron-overload genes | — | Genetic | Liver/heart/endocrine disease | Family screening | Phlebotomy |
| 842 | Wilson disease | Copper accumulation | — | ATP7B mutation | Liver/neurological disease | Family screening | Chelation/zinc |
| 843 | Alpha-1 antitrypsin deficiency | SERPINA1 | — | Genetic | Lung/liver disease | No smoking | Supportive/augmentation selected cases |
| 844 | Familial Mediterranean fever | MEFV mutation | — | Genetic | Recurrent fever/serositis | Genetic counseling | Colchicine |
| 845 | Hereditary periodic fever syndromes | Various immune genes | — | Genetic | Recurrent fever/inflammation | Genetic counseling | Targeted anti-inflammatory therapy |
| 846 | Systemic amyloidosis | Amyloid protein deposition | — | Plasma-cell/genetic/inflammatory causes | Multiorgan disease | Treat underlying cause | Type-specific |
| 847 | AL amyloidosis | Immunoglobulin light chains | — | Plasma-cell disorder | Heart/kidney/nerve disease | — | Plasma-cell-directed therapy |
| 848 | ATTR amyloidosis | Transthyretin | — | Hereditary or age-related | Heart/nerve disease | Genetic counseling where appropriate | TTR-targeted therapy |
| 849 | Sarcoidosis | Granulomatous immune disease | — | Unknown | Lung/skin/eye disease | — | Steroids/immunosuppression |
| 850 | Eosinophilic granulomatosis with polyangiitis | Autoimmune vasculitis | — | Immune-mediated | Asthma, sinus/lung/nerve disease | — | Immunosuppression |
| 851 | IgG4-related disease | Immune-mediated fibroinflammation | — | Autoimmune-like | Organ enlargement/fibrosis | — | Corticosteroids/immunotherapy |
| 852 | Relapsing polychondritis | Autoimmune cartilage inflammation | — | Immune-mediated | Ear/nose/joint/airway inflammation | — | Immunosuppression |
| 853 | Adult-onset Still disease | Autoinflammatory disorder | — | Immune-mediated | Fever, rash, arthritis | — | NSAIDs/steroids/biologics |
| 854 | Familial Mediterranean fever | MEFV mutation | — | Genetic | Fever/serositis | Genetic counseling | Colchicine |
| 855 | Systemic juvenile idiopathic arthritis | Autoinflammatory | — | Immune-mediated | Fever, arthritis, rash | — | Biologic/immunosuppressive therapy |
| 856 | Juvenile idiopathic arthritis | Childhood autoimmune arthritis | — | Immune-mediated | Joint swelling/stiffness | — | DMARDs/biologics |
| 857 | Ankylosing spondylitis | Immune-mediated spondyloarthritis | — | Genetic/environmental | Back pain/stiffness | Exercise | NSAIDs/biologics |
| 858 | Psoriatic arthritis | Immune-mediated | — | Associated with psoriasis | Joint pain/swelling | — | DMARDs/biologics |
| 859 | Reactive arthritis | Immune reaction after infection | — | Post-infectious | Arthritis, eye/urinary symptoms | Infection prevention | NSAIDs/antibiotics if infection persists |
| 860 | Osteomyelitis | Bacteria/fungi | — | Blood/wound spread | Bone pain/fever | Wound care | Antimicrobials ± surgery |
| 861 | Septic arthritis | Bacteria/fungi | — | Joint infection | Hot swollen joint | Infection prevention | Drainage + antibiotics |
| 862 | Bursitis | Bursa inflammation | — | Trauma/infection/inflammatory disease | Local pain/swelling | Ergonomics | Rest/NSAIDs ± drainage |
| 863 | Tendinitis | Tendon inflammation/degeneration | — | Overuse/injury | Local pain | Ergonomics/training | Rest/rehabilitation |
| 864 | Carpal tunnel syndrome | Median nerve compression | — | Repetitive/structural | Hand numbness | Ergonomics | Splint/injection/surgery |
| 865 | Osteonecrosis | Bone blood-supply loss | — | Steroids, alcohol, trauma etc. | Joint pain | Risk-factor reduction | Conservative/surgery |
| 866 | Paget disease of bone | Abnormal bone remodeling | — | Genetic/age-related | Bone pain/deformity | — | Bisphosphonates |
| 867 | Fibrous dysplasia | GNAS mutation | — | Genetic/mosaic | Bone lesions/deformity | — | Monitoring/pain treatment/surgery |
| 868 | Primary bone lymphoma | Malignant lymphoid cells | — | Cancer | Bone pain/swelling | — | Chemotherapy/radiation |
| 869 | Osteosarcoma | Malignant bone cells | — | Genetic/cellular | Bone pain/swelling | — | Surgery + chemotherapy |
| 870 | Ewing sarcoma | EWSR1-related cancer | — | Genetic/cellular | Bone/soft-tissue mass | — | Chemotherapy + surgery/radiation |
| 871 | Chondrosarcoma | Cartilage-producing cancer | — | Genetic/cellular | Bone pain/mass | — | Surgery ± systemic therapy |
| 872 | Rhabdomyosarcoma | Skeletal-muscle cancer | — | Genetic/cellular | Soft-tissue mass | — | Multimodal cancer therapy |
| 873 | Neuroblastoma | Developing nerve-cell cancer | — | Genetic/cellular | Abdominal mass, bone symptoms | — | Multimodal cancer therapy |
| 874 | Wilms tumor | Kidney embryonal cancer | — | Genetic/developmental | Abdominal mass | Genetic surveillance in high-risk children | Surgery/chemotherapy |
| 875 | Retinoblastoma | RB1 mutation | — | Genetic/sporadic | White pupil, eye abnormality | Genetic screening | Eye-sparing therapy/surgery |
| 876 | Medulloblastoma | Embryonal brain tumor | — | Cellular/genetic | Headache, vomiting, balance problems | — | Surgery/radiation/chemotherapy |
| 877 | Glioblastoma | Malignant glial cells | — | Cellular mutations | Headache, seizures, neurological deficits | — | Surgery/radiation/chemotherapy |
| 878 | Meningioma | Meningeal tumor | — | Cellular/genetic | Headache, seizures, neurological deficits | — | Observation/surgery/radiation |
| 879 | Acoustic neuroma | Vestibular schwannoma | — | Usually sporadic; NF2 association | Hearing loss, tinnitus, imbalance | — | Observation/surgery/radiation |
| 880 | Pituitary adenoma | Pituitary tumor | — | Cellular/genetic | Hormonal or pressure symptoms | — | Medicines/surgery/radiation |
| 881 | Thyroid adenoma | Benign thyroid nodule | — | Cellular | Neck nodule/hyperthyroidism | — | Observation/surgery/radioiodine |
| 882 | Pheochromocytoma | Catecholamine tumor | — | Adrenal/genetic | Hypertension, palpitations | Genetic testing in selected cases | Surgery |
| 883 | Neuroendocrine tumor | Neuroendocrine cells | — | Genetic/cellular | Hormonal or mass effects | — | Surgery/systemic therapy |
| 884 | Gastrinoma | Gastrin-producing tumor | — | Neuroendocrine/genetic | Ulcers, diarrhea | — | Acid suppression/surgery |
| 885 | Insulinoma | Insulin-producing tumor | — | Pancreatic neuroendocrine | Hypoglycemia | — | Surgery/medical therapy |
| 886 | Carcinoid syndrome | Hormone-secreting neuroendocrine tumor | — | Tumor | Flushing, diarrhea, wheezing | — | Somatostatin analogues/tumor treatment |
| 887 | Gastrointestinal stromal tumor | KIT/PDGFRA mutations | — | Cellular/genetic | GI mass/bleeding | — | Surgery/tyrosine kinase inhibitors |
| 888 | Kaposi sarcoma | HHV-8-associated cancer | — | Viral/immune-associated | Purple skin/mucosal lesions | HIV prevention/immune management | ART/local/systemic cancer therapy |
| 889 | Burkitt lymphoma | MYC-related B-cell cancer | — | Genetic; EBV-associated in endemic areas | Rapidly growing mass | — | Intensive chemotherapy |
| 890 | Multiple myeloma | Malignant plasma cells | — | Genetic/cellular | Bone pain/anemia/kidney disease | — | Systemic therapy |
| 891 | Myelodysplastic syndromes | Abnormal marrow stem cells | — | Genetic/acquired | Anemia/infections/bleeding | Avoid some exposures | Supportive/targeted therapy |
| 892 | Myelofibrosis | Abnormal marrow fibrosis | — | JAK-pathway mutations | Enlarged spleen/anemia | — | JAK inhibitors/transplant selected cases |
| 893 | Polycythemia vera | JAK2 mutation | — | Myeloproliferative neoplasm | High RBC count, itching, thrombosis | Risk management | Phlebotomy/cytoreduction |
| 894 | Essential thrombocythemia | Myeloproliferative neoplasm | — | JAK2/CALR/MPL mutations | High platelets, clotting/bleeding | Risk management | Aspirin/cytoreduction selected |
| 895 | Waldenström macroglobulinemia | IgM-producing lymphoplasmacytic cancer | — | Cellular/genetic | Hyperviscosity, fatigue | — | Systemic therapy/plasmapheresis |
| 896 | Hairy cell leukemia | B-cell leukemia | — | Genetic/cellular | Low blood counts, enlarged spleen | — | Purine analogues/targeted therapy |
| 897 | Acute promyelocytic leukemia | PML-RARA fusion | — | Genetic | Severe bleeding risk | — | ATRA + arsenic/chemotherapy |
| 898 | Chronic myelomonocytic leukemia | Myeloid neoplasm | — | Acquired mutations | Monocytosis, anemia, spleen enlargement | — | Supportive/targeted/transplant |
| 899 | Castleman disease | Lymphoproliferative disorder | — | HHV-8 or idiopathic immune process | Enlarged nodes, systemic inflammation | — | Type-specific immunotherapy |
| 900 | Langerhans cell histiocytosis | Abnormal dendritic cells | — | MAPK-pathway mutations | Bone/skin/lung/multisystem disease | — | Observation, chemotherapy/targeted therapy |
| # | Disease | Cause / Organism | Vector | Transmission / Origin | Main symptoms | Prevention | Treatment |
| 901 | Histiocytosis | Abnormal histiocytes | — | Genetic/cellular | Skin/bone/organ disease | — | Type-specific |
| 902 | Erdheim-Chester disease | MAPK-pathway mutations | — | Rare neoplastic disorder | Bone pain, cardiovascular/renal disease | — | Targeted therapy |
| 903 | Rosai-Dorfman disease | Histiocytic disorder | — | Immune/genetic | Enlarged lymph nodes, masses | — | Observation/steroids/surgery/systemic therapy |
| 904 | Castleman disease | Lymphoid proliferation | — | HHV-8 or idiopathic | Lymph-node enlargement/systemic symptoms | — | Immunotherapy/type-specific |
| 905 | Amyloidosis | Amyloid deposition | — | Protein misfolding | Organ dysfunction | Treat underlying cause | Type-specific |
| 906 | Sarcomatoid carcinoma | Aggressive epithelial cancer | — | Cellular mutations | Mass/organ-specific symptoms | Risk-factor reduction | Cancer-specific |
| 907 | Renal cell carcinoma | Kidney epithelial cancer | — | Genetic/environmental | Blood in urine, pain, mass | Smoking/BP control | Surgery/targeted/immunotherapy |
| 908 | Urothelial carcinoma | Urothelial cancer | — | Tobacco/chemical exposure | Hematuria | Smoking cessation | Surgery/immunotherapy/chemotherapy |
| 909 | Cholangiocarcinoma | Bile-duct cancer | — | Genetic/environmental/chronic inflammation | Jaundice, abdominal pain | Treat risk conditions | Surgery/systemic therapy |
| 910 | Gallbladder cancer | Gallbladder epithelial cancer | — | Genetic/chronic inflammation | Abdominal pain/jaundice | Risk management | Surgery/systemic therapy |
| 911 | Esophageal cancer | Esophageal epithelial cancer | — | Tobacco/alcohol/reflux etc. | Difficulty swallowing, weight loss | Tobacco/alcohol reduction | Surgery/chemotherapy/radiation |
| 912 | Gastric cancer | Stomach epithelial cancer | — | H. pylori, genetic/environmental | Weight loss, pain, anemia | H. pylori treatment/risk reduction | Surgery/systemic therapy |
| 913 | Anal cancer | Usually high-risk HPV | — | Sexual HPV transmission | Bleeding, pain, mass | HPV vaccine/screening | Chemoradiation/surgery |
| 914 | Vulvar cancer | HPV and other factors | — | Viral/noninfectious | Vulvar lesion/itching | HPV vaccination | Surgery/radiation |
| 915 | Vaginal cancer | HPV/other factors | — | Sexual HPV exposure/other | Bleeding, mass | HPV prevention | Radiation/surgery |
| 916 | Penile cancer | HPV/tobacco/other factors | — | Sexual HPV exposure | Penile lesion | HPV vaccination/hygiene | Surgery ± radiation |
| 917 | Mesothelioma | Usually asbestos | — | Fiber inhalation | Chest/abdominal disease | Asbestos avoidance | Surgery/systemic therapy |
| 918 | Thymoma | Thymic epithelial tumor | — | Cellular | Chest mass, autoimmune association | — | Surgery ± radiation/systemic therapy |
| 919 | Testicular seminoma | Germ-cell cancer | — | Cellular/genetic | Testicular mass | — | Surgery ± radiation/chemotherapy |
| 920 | Testicular nonseminoma | Germ-cell cancer | — | Cellular/genetic | Testicular mass | — | Surgery/chemotherapy |
| 921 | Ovarian germ-cell tumor | Germ-cell cancer | — | Cellular | Pelvic mass/pain | — | Surgery/chemotherapy |
| 922 | Pancreatic neuroendocrine tumor | Neuroendocrine cells | — | Genetic/cellular | Hormonal/mass symptoms | — | Surgery/systemic therapy |
| 923 | Adrenocortical carcinoma | Adrenal cortex cancer | — | Genetic/cellular | Hormonal excess/mass | — | Surgery/systemic therapy |
| 924 | Hepatoblastoma | Childhood liver cancer | — | Developmental/genetic | Abdominal mass | — | Surgery/chemotherapy |
| 925 | Cholangiocarcinoma | Bile duct malignancy | — | Chronic inflammation/genetic | Jaundice | Risk-factor control | Surgery/systemic |
| 926 | Dermatofibrosarcoma protuberans | Skin connective-tissue cancer | — | COL1A1-PDGFB alteration | Slow-growing skin mass | — | Wide surgical excision/targeted therapy |
| 927 | Merkel cell carcinoma | Neuroendocrine skin cancer | — | UV/polyomavirus association | Fast-growing skin nodule | Sun protection | Surgery/radiation/immunotherapy |
| 928 | Cutaneous T-cell lymphoma | Malignant T cells | — | Cellular/genetic | Persistent rash/plaques | — | Skin-directed/systemic therapy |
| 929 | Mycosis fungoides | Cutaneous T-cell lymphoma | — | Cellular | Chronic skin patches/plaques | — | Skin-directed/systemic therapy |
| 930 | Sézary syndrome | Advanced cutaneous T-cell lymphoma | — | Cellular | Generalized redness, blood involvement | — | Systemic therapy |
| 931 | Basal cell nevus syndrome | PTCH pathway mutation | — | Genetic | Multiple basal cell cancers | Sun protection/genetic counseling | Dermatologic/surgical treatment |
| 932 | Xeroderma pigmentosum | DNA repair defect | — | Genetic | Extreme UV sensitivity, skin cancers | Strict UV protection | Lesion removal/cancer surveillance |
| 933 | Peutz-Jeghers syndrome | STK11 mutation | — | Genetic | GI polyps, pigmentation | Genetic surveillance | Polyp/cancer management |
| 934 | Gardner syndrome | APC mutation | — | Genetic | Polyposis, bone/soft-tissue tumors | Genetic screening | Surveillance/surgery |
| 935 | Cowden syndrome | PTEN mutation | — | Genetic | Multiple hamartomas/cancer risk | Genetic surveillance | Screening/risk management |
| 936 | MEN type 1 | MEN1 mutation | — | Genetic | Multiple endocrine tumors | Genetic screening | Tumor-specific treatment |
| 937 | MEN type 2 | RET mutation | — | Genetic | Medullary thyroid/adrenal tumors | Genetic screening | Prophylactic/therapeutic surgery |
| 938 | Neurofibromatosis type 1 | NF1 mutation | — | Genetic | Neurofibromas, pigment changes | Genetic counseling | Monitoring/targeted therapy |
| 939 | Neurofibromatosis type 2 | NF2 mutation | — | Genetic | Schwannomas/meningiomas | Genetic counseling | Monitoring/surgery/targeted treatment |
| 940 | Tuberous sclerosis complex | TSC1/TSC2 | — | Genetic | Brain/kidney/skin tumors | Genetic counseling | Antiseizure/targeted therapy |
| 941 | Von Hippel-Lindau disease | VHL mutation | — | Genetic | Multiple tumors | Genetic surveillance | Surgery/targeted treatment |
| 942 | Familial adenomatous polyposis | APC mutation | — | Genetic | Hundreds of colon polyps | Screening | Surveillance/colectomy |
| 943 | Lynch syndrome | Mismatch-repair gene mutation | — | Genetic | Colorectal/endometrial cancers | Genetic testing/surveillance | Cancer prevention/treatment |
| 944 | Hereditary diffuse gastric cancer | CDH1 mutation | — | Genetic | Gastric/lobular breast cancer risk | Genetic counseling | Intensive surveillance/prophylactic surgery selected |
| 945 | Hereditary breast-ovarian cancer syndrome | BRCA1/2 | — | Genetic | Breast/ovarian and related cancers | Genetic counseling/screening | Risk-reduction/cancer therapy |
| 946 | Li-Fraumeni syndrome | TP53 mutation | — | Genetic | Multiple early cancers | Genetic surveillance | Cancer-specific |
| 947 | Bloom syndrome | BLM mutation | — | Genetic | Growth deficiency, sun sensitivity, cancer risk | Genetic counseling/UV protection | Supportive/cancer care |
| 948 | Fanconi anemia | DNA repair defects | — | Genetic | Bone-marrow failure, congenital anomalies | Genetic counseling | Transfusion/support/stem-cell transplant |
| 949 | Ataxia-telangiectasia | ATM mutation | — | Genetic | Ataxia, immune deficiency | Genetic counseling | Supportive |
| 950 | Cockayne syndrome | DNA repair defects | — | Genetic | Growth failure, neurological/UV sensitivity | Genetic counseling/UV protection | Supportive |
| 951 | Werner syndrome | WRN mutation | — | Genetic | Premature aging features | Genetic counseling | Supportive |
| 952 | Hutchinson-Gilford progeria | LMNA mutation | — | Genetic | Premature aging | Genetic counseling | Specialist/supportive therapy |
| 953 | Rett syndrome | MECP2 mutation | — | Genetic | Developmental regression | — | Supportive |
| 954 | Smith-Lemli-Opitz syndrome | Cholesterol synthesis defect | — | Genetic | Developmental/congenital abnormalities | Prenatal/genetic screening | Cholesterol supplementation/support |
| 955 | Prader-Willi syndrome | Chromosome 15 imprinting | — | Genetic | Hyperphagia, developmental/endocrine issues | Nutritional control | Growth hormone/endocrine care |
| 956 | Angelman syndrome | UBE3A dysfunction | — | Genetic | Developmental delay, seizures | Genetic counseling | Supportive/antiseizure |
| 957 | Williams syndrome | 7q11.23 deletion | — | Genetic | Cardiovascular/developmental features | Genetic counseling | Cardiac/developmental care |
| 958 | Cri-du-chat syndrome | 5p deletion | — | Chromosomal | Developmental delay, characteristic cry | Genetic counseling | Supportive |
| 959 | DiGeorge syndrome | 22q11.2 deletion | — | Genetic | Heart/immune/calcium abnormalities | Genetic counseling | Organ-specific treatment |
| 960 | Noonan syndrome | RAS/MAPK mutations | — | Genetic | Short stature, heart defects | Genetic counseling | Cardiac/endocrine care |
| 961 | Achondroplasia | FGFR3 mutation | — | Genetic | Short-limb stature | Genetic counseling | Supportive/targeted therapy |
| 962 | Osteogenesis imperfecta | Collagen mutations | — | Genetic | Fragile bones | Genetic counseling | Fracture prevention/treatment |
| 963 | Ehlers-Danlos syndrome | Connective-tissue gene defects | — | Genetic | Joint hypermobility, fragile tissues | Genetic counseling | Supportive |
| 964 | Marfan syndrome | FBN1 mutation | — | Genetic | Aortic/eye/skeletal abnormalities | Genetic surveillance | BP medicines/surgery when indicated |
| 965 | Alport syndrome | COL4A mutations | — | Genetic | Kidney/hearing/eye disease | Genetic counseling | Kidney protection |
| 966 | Fabry disease | Alpha-galactosidase A deficiency | — | Genetic | Kidney/heart/nerve disease | Genetic testing | Enzyme/chaperone therapy |
| 967 | Gaucher disease | Glucocerebrosidase deficiency | — | Genetic | Liver/spleen/bone disease | Genetic counseling | Enzyme replacement |
| 968 | Pompe disease | Acid alpha-glucosidase deficiency | — | Genetic | Muscle/heart disease | Newborn/genetic screening | Enzyme replacement |
| 969 | Tay-Sachs disease | Hexosaminidase A deficiency | — | Genetic | Progressive neurological disease | Carrier screening | Supportive |
| 970 | Niemann-Pick disease | Lipid-storage disorders | — | Genetic | Neurological/liver/spleen disease | Genetic counseling | Type-specific therapy |
| 971 | Krabbe disease | Galactocerebrosidase deficiency | — | Genetic | Severe neurological degeneration | Newborn screening | Stem-cell therapy selected cases/support |
| 972 | Metachromatic leukodystrophy | Arylsulfatase A deficiency | — | Genetic | Progressive neurological disease | Genetic screening | Gene/stem-cell therapy selected cases |
| 973 | Adrenoleukodystrophy | ABCD1 mutation | — | X-linked | Brain/adrenal disease | Newborn screening | Steroid replacement; stem-cell/gene therapy selected |
| 974 | Canavan disease | ASPA mutation | — | Genetic | Developmental/neurological disease | Carrier screening | Supportive |
| 975 | Rett syndrome | MECP2 | — | Genetic | Developmental regression | — | Supportive |
| 976 | Spinal muscular atrophy | SMN1 mutation | — | Genetic | Motor weakness | Newborn screening | Gene/nusinersen/risdiplam therapies |
| 977 | Duchenne muscular dystrophy | DMD mutation | — | X-linked | Progressive muscle weakness | Genetic counseling | Steroids/gene-targeted therapy |
| 978 | Becker muscular dystrophy | DMD mutation | — | X-linked | Muscle weakness | Genetic counseling | Supportive/disease-modifying |
| 979 | Myotonic dystrophy | DMPK mutation | — | Autosomal dominant | Myotonia, muscle weakness | Genetic counseling | Symptom management |
| 980 | Facioscapulohumeral muscular dystrophy | DUX4-related genetic disorder | — | Genetic | Face/shoulder/arm weakness | Genetic counseling | Supportive/rehabilitation |
| 981 | Friedreich ataxia | FXN mutation | — | Genetic | Ataxia, neuropathy, cardiomyopathy | Genetic counseling | Supportive/targeted therapy |
| 982 | Charcot-Marie-Tooth disease | Peripheral nerve gene disorders | — | Genetic | Distal weakness, sensory loss | Genetic counseling | Rehabilitation/orthotics |
| 983 | Hereditary spastic paraplegia | Many genetic causes | — | Genetic | Progressive leg stiffness/weakness | Genetic counseling | Physiotherapy/medications |
| 984 | Wilson disease | ATP7B mutation | — | Genetic | Copper accumulation | Family screening | Chelation/zinc |
| 985 | Hemochromatosis | Iron overload | — | Genetic/acquired | Liver/heart/endocrine disease | Screening | Phlebotomy |
| 986 | Alpha-1 antitrypsin deficiency | SERPINA1 mutation | — | Genetic | Lung/liver disease | Avoid smoking | Supportive/augmentation selected |
| 987 | Cystic fibrosis | CFTR mutation | — | Genetic | Lung/digestive disease | Genetic/newborn screening | CFTR modulators + supportive therapy |
| 988 | Primary ciliary dyskinesia | Ciliary gene defects | — | Genetic | Recurrent respiratory infections | Infection prevention | Airway clearance/antibiotics |
| 989 | Kartagener syndrome | Primary ciliary dyskinesia + situs inversus | — | Genetic | Sinus/lung disease, infertility | Infection prevention | Airway clearance/antibiotics |
| 990 | Hereditary pancreatitis | PRSS1/other mutations | — | Genetic | Recurrent pancreatitis | Avoid triggers/alcohol | Pancreatitis treatment |
| 991 | Familial hypercholesterolemia | LDL pathway mutation | — | Genetic | Very high LDL | Family screening | Statins/other lipid therapy |
| 992 | Long QT syndrome | Cardiac ion-channel mutations | — | Genetic | Fainting/arrhythmias | Avoid triggers/drugs; screening | Beta-blockers/ICD selected |
| 993 | Brugada syndrome | Sodium-channel/cardiac electrical disorder | — | Genetic | Dangerous arrhythmias/syncope | Fever/drug precautions | ICD in high-risk cases |
| 994 | Arrhythmogenic right ventricular cardiomyopathy | Desmosomal mutations | — | Genetic | Arrhythmias/cardiomyopathy | Family screening | Exercise restriction/medicines/ICD |
| 995 | Familial dilated cardiomyopathy | Various cardiac genes | — | Genetic | Heart failure/arrhythmia | Family screening | Heart-failure therapy |
| 996 | Hypertrophic cardiomyopathy | Sarcomere mutations | — | Genetic | Thickened heart muscle, arrhythmia | Family screening | Medicines/ICD/surgery selected |
| 997 | Catecholaminergic polymorphic ventricular tachycardia | Calcium-handling gene mutations | — | Genetic | Exercise-triggered fainting/arrhythmia | Avoid strenuous triggers | Beta-blockers/ICD selected |
| 998 | Familial Mediterranean fever | MEFV mutation | — | Genetic | Recurrent fever/serositis | Genetic counseling | Colchicine |
| 999 | Periodic fever syndrome | Autoinflammatory gene mutations | — | Genetic | Recurrent fever/inflammation | Genetic counseling | Targeted anti-inflammatory therapy |
| 1000 | Multisystem inflammatory disease | Immune/autoinflammatory disorders | — | Immune-mediated | Fever and multiple-organ inflammation | Cause-specific | Specialist immunomodulatory treatment |
| # | Disease / Condition | Cause / Organism | Transmission / Origin | Main Features | Prevention / Treatment | ||
| 1001 | Acute bacterial meningitis | S. pneumoniae, N. meningitidis, others | Respiratory/contact | Fever, headache, neck stiffness | Vaccination; urgent antibiotics | ||
| 1002 | Meningococcal meningitis | N. meningitidis | Respiratory droplets | Meningitis, petechial rash | Vaccine; antibiotics | ||
| 1003 | Pneumococcal meningitis | S. pneumoniae | Respiratory spread | Fever, meningitis | Pneumococcal vaccine; antibiotics | ||
| 1004 | Tuberculous meningitis | M. tuberculosis | Airborne TB infection | Subacute meningitis, cranial nerve signs | TB prevention; multidrug therapy | ||
| 1005 | Cryptococcal meningitis | Cryptococcus | Environmental inhalation/opportunistic | Headache, fever, raised ICP | Antifungal therapy | ||
| 1006 | Brain abscess | Bacteria/fungi/parasites | Spread from infection/blood | Headache, fever, focal deficits | Antibiotics ± drainage | ||
| 1007 | Subdural empyema | Bacteria | Spread from infection | Fever, headache, neurological deficits | Surgery + antibiotics | ||
| 1008 | Epidural abscess | Bacteria, often S. aureus | Blood/spinal infection | Back pain, weakness | Emergency antibiotics/surgery | ||
| 1009 | Neurocysticercosis | Taenia solium larvae | Fecal-oral eggs | Seizures, headache | Sanitation; antiparasitic therapy | ||
| 1010 | Cerebral malaria | P. falciparum | Anopheles mosquito | Coma, seizures, fever | Mosquito prevention; urgent antimalarial | ||
| 1011 | Guillain-Barré syndrome | Immune-mediated | Often post-infectious | Ascending weakness | IVIG/plasma exchange | ||
| 1012 | Miller Fisher syndrome | Immune-mediated | Often post-infectious | Ophthalmoplegia, ataxia, areflexia | IVIG/plasma exchange | ||
| 1013 | Multiple sclerosis | Autoimmune CNS disease | Immune/genetic factors | Relapsing neurological deficits | Disease-modifying therapy | ||
| 1014 | Neuromyelitis optica | AQP4-IgG autoimmune disease | Autoimmune | Optic neuritis, myelitis | Immunotherapy | ||
| 1015 | MOG-associated disease | MOG antibodies | Autoimmune | Optic neuritis/brain inflammation | Steroids/immunotherapy | ||
| 1016 | Transverse myelitis | Inflammatory spinal cord disease | Autoimmune/post-infectious | Weakness, sensory loss, bladder dysfunction | Steroids/plasma exchange | ||
| 1017 | Acute disseminated encephalomyelitis | Immune-mediated | Often post-infectious | Encephalopathy + deficits | High-dose steroids | ||
| 1018 | Myasthenia gravis | AChR/MuSK autoantibodies | Autoimmune | Fatigable weakness | Pyridostigmine/immunotherapy | ||
| 1019 | Lambert-Eaton syndrome | VGCC antibodies | Autoimmune/paraneoplastic | Proximal weakness, autonomic symptoms | Treat cause/immunotherapy | ||
| 1020 | Guillain-Barré respiratory failure | Severe GBS | Post-infectious immune | Respiratory muscle paralysis | ICU ventilation + immunotherapy | ||
| 1021 | Parkinson disease | Neurodegeneration | Multifactorial | Tremor, rigidity, bradykinesia | Levodopa and other therapies | ||
| 1022 | Huntington disease | HTT CAG expansion | Autosomal dominant | Chorea, psychiatric/cognitive decline | Symptomatic/genetic counseling | ||
| 1023 | Amyotrophic lateral sclerosis | Motor neuron degeneration | Sporadic/genetic | Progressive weakness | Multidisciplinary care | ||
| 1024 | Spinal bulbar muscular atrophy | Androgen receptor mutation | X-linked | Weakness, bulbar symptoms | Supportive/endocrine care | ||
| 1025 | Progressive supranuclear palsy | Neurodegeneration | Sporadic | Falls, vertical gaze palsy | Supportive | ||
| 1026 | Multiple system atrophy | Neurodegeneration | Sporadic | Parkinsonism/autonomic failure | Supportive | ||
| 1027 | Lewy body dementia | Alpha-synuclein disease | Neurodegenerative | Dementia, hallucinations, fluctuations | Symptomatic treatment | ||
| 1028 | Frontotemporal dementia | Neurodegeneration | Genetic/sporadic | Behavior/language changes | Supportive | ||
| 1029 | Vascular dementia | Cerebrovascular disease | Multiple strokes/small vessel disease | Cognitive decline | Vascular risk control | ||
| 1030 | Normal-pressure hydrocephalus | CSF circulation disorder | Various | Gait, cognition, urinary symptoms | Shunt in selected cases | ||
| 1031 | Essential tremor | Neurological disorder | Genetic/sporadic | Action tremor | Propranolol/primidone; procedures | ||
| 1032 | Dystonia | Motor network disorder | Genetic/acquired | Sustained abnormal movements | Botulinum toxin/medications | ||
| 1033 | Tourette syndrome | Neurodevelopmental | Genetic/environmental | Motor and vocal tics | Behavioral therapy/medications | ||
| 1034 | Restless legs syndrome | Neurological disorder | Genetic/iron-related | Urge to move legs | Iron correction/medications | ||
| 1035 | Narcolepsy | Orexin deficiency | Autoimmune/genetic factors | Daytime sleepiness/cataplexy | Wake-promoting therapy | ||
| 1036 | Obstructive sleep apnea | Upper-airway collapse | Obesity/anatomy etc. | Snoring, apnea, daytime sleepiness | Weight management/CPAP | ||
| 1037 | Central sleep apnea | Abnormal respiratory drive | Cardiac/neurological/drug causes | Pauses in breathing | Treat cause/positive airway therapy | ||
| 1038 | Insomnia disorder | Sleep regulation disorder | Stress/medical/psychiatric | Difficulty sleeping | Sleep therapy/CBT-I | ||
| 1039 | REM sleep behavior disorder | REM atonia failure | Neurodegenerative association | Acting out dreams | Safety/melatonin etc. | ||
| 1040 | Cluster headache | Trigeminal autonomic disorder | Neurological | Severe unilateral orbital pain | Oxygen/triptans; prevention | ||
| 1041 | Migraine with aura | Neurovascular disorder | Genetic/environmental | Headache + visual/sensory aura | Trigger management/acute & preventive therapy | ||
| 1042 | Chronic migraine | Migraine disorder | Neurological | ≥15 headache days/month | Preventive therapy | ||
| 1043 | Tension-type headache | Primary headache | Multifactorial | Bilateral pressure-like headache | Analgesics/prevention | ||
| 1044 | Trigeminal neuralgia | Trigeminal nerve disorder | Compression/demyelination | Electric-shock facial pain | Carbamazepine/procedures | ||
| 1045 | Bell palsy | Facial nerve palsy | Often HSV-associated | Acute facial weakness | Steroids ± antivirals | ||
| 1046 | Ménière disease | Inner-ear fluid disorder | Multifactorial | Vertigo, hearing loss, tinnitus | Salt reduction/medications | ||
| 1047 | Benign paroxysmal positional vertigo | Otolith displacement | Inner ear | Brief positional vertigo | Canalith repositioning | ||
| 1048 | Vestibular neuritis | Vestibular nerve inflammation | Often viral | Acute vertigo | Vestibular rehab/medications | ||
| 1049 | Labyrinthitis | Inner-ear inflammation | Viral/bacterial | Vertigo + hearing symptoms | Cause-specific treatment | ||
| 1050 | Acoustic neuritis | Vestibular nerve inflammation | Inflammatory/infectious | Hearing/vestibular symptoms | Cause-specific | ||
| # | Disease / Condition | Cause / Organism | Transmission / Origin | Main Features | Prevention / Treatment | ||
| 1051 | Acute otitis media | Bacteria/viruses | Respiratory infection | Ear pain, fever | Vaccination; analgesia ± antibiotics | ||
| 1052 | Otitis externa | Bacteria/fungi | Water/trauma | Ear canal pain | Ear protection; topical treatment | ||
| 1053 | Mastoiditis | Usually bacterial | Complication of otitis media | Ear pain, swelling | Antibiotics ± surgery | ||
| 1054 | Cholesteatoma | Keratinizing epithelial lesion | Chronic ear disease | Hearing loss, discharge | Surgical treatment | ||
| 1055 | Chronic suppurative otitis media | Bacteria | Chronic middle-ear infection | Persistent ear discharge | Ear care/antibiotics ± surgery | ||
| 1056 | Acute sinusitis | Viral/bacterial | Respiratory infection | Facial pain, nasal discharge | Supportive ± antibiotics | ||
| 1057 | Chronic rhinosinusitis | Inflammatory/infectious | Nasal/sinus disease | Congestion, facial pressure | Saline/steroids ± surgery | ||
| 1058 | Nasal polyposis | Chronic inflammation | Allergic/inflammatory | Nasal obstruction | Intranasal steroids/surgery | ||
| 1059 | Allergic rhinitis | IgE-mediated allergy | Environmental allergens | Sneezing, rhinorrhea | Allergen control/antihistamines | ||
| 1060 | Deviated nasal septum | Structural | Trauma/development | Nasal obstruction | Medical therapy/surgery | ||
| 1061 | Laryngitis | Viral/irritant | Respiratory/contact | Hoarseness | Voice rest/supportive | ||
| 1062 | Epistaxis | Vascular/nasal causes | Trauma, dryness, hypertension etc. | Nosebleed | Pressure; cautery if needed | ||
| 1063 | Vocal cord nodules | Voice overuse | Mechanical | Hoarseness | Voice therapy | ||
| 1064 | Vocal cord polyps | Voice trauma | Mechanical/smoking | Hoarseness | Voice therapy/surgery | ||
| 1065 | Laryngeal papillomatosis | HPV 6/11 | Respiratory/perinatal | Recurrent airway papillomas | Surgical treatment ± antiviral | ||
| 1066 | Oral candidiasis | Candida | Overgrowth | White oral plaques | Oral hygiene; antifungal | ||
| 1067 | Aphthous ulcers | Immune/inflammatory | Noninfectious | Painful oral ulcers | Symptomatic/topical steroids | ||
| 1068 | Oral leukoplakia | Mucosal keratosis | Tobacco/irritants | White oral patch | Remove risks; biopsy | ||
| 1069 | Oral lichen planus | Immune-mediated | Autoimmune-associated | White/erosive oral lesions | Topical steroids | ||
| 1070 | Oral submucous fibrosis | Areca nut-associated fibrosis | Chronic chewing exposure | Reduced mouth opening | Stop areca nut; treatment/rehab | ||
| 1071 | Dental caries | Acidogenic oral bacteria | Plaque/diet | Tooth destruction | Fluoride/oral hygiene; restorations | ||
| 1072 | Gingivitis | Dental plaque bacteria | Poor oral hygiene | Bleeding gums | Oral hygiene/scaling | ||
| 1073 | Periodontitis | Polymicrobial biofilm | Dental plaque | Gum/bone destruction | Dental treatment | ||
| 1074 | Dental abscess | Oral bacteria | Tooth infection | Tooth pain/swelling | Drainage + dental treatment | ||
| 1075 | Pericoronitis | Oral bacteria | Impacted tooth | Gum pain/swelling | Dental treatment | ||
| 1076 | Pulpitis | Dental pulp inflammation | Caries/trauma | Severe toothache | Dental treatment/root canal | ||
| 1077 | Oral squamous cell carcinoma | Malignant epithelial cells | Tobacco/alcohol/HPV risks | Oral ulcer/mass | Tobacco cessation; surgery/oncology | ||
| 1078 | Nasopharyngeal carcinoma | Epithelial cancer, EBV association | Genetic/environmental | Neck mass, nasal symptoms | Risk reduction; radiotherapy | ||
| 1079 | Laryngeal carcinoma | Squamous cell cancer | Tobacco/alcohol | Hoarseness | Tobacco cessation; oncology | ||
| 1080 | Oropharyngeal cancer | Often HPV-related | HPV/tobacco | Throat mass/neck nodes | HPV vaccination; oncology | ||
| # | Disease / Condition | Cause / Organism | Transmission / Origin | Main Features | Prevention / Treatment | ||
| 1081 | GERD | Reflux of gastric contents | Lower esophageal sphincter dysfunction | Heartburn/regurgitation | Lifestyle; acid suppression | ||
| 1082 | Barrett esophagus | Chronic GERD-related metaplasia | Long-term reflux | Increased esophageal cancer risk | GERD control/surveillance | ||
| 1083 | Achalasia | Esophageal motility disorder | Myenteric nerve dysfunction | Dysphagia/regurgitation | Pneumatic dilation/POEM/surgery | ||
| 1084 | Esophageal spasm | Motility disorder | Abnormal contractions | Chest pain/dysphagia | Smooth-muscle therapy/POEM selected | ||
| 1085 | Peptic ulcer disease | H. pylori/NSAIDs | Infection/drugs | Epigastric pain/bleeding | H. pylori eradication/PPI | ||
| 1086 | Gastritis | H. pylori, NSAIDs, autoimmune | Infection/drugs/immune | Epigastric pain | Remove cause/PPI | ||
| 1087 | Autoimmune gastritis | Autoimmune parietal-cell injury | Autoimmune | B12 deficiency | B12 replacement | ||
| 1088 | Atrophic gastritis | Chronic inflammation | H. pylori/autoimmune | Gastric atrophy | Treat cause/surveillance | ||
| 1089 | Gastroparesis | Delayed gastric emptying | Diabetes/surgery/idiopathic | Nausea, early satiety | Diet/prokinetics | ||
| 1090 | Dumping syndrome | Rapid gastric emptying | Post-gastric surgery | Cramping, diarrhea, vasomotor symptoms | Dietary modification | ||
| 1091 | Celiac disease | Gluten-triggered autoimmunity | Genetic/environmental | Diarrhea, malabsorption | Lifelong gluten-free diet | ||
| 1092 | Tropical sprue | Malabsorption disorder | Possibly infectious | Diarrhea/weight loss | Antibiotics + folate/nutrition | ||
| 1093 | Whipple disease | Tropheryma whipplei | Bacterial infection | Diarrhea, weight loss, arthralgia | Prolonged antibiotics | ||
| 1094 | Lactose intolerance | Lactase deficiency | Genetic/acquired | Bloating/diarrhea after dairy | Lactose reduction | ||
| 1095 | Fructose malabsorption | Carbohydrate malabsorption | GI functional | Bloating/diarrhea | Dietary modification | ||
| 1096 | Short bowel syndrome | Loss of small intestine | Surgery/disease | Malabsorption/diarrhea | Nutrition/intestinal rehabilitation | ||
| 1097 | Intestinal pseudo-obstruction | Motility disorder | Neuromuscular disease | Obstruction symptoms without blockage | Nutritional/medical management | ||
| 1098 | Hirschsprung disease | Enteric ganglion absence | Congenital | Neonatal obstruction/constipation | Surgical pull-through | ||
| 1099 | Intussusception | Bowel telescoping | Often childhood infection/lead point | Colicky pain, bloody stool | Air/contrast reduction | ||
| 1100 | Volvulus | Bowel twisting | Anatomical/motility | Obstruction/ischemia | Urgent decompression/surgery | ||
| # | Disease / Condition | Cause / Organism | Transmission / Origin | Main Features | Prevention / Treatment | ||
| 1101 | Appendicitis | Luminal obstruction/inflammation | Usually fecalith etc. | Right lower abdominal pain | Appendectomy ± antibiotics | ||
| 1102 | Diverticulosis | Colonic diverticula | Age/diet factors | Often asymptomatic | Fiber/lifestyle | ||
| 1103 | Diverticulitis | Inflamed diverticulum | Complication of diverticulosis | LLQ pain, fever | Antibiotics selected; drainage/surgery if complicated | ||
| 1104 | Ulcerative colitis | Immune-mediated IBD | Genetic/environmental | Bloody diarrhea | 5-ASA/steroids/biologics/surgery | ||
| 1105 | Crohn disease | Immune-mediated IBD | Genetic/environmental | Abdominal pain, diarrhea, fistula | Immunomodulators/biologics/surgery | ||
| 1106 | Microscopic colitis | Immune/inflammatory | Multifactorial | Chronic watery diarrhea | Stop triggers/budesonide | ||
| 1107 | Ischemic colitis | Reduced colonic blood flow | Vascular disease | Abdominal pain, bloody stool | Supportive/revascularization/surgery | ||
| 1108 | Mesenteric ischemia | Arterial/venous insufficiency | Vascular disease | Severe abdominal pain | Emergency revascularization/surgery | ||
| 1109 | C. difficile colitis | C. difficile toxin | Antibiotic-associated | Watery diarrhea | Antibiotic stewardship; specific therapy | ||
| 1110 | Protein-losing enteropathy | GI mucosal/lymphatic disease | Multiple causes | Edema, low albumin | Treat underlying cause | ||
| 1111 | Hemorrhoids | Dilated anorectal veins | Straining/pregnancy etc. | Bleeding, itching | Fiber; procedures if needed | ||
| 1112 | Anal fissure | Anal mucosal tear | Hard stool/trauma | Severe pain during defecation | Fiber/stool softening/topical therapy | ||
| 1113 | Anal fistula | Chronic anorectal tract | Abscess/Crohn disease | Discharge near anus | Surgical management | ||
| 1114 | Perianal abscess | Bacterial infection | Anorectal glands | Severe pain/swelling | Urgent drainage | ||
| 1115 | Pilonidal disease | Hair/debris sinus | Sacrococcygeal skin | Pain/drainage | Hygiene; drainage/excision | ||
| 1116 | Acute pancreatitis | Gallstones/alcohol etc. | Noninfectious | Severe epigastric pain | Treat cause/supportive care | ||
| 1117 | Chronic pancreatitis | Alcohol/genetic/obstruction | Repeated injury | Pain, malabsorption | Stop causes; enzymes/interventions | ||
| 1118 | Pancreatic pseudocyst | Post-pancreatitis collection | Pancreatic inflammation | Pain/fullness | Observation/drainage | ||
| 1119 | Autoimmune pancreatitis | IgG4-related/immune | Autoimmune | Pancreatic enlargement/jaundice | Steroids | ||
| 1120 | Acute liver failure | Viral/drug/autoimmune etc. | Multiple causes | Jaundice, encephalopathy | Emergency specialist care/transplant | ||
| 1121 | Alcohol-associated liver disease | Chronic alcohol | Toxic injury | Steatosis/hepatitis/cirrhosis | Abstinence; medical treatment | ||
| 1122 | Metabolic dysfunction-associated steatotic liver disease | Metabolic dysfunction | Obesity/diabetes etc. | Fatty liver | Weight/metabolic management | ||
| 1123 | Autoimmune hepatitis | Autoantibodies | Autoimmune | Hepatitis/cirrhosis | Steroids/immunosuppression | ||
| 1124 | Primary biliary cholangitis | Autoimmune bile-duct injury | Autoimmune | Cholestasis/pruritus | Ursodeoxycholic acid/other therapy | ||
| 1125 | Primary sclerosing cholangitis | Bile-duct inflammation/fibrosis | Immune-associated | Cholestasis/strictures | Monitoring/transplant when advanced | ||
| 1126 | Budd-Chiari syndrome | Hepatic venous obstruction | Thrombosis | Abdominal pain, hepatomegaly | Anticoagulation/intervention | ||
| 1127 | Hepatorenal syndrome | Cirrhosis-related renal dysfunction | Advanced liver disease | Kidney failure | Albumin/vasoconstrictors/transplant | ||
| 1128 | Hepatic encephalopathy | Toxin accumulation in liver failure | Advanced liver disease | Confusion/asterixis | Lactulose/rifaximin; treat trigger | ||
| 1129 | Portal hypertension | Increased portal pressure | Cirrhosis/thrombosis | Varices, splenomegaly | Treat cause; beta-blocker/endoscopy | ||
| 1130 | Esophageal varices | Portal hypertension | Liver disease | GI bleeding | Screening/banding/beta-blockers | ||
| 1131 | Nephrotic syndrome | Glomerular diseases | Immune/metabolic etc. | Heavy proteinuria, edema | Cause-specific treatment | ||
| 1132 | Nephritic syndrome | Glomerular inflammation | Immune/infectious | Hematuria, hypertension | Cause-specific treatment | ||
| 1133 | IgA nephropathy | IgA immune deposits | Immune/genetic | Hematuria/proteinuria | BP control; immunotherapy selected | ||
| 1134 | Minimal change disease | Podocyte dysfunction | Immune-associated | Nephrotic syndrome | Steroids | ||
| 1135 | FSGS | Glomerular scarring | Primary/secondary/genetic | Proteinuria | Cause-specific; immunotherapy selected | ||
| 1136 | Membranous nephropathy | Immune complexes/PLA2R | Autoimmune/secondary | Nephrotic syndrome | Risk-based immunotherapy | ||
| 1137 | Post-streptococcal glomerulonephritis | Immune response to GAS | After strep infection | Hematuria/edema | Treat infection/support | ||
| 1138 | Rapidly progressive glomerulonephritis | Severe glomerular inflammation | Autoimmune/infectious | Rapid kidney failure | Emergency immunosuppression | ||
| 1139 | Diabetic nephropathy | Diabetes-related kidney damage | Chronic hyperglycemia | Albuminuria/CKD | Glycemic/BP control | ||
| 1140 | Hypertensive nephrosclerosis | Chronic hypertension | Vascular injury | Progressive CKD | BP control | ||
| 1141 | Acute interstitial nephritis | Drug/infection/immune | Hypersensitivity | AKI, rash sometimes | Stop cause/steroids selected | ||
| 1142 | Acute tubular necrosis | Ischemia/toxins | Kidney injury | AKI | Supportive/treat cause | ||
| 1143 | Chronic kidney disease | Multiple renal diseases | Progressive kidney damage | Reduced kidney function | Cause control; dialysis/transplant | ||
| 1144 | Acute kidney injury | Multiple causes | Acute renal insult | Creatinine rise/oliguria | Treat cause/support | ||
| 1145 | Polycystic kidney disease | PKD1/PKD2 | Genetic | Enlarged kidneys/cysts | BP control; disease-specific therapy | ||
| 1146 | Medullary cystic kidney disease | Genetic tubulointerstitial disease | Genetic | CKD, concentrating defect | Supportive/transplant | ||
| 1147 | Renal tubular acidosis | Tubular acidification defect | Autoimmune/genetic/drug etc. | Metabolic acidosis | Alkali/cause-specific | ||
| 1148 | Nephrogenic diabetes insipidus | ADH resistance | Lithium/genetic etc. | Polyuria/polydipsia | Remove cause/thiazide etc. | ||
| 1149 | Central diabetes insipidus | ADH deficiency | Pituitary/hypothalamic | Polyuria/polydipsia | Desmopressin/cause treatment | ||
| 1150 | SIADH | Excess ADH | CNS/lung/drugs etc. | Hyponatremia | Fluid restriction/cause-specific | ||
| # | Disease / Condition | Cause / Organism | Transmission / Origin | Main Features | Prevention / Treatment | ||
| 1151 | Type 1 diabetes mellitus | Autoimmune β-cell destruction | Genetic/environmental | Hyperglycemia, ketosis | Insulin | ||
| 1152 | Type 2 diabetes mellitus | Insulin resistance/β-cell dysfunction | Genetic/metabolic | Hyperglycemia | Lifestyle + glucose-lowering drugs | ||
| 1153 | Gestational diabetes | Pregnancy-related insulin resistance | Pregnancy | Maternal/fetal complications | Screening; diet/insulin as needed | ||
| 1154 | Diabetic ketoacidosis | Severe insulin deficiency | Diabetes | Acidosis, ketosis | Emergency fluids/insulin | ||
| 1155 | Hyperosmolar hyperglycemic state | Severe hyperglycemia | Usually type 2 DM | Dehydration/altered sensorium | Emergency fluids/insulin | ||
| 1156 | Hypoglycemia | Low blood glucose | Diabetes drugs/endocrine etc. | Sweating, confusion, seizures | Glucose; treat cause | ||
| 1157 | Hyperthyroidism | Graves/toxic nodules | Autoimmune/nodular | Weight loss, tremor, tachycardia | Antithyroid drugs/radioiodine/surgery | ||
| 1158 | Hypothyroidism | Hashimoto/iodine deficiency etc. | Autoimmune/nutritional | Fatigue, weight gain | Levothyroxine | ||
| 1159 | Hashimoto thyroiditis | Autoimmune | Immune | Hypothyroidism/goiter | Levothyroxine when hypothyroid | ||
| 1160 | Graves disease | TSH-receptor antibodies | Autoimmune | Hyperthyroidism/eye disease | Antithyroid/radioiodine/surgery | ||
| 1161 | Thyroid storm | Severe thyrotoxicosis | Hyperthyroidism trigger | Fever, tachycardia, delirium | ICU antithyroid therapy | ||
| 1162 | Myxedema coma | Severe hypothyroidism | Untreated hypothyroidism | Hypothermia, altered consciousness | Emergency thyroid hormone/support | ||
| 1163 | Primary hyperparathyroidism | Parathyroid adenoma/hyperplasia | Sporadic/genetic | Hypercalcemia, stones | Surgery selected | ||
| 1164 | Hypoparathyroidism | Low PTH | Surgery/autoimmune/genetic | Hypocalcemia, tetany | Calcium/vitamin D | ||
| 1165 | Hyperparathyroid crisis | Severe hypercalcemia | Hyperparathyroidism | Dehydration/confusion | Emergency fluids + treatment | ||
| 1166 | Cushing syndrome | Excess cortisol | Steroids/tumor | Obesity, hypertension, weakness | Remove cause/medical therapy | ||
| 1167 | Addison disease | Adrenal insufficiency | Autoimmune/infection | Weight loss, hypotension, pigmentation | Lifelong glucocorticoid/mineralocorticoid | ||
| 1168 | Adrenal crisis | Acute cortisol deficiency | Addison/steroid withdrawal | Shock, vomiting | Emergency hydrocortisone/fluids | ||
| 1169 | Conn syndrome | Aldosterone-producing adenoma/hyperplasia | Adrenal | Hypertension, hypokalemia | Surgery/aldosterone blockade | ||
| 1170 | Congenital adrenal hyperplasia | CYP21A2 etc. | Genetic | Virilization/salt wasting | Steroid replacement | ||
| 1171 | Acromegaly | Growth hormone excess | Pituitary adenoma | Enlarged hands/face | Surgery/medical therapy | ||
| 1172 | Gigantism | GH excess before epiphyseal closure | Pituitary | Excessive height | Tumor treatment | ||
| 1173 | Growth hormone deficiency | GH deficiency | Congenital/acquired | Short stature | GH in selected patients | ||
| 1174 | Prolactinoma | Prolactin-secreting adenoma | Pituitary | Galactorrhea/amenorrhea | Dopamine agonist | ||
| 1175 | Panhypopituitarism | Multiple pituitary hormone deficiencies | Tumor/surgery/immune etc. | Multiple endocrine deficiencies | Hormone replacement | ||
| 1176 | Diabetes insipidus | ADH disorder | Central/nephrogenic | Polyuria/polydipsia | Cause-specific | ||
| 1177 | MEN syndrome | Genetic endocrine tumor syndromes | MEN1/RET etc. | Multiple endocrine tumors | Genetic screening/surveillance | ||
| 1178 | Osteoporosis | Low bone density | Aging/hormonal/drugs | Fragility fractures | Calcium/vitamin D/exercise; drugs | ||
| 1179 | Osteomalacia | Poor bone mineralization | Vitamin D/phosphate deficiency | Bone pain/weakness | Vitamin D/mineral replacement | ||
| 1180 | Rickets | Defective bone mineralization | Vitamin D/phosphate deficiency | Skeletal deformity | Vitamin D/mineral replacement | ||
| 1181 | Gout | Monosodium urate crystals | Hyperuricemia | Acute arthritis | Urate lowering/anti-inflammatory | ||
| 1182 | Pseudogout | CPPD crystals | Crystal deposition | Acute arthritis | NSAIDs/colchicine | ||
| 1183 | Rheumatoid arthritis | Autoimmune | Immune/genetic | Symmetric inflammatory arthritis | DMARDs/biologics | ||
| 1184 | Systemic lupus erythematosus | Autoimmune | Immune/genetic | Multisystem inflammation | Hydroxychloroquine/immunosuppression | ||
| 1185 | Systemic sclerosis | Autoimmune fibrosis | Immune/genetic | Skin thickening/organ fibrosis | Organ-specific immunotherapy | ||
| 1186 | Sjögren syndrome | Autoimmune exocrine disease | Immune | Dry eyes/mouth | Lubricants/immunomodulation | ||
| 1187 | Dermatomyositis | Autoimmune muscle/skin disease | Immune | Proximal weakness/rash | Immunosuppression | ||
| 1188 | Polymyositis | Immune myopathy | Autoimmune | Proximal weakness | Immunosuppression | ||
| 1189 | Polymyalgia rheumatica | Inflammatory disease | Immune/age-related | Shoulder/hip stiffness | Glucocorticoids | ||
| 1190 | Giant cell arteritis | Large-vessel vasculitis | Immune | Headache, jaw pain, visual risk | Urgent steroids | ||
| 1191 | Takayasu arteritis | Large-vessel vasculitis | Autoimmune | Young patient, pulse deficits | Immunosuppression | ||
| 1192 | Polyarteritis nodosa | Medium-vessel vasculitis | Immune; HBV association | Systemic/renal/nerve symptoms | Immunosuppression | ||
| 1193 | Granulomatosis with polyangiitis | ANCA-associated vasculitis | Autoimmune | ENT/lung/kidney disease | Immunosuppression | ||
| 1194 | Microscopic polyangiitis | ANCA-associated vasculitis | Autoimmune | Kidney/lung disease | Immunosuppression | ||
| 1195 | Behçet disease | Systemic inflammatory disease | Immune/genetic | Oral/genital ulcers, eye disease | Immunomodulation | ||
| 1196 | Antiphospholipid syndrome | Autoantibodies | Autoimmune | Thrombosis/pregnancy morbidity | Anticoagulation | ||
| 1197 | Mixed connective tissue disease | Autoimmune | Anti-U1 RNP | Raynaud/arthritis/organ disease | Immunosuppression | ||
| 1198 | Undifferentiated connective tissue disease | Autoimmune | Immune | Variable connective-tissue symptoms | Monitoring/symptom treatment | ||
| 1199 | Raynaud phenomenon | Vasospasm | Primary/secondary | Finger color changes with cold/stress | Avoid triggers/vasodilators | ||
| 1200 | Chronic fatigue syndrome / ME | Complex multisystem condition | Multifactorial | Post-exertional malaise, fatigue | Pacing/symptom management |
Diseases and Medical Conditions: Causes, Symptoms, Prevention & Treatment
Diseases and Medical Conditions: Causes, Symptoms, Prevention & Treatment
Diseases FAQ With Answers
1. Malaria
Q1. What causes malaria?
Answer: Malaria is caused by Plasmodium species.
Q2. What is the vector for malaria?
Answer: Female Anopheles mosquitoes.
Q3. How is malaria transmitted?
Answer: It is transmitted through a mosquito bite.
Q4. What are the main symptoms of malaria?
Answer: Fever, chills, and sweating.
Q5. How can malaria be prevented?
Answer: Use mosquito nets, repellents, and vector-control measures.
Q6. How is malaria treated?
Answer: Malaria is treated with antimalarial drugs.
2. Dengue
Q1. What causes dengue?
Answer: Dengue is caused by the dengue virus.
Q2. What is the vector for dengue?
Answer: Aedes mosquitoes.
Q3. How is dengue transmitted?
Answer: It is transmitted through a mosquito bite.
Q4. What are the main symptoms of dengue?
Answer: Fever, headache, and muscle or joint pain.
Q5. How can dengue be prevented?
Answer: Remove standing water and use mosquito repellents.
Q6. How is dengue treated?
Answer: Treatment is mainly supportive; severe cases need hospital care.
3. Chikungunya
Q1. What causes chikungunya?
Answer: Chikungunya is caused by the chikungunya virus.
Q2. What is the vector for chikungunya?
Answer: Aedes mosquitoes.
Q3. How is chikungunya transmitted?
Answer: It is transmitted through a mosquito bite.
Q4. What are the main symptoms of chikungunya?
Answer: Fever and severe joint pain.
Q5. How can chikungunya be prevented?
Answer: Through mosquito-control measures.
Q6. How is chikungunya treated?
Answer: Treatment is supportive care.
4. Zika
Q1. What causes Zika?
Answer: Zika is caused by the Zika virus.
Q2. What is the vector for Zika?
Answer: Aedes mosquitoes.
Q3. How is Zika transmitted?
Answer: Through mosquito bites and also through sexual transmission.
Q4. What are the main symptoms of Zika?
Answer: Fever, rash, and joint pain.
Q5. How can Zika be prevented?
Answer: Use mosquito-control measures and take appropriate sexual precautions.
Q6. How is Zika treated?
Answer: Treatment is supportive care.
5. Yellow Fever
Q1. What causes yellow fever?
Answer: Yellow fever is caused by the yellow fever virus.
Q2. What is the vector for yellow fever?
Answer: Mosquitoes.
Q3. How is yellow fever transmitted?
Answer: Through a mosquito bite.
Q4. What are the main symptoms of yellow fever?
Answer: Fever, jaundice, and headache.
Q5. How can yellow fever be prevented?
Answer: Through vaccination and mosquito control.
Q6. How is yellow fever treated?
Answer: Supportive and hospital care may be required.
6. Japanese Encephalitis
Q1. What causes Japanese encephalitis?
Answer: Japanese encephalitis is caused by the JE virus.
Q2. What is the vector for Japanese encephalitis?
Answer: Culex mosquitoes.
Q3. How is Japanese encephalitis transmitted?
Answer: Through a mosquito bite.
Q4. What are the main symptoms?
Answer: Fever, confusion, and seizures.
Q5. How can it be prevented?
Answer: Through vaccination and mosquito control.
Q6. How is it treated?
Answer: Supportive hospital care is used.
7. West Nile Disease
Q1. What causes West Nile disease?
Answer: West Nile disease is caused by the West Nile virus.
Q2. What is the vector?
Answer: Culex mosquitoes.
Q3. How is it transmitted?
Answer: Through a mosquito bite.
Q4. What are the main symptoms?
Answer: Fever and, in some cases, encephalitis.
Q5. How can it be prevented?
Answer: Through mosquito-control measures.
Q6. How is it treated?
Answer: Treatment is supportive care.
8. Lymphatic Filariasis
Q1. What causes lymphatic filariasis?
Answer: It is caused by filarial worms.
Q2. What is the vector?
Answer: Mosquitoes.
Q3. How is it transmitted?
Answer: Through a mosquito bite.
Q4. What are the main symptoms?
Answer: Limb and genital swelling.
Q5. How can it be prevented?
Answer: Through mosquito control and mass drug programs.
Q6. How is it treated?
Answer: Antifilarial medicines and supportive care are used.
9. Rift Valley Fever
Q1. What causes Rift Valley fever?
Answer: It is caused by RVF virus.
Q2. What is the vector?
Answer: Mosquitoes.
Q3. How is it transmitted?
Answer: Through mosquito bites and contact involving infected animals.
Q4. What are the main symptoms?
Answer: Fever and weakness.
Q5. How can it be prevented?
Answer: Through mosquito and vector control.
Q6. How is it treated?
Answer: Treatment is supportive care.
10. Rabies
Q1. What causes rabies?
Answer: Rabies is caused by the rabies virus.
Q2. What is the vector or source?
Answer: The source is an infected animal.
Q3. How is rabies transmitted?
Answer: Through the bite or saliva of an infected animal.
Q4. What are the main symptoms?
Answer: Fever and neurological symptoms.
Q5. How can rabies be prevented?
Answer: Through vaccination and avoiding animal bites.
Q6. How is rabies treated?
Answer: Immediate post-exposure treatment is required; once symptoms appear, rabies is usually fatal.
11. Tuberculosis
Q1. What causes tuberculosis?
Answer: Tuberculosis is caused by Mycobacterium tuberculosis.
Q2. What is the vector or source?
Answer: No vector is stated in the source.
Q3. How is tuberculosis transmitted?
Answer: Through the airborne route.
Q4. What are the main symptoms?
Answer: Cough, fever, and weight loss.
Q5. How can tuberculosis be prevented?
Answer: Vaccination where recommended and good ventilation are listed as preventive measures.
Q6. How is tuberculosis treated?
Answer: Treatment uses combination antibiotics.
12. Cholera
Q1. What causes cholera?
Answer: Cholera is caused by Vibrio cholerae.
Q2. What is the vector or source?
Answer: No vector is stated in the source.
Q3. How is cholera transmitted?
Answer: Through contaminated food or water.
Q4. What is the main symptom?
Answer: Profuse watery diarrhea.
Q5. How can cholera be prevented?
Answer: Use safe water and maintain sanitation.
Q6. How is cholera treated?
Answer: Rehydration is the main treatment; antibiotics may be used in selected cases.
13. Typhoid Fever
Q1. What causes typhoid fever?
Answer: Typhoid fever is caused by Salmonella Typhi.
Q2. What is the vector or source?
Answer: No vector is stated in the source.
Q3. How is typhoid fever transmitted?
Answer: Through contaminated food and water.
Q4. What are the main symptoms?
Answer: Prolonged fever and abdominal symptoms.
Q5. How can typhoid fever be prevented?
Answer: Through safe food and water practices and vaccination.
Q6. How is typhoid fever treated?
Answer: With antibiotics guided by resistance patterns.
14. Paratyphoid Fever
Q1. What causes paratyphoid fever?
Answer: It is caused by Salmonella Paratyphi.
Q2. What is the vector or source?
Answer: No vector is stated in the source.
Q3. How is it transmitted?
Answer: Through food and water.
Q4. What are the main symptoms?
Answer: Fever and abdominal symptoms.
Q5. How can it be prevented?
Answer: Through food and water hygiene.
Q6. How is it treated?
Answer: With antibiotics.
15. Diphtheria
Q1. What causes diphtheria?
Answer: Diphtheria is caused by Corynebacterium diphtheriae.
Q2. What is the vector or source?
Answer: No vector is stated in the source.
Q3. How is diphtheria transmitted?
Answer: Through respiratory droplets or contact.
Q4. What are the main symptoms?
Answer: Sore throat, a membrane, and breathing difficulty.
Q5. How can diphtheria be prevented?
Answer: Through vaccination.
Q6. How is diphtheria treated?
Answer: With antitoxin and antibiotics.
16. Tetanus
Q1. What causes tetanus?
Answer: Tetanus is caused by Clostridium tetani.
Q2. What is the vector or source?
Answer: No vector is stated in the source.
Q3. How is tetanus transmitted?
Answer: Spores enter through wounds.
Q4. What are the main symptoms?
Answer: Muscle stiffness and spasms.
Q5. How can tetanus be prevented?
Answer: Through vaccination and proper wound care.
Q6. How is tetanus treated?
Answer: With antitoxin, antibiotics, and supportive care.
17. Pertussis
Q1. What causes pertussis?
Answer: Pertussis is caused by Bordetella pertussis.
Q2. What is the vector or source?
Answer: No vector is stated in the source.
Q3. How is pertussis transmitted?
Answer: Through respiratory droplets.
Q4. What are the main symptoms?
Answer: Severe coughing fits.
Q5. How can pertussis be prevented?
Answer: Through vaccination.
Q6. How is pertussis treated?
Answer: With antibiotics and supportive care.
18. Pneumococcal Disease
Q1. What causes pneumococcal disease?
Answer: It is caused by Streptococcus pneumoniae.
Q2. What is the vector or source?
Answer: No vector is stated in the source.
Q3. How is it transmitted?
Answer: Through respiratory droplets.
Q4. What are the main symptoms or conditions?
Answer: Pneumonia, meningitis, and ear infection.
Q5. How can it be prevented?
Answer: Through vaccination.
Q6. How is it treated?
Answer: With antibiotics.
19. Meningococcal Disease
Q1. What causes meningococcal disease?
Answer: It is caused by Neisseria meningitidis.
Q2. What is the vector or source?
Answer: No vector is stated in the source.
Q3. How is it transmitted?
Answer: Through respiratory secretions.
Q4. What are the main symptoms?
Answer: Fever, meningitis, and rash.
Q5. How can it be prevented?
Answer: Through vaccination.
Q6. How is it treated?
Answer: Urgent antibiotics are required.
20. Leprosy
Q1. What causes leprosy?
Answer: Leprosy is caused by Mycobacterium leprae.
Q2. What is the vector or source?
Answer: No vector is stated in the source.
Q3. How is leprosy transmitted?
Answer: Through prolonged close contact; the respiratory route is listed as likely.
Q4. What are the main symptoms?
Answer: Skin lesions, numbness, and nerve damage.
Q5. How can leprosy be prevented?
Answer: Through early diagnosis and treatment.
Q6. How is leprosy treated?
Answer: With multidrug therapy.
Diseases and Medical Conditions: Causes, Symptoms, Prevention & Treatment
Diseases 21–100 — FAQ With Answers
21. Gonorrhea
Q1. What causes gonorrhea?
Answer: Gonorrhea is caused by Neisseria gonorrhoeae.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is gonorrhea transmitted?
Answer: Through sexual contact.
Q4. What are the main symptoms?
Answer: Discharge and painful urination; it may also be asymptomatic.
Q5. How can gonorrhea be prevented?
Answer: Use condoms and undergo testing.
Q6. How is gonorrhea treated?
Answer: With antibiotics.
22. Syphilis
Q1. What causes syphilis?
Answer: Syphilis is caused by Treponema pallidum.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is syphilis transmitted?
Answer: Through sexual or vertical transmission.
Q4. What are the main symptoms?
Answer: Sores and rash; later organ damage can occur.
Q5. How can syphilis be prevented?
Answer: Safer sex practices and testing.
Q6. How is syphilis treated?
Answer: Penicillin-based treatment.
23. Chlamydia
Q1. What causes chlamydia?
Answer: Chlamydia is caused by Chlamydia trachomatis.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is chlamydia transmitted?
Answer: Through sexual contact.
Q4. What are the main symptoms?
Answer: It is often asymptomatic; discharge or pelvic pain may occur.
Q5. How can chlamydia be prevented?
Answer: Use condoms and undergo testing.
Q6. How is chlamydia treated?
Answer: With antibiotics.
24. Lyme Disease
Q1. What causes Lyme disease?
Answer: Lyme disease is caused by Borrelia species.
Q2. What is the vector?
Answer: Ticks.
Q3. How is Lyme disease transmitted?
Answer: Through a tick bite.
Q4. What are the main symptoms?
Answer: Rash, fever, and joint or nerve problems.
Q5. How can Lyme disease be prevented?
Answer: Avoid tick exposure.
Q6. How is Lyme disease treated?
Answer: With antibiotics.
25. Plague
Q1. What causes plague?
Answer: Plague is caused by Yersinia pestis.
Q2. What is the vector?
Answer: Fleas.
Q3. How is plague transmitted?
Answer: Through flea bites or contact with infected animals.
Q4. What are the main symptoms?
Answer: Fever and swollen lymph nodes.
Q5. How can plague be prevented?
Answer: Rodent and flea control.
Q6. How is plague treated?
Answer: Urgent antibiotic treatment.
26. Scrub Typhus
Q1. What causes scrub typhus?
Answer: Scrub typhus is caused by Orientia tsutsugamushi.
Q2. What is the vector?
Answer: Chiggers or mites.
Q3. How is scrub typhus transmitted?
Answer: Through a mite bite.
Q4. What are the main symptoms?
Answer: Fever, headache, and rash.
Q5. How can scrub typhus be prevented?
Answer: Avoid mite exposure.
Q6. How is scrub typhus treated?
Answer: With antibiotics.
27. Typhus
Q1. What causes typhus?
Answer: Typhus is caused by Rickettsia species.
Q2. What is the vector?
Answer: Lice, fleas, or mites depending on the type.
Q3. How is typhus transmitted?
Answer: Through arthropod bites.
Q4. What are the main symptoms?
Answer: Fever, headache, and rash.
Q5. How can typhus be prevented?
Answer: Hygiene and vector control.
Q6. How is typhus treated?
Answer: With antibiotics.
28. Rocky Mountain Spotted Fever
Q1. What causes Rocky Mountain spotted fever?
Answer: It is caused by Rickettsia rickettsii.
Q2. What is the vector?
Answer: Ticks.
Q3. How is it transmitted?
Answer: Through a tick bite.
Q4. What are the main symptoms?
Answer: Fever, headache, and rash.
Q5. How can it be prevented?
Answer: Avoid tick exposure.
Q6. How is it treated?
Answer: With doxycycline.
29. Brucellosis
Q1. What causes brucellosis?
Answer: Brucellosis is caused by Brucella species.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is brucellosis transmitted?
Answer: Through unpasteurized dairy products or animal contact.
Q4. What are the main symptoms?
Answer: Fever, sweating, and joint pain.
Q5. How can brucellosis be prevented?
Answer: Pasteurization and animal precautions.
Q6. How is brucellosis treated?
Answer: With combination antibiotics.
30. Anthrax
Q1. What causes anthrax?
Answer: Anthrax is caused by Bacillus anthracis.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is anthrax transmitted?
Answer: Through animal products or exposure to spores.
Q4. What are the main symptoms?
Answer: A skin lesion or severe systemic disease.
Q5. How can anthrax be prevented?
Answer: Occupational precautions and vaccination for selected groups.
Q6. How is anthrax treated?
Answer: With antibiotics.
31. Botulism
Q1. What causes botulism?
Answer: Botulism is caused by Clostridium botulinum toxin.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is botulism transmitted?
Answer: Through contaminated food, wounds, or in infants through the relevant exposure route.
Q4. What are the main symptoms?
Answer: Paralysis and difficulty breathing.
Q5. How can botulism be prevented?
Answer: Safe food preservation.
Q6. How is botulism treated?
Answer: Antitoxin and intensive care.
32. Salmonellosis
Q1. What causes salmonellosis?
Answer: Salmonellosis is caused by Salmonella species.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is salmonellosis transmitted?
Answer: Through contaminated food or water.
Q4. What are the main symptoms?
Answer: Diarrhea, fever, and cramps.
Q5. How can salmonellosis be prevented?
Answer: Food safety.
Q6. How is salmonellosis treated?
Answer: Fluids are used; antibiotics are used for selected severe cases.
33. Shigellosis
Q1. What causes shigellosis?
Answer: Shigellosis is caused by Shigella species.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is shigellosis transmitted?
Answer: Through the fecal-oral route.
Q4. What are the main symptoms?
Answer: Bloody diarrhea and fever.
Q5. How can shigellosis be prevented?
Answer: Handwashing and sanitation.
Q6. How is shigellosis treated?
Answer: Fluids and antibiotics in selected cases.
34. Campylobacteriosis
Q1. What causes campylobacteriosis?
Answer: It is caused by Campylobacter species.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is it transmitted?
Answer: Through undercooked food or contamination.
Q4. What are the main symptoms?
Answer: Diarrhea, fever, and cramps.
Q5. How can it be prevented?
Answer: Food hygiene.
Q6. How is it treated?
Answer: Fluids and antibiotics in selected cases.
35. Listeriosis
Q1. What causes listeriosis?
Answer: Listeriosis is caused by Listeria monocytogenes.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is listeriosis transmitted?
Answer: Through contaminated food.
Q4. What are the main symptoms?
Answer: Fever; severe disease can occur in pregnancy and newborns.
Q5. How can listeriosis be prevented?
Answer: Food safety.
Q6. How is listeriosis treated?
Answer: With antibiotics.
36. Hepatitis A
Q1. What causes hepatitis A?
Answer: Hepatitis A is caused by HAV.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is hepatitis A transmitted?
Answer: Through contaminated food or water and close contact.
Q4. What are the main symptoms?
Answer: Fever, nausea, and jaundice.
Q5. How can hepatitis A be prevented?
Answer: Vaccination and sanitation.
Q6. How is hepatitis A treated?
Answer: Supportive care.
37. Hepatitis B
Q1. What causes hepatitis B?
Answer: Hepatitis B is caused by HBV.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is hepatitis B transmitted?
Answer: Through blood, sexual transmission, and mother-to-child transmission.
Q4. What are the main symptoms?
Answer: Liver inflammation; chronic disease is possible.
Q5. How can hepatitis B be prevented?
Answer: Vaccination and safe blood and sexual practices.
Q6. How is hepatitis B treated?
Answer: Antiviral treatment is used for selected chronic cases.
38. Hepatitis C
Q1. What causes hepatitis C?
Answer: Hepatitis C is caused by HCV.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is hepatitis C transmitted?
Answer: Through blood exposure.
Q4. What are the main symptoms?
Answer: It is often silent and may cause chronic liver disease.
Q5. How can hepatitis C be prevented?
Answer: Safe injections and safe blood practices.
Q6. How is hepatitis C treated?
Answer: Direct-acting antivirals can cure most infections.
39. Hepatitis E
Q1. What causes hepatitis E?
Answer: Hepatitis E is caused by HEV.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is hepatitis E transmitted?
Answer: Mainly through contaminated water or food.
Q4. What are the main symptoms?
Answer: Hepatitis and jaundice.
Q5. How can hepatitis E be prevented?
Answer: Safe water and food.
Q6. How is hepatitis E treated?
Answer: Usually with supportive care.
40. HIV Infection / AIDS
Q1. What causes HIV infection/AIDS?
Answer: It is caused by HIV.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is HIV transmitted?
Answer: Through sexual transmission, blood exposure, and mother-to-child transmission.
Q4. What are the main symptoms/features?
Answer: Immune-system damage and opportunistic infections.
Q5. How can HIV infection be prevented?
Answer: Prevention, testing, and PrEP/PEP where appropriate.
Q6. How is HIV infection treated?
Answer: Lifelong antiretroviral therapy.
41. COVID-19
Q1. What causes COVID-19?
Answer: COVID-19 is caused by SARS-CoV-2.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is COVID-19 transmitted?
Answer: Through respiratory particles.
Q4. What are the main symptoms?
Answer: Fever, cough, and sore throat; severe respiratory disease is possible.
Q5. How can COVID-19 be prevented?
Answer: Vaccination, ventilation, and infection-control measures.
Q6. How is COVID-19 treated?
Answer: Supportive care; antivirals may be used for eligible high-risk patients.
42. Influenza
Q1. What causes influenza?
Answer: Influenza is caused by influenza viruses.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is influenza transmitted?
Answer: Through respiratory droplets and aerosols.
Q4. What are the main symptoms?
Answer: Fever, cough, and body aches.
Q5. How can influenza be prevented?
Answer: Annual vaccination and hygiene.
Q6. How is influenza treated?
Answer: Supportive care; antivirals are used for selected patients.
43. Measles
Q1. What causes measles?
Answer: Measles is caused by the measles virus.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is measles transmitted?
Answer: Through airborne transmission.
Q4. What are the main symptoms?
Answer: Fever, cough, and rash.
Q5. How can measles be prevented?
Answer: MMR vaccination.
Q6. How is measles treated?
Answer: Supportive care; vitamin A may be used in children where recommended.
44. Mumps
Q1. What causes mumps?
Answer: Mumps is caused by the mumps virus.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is mumps transmitted?
Answer: Through respiratory droplets.
Q4. What are the main symptoms?
Answer: Swollen salivary glands and fever.
Q5. How can mumps be prevented?
Answer: MMR vaccination.
Q6. How is mumps treated?
Answer: Supportive care.
45. Rubella
Q1. What causes rubella?
Answer: Rubella is caused by the rubella virus.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is rubella transmitted?
Answer: Through respiratory droplets.
Q4. What are the main symptoms?
Answer: Mild fever and rash.
Q5. How can rubella be prevented?
Answer: MMR vaccination.
Q6. How is rubella treated?
Answer: Supportive care.
46. Chickenpox
Q1. What causes chickenpox?
Answer: Chickenpox is caused by varicella-zoster virus.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is chickenpox transmitted?
Answer: Through airborne transmission or contact.
Q4. What are the main symptoms?
Answer: An itchy blistering rash and fever.
Q5. How can chickenpox be prevented?
Answer: Vaccination.
Q6. How is chickenpox treated?
Answer: Supportive care; antivirals are used for selected patients.
47. Shingles
Q1. What causes shingles?
Answer: Shingles is caused by reactivation of varicella-zoster virus.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is shingles transmitted?
Answer: Contact with blister fluid can transmit chickenpox.
Q4. What are the main symptoms?
Answer: A painful localized rash.
Q5. How can shingles be prevented?
Answer: Through shingles vaccination.
Q6. How is shingles treated?
Answer: With antiviral medicines and pain management.
48. Polio
Q1. What causes polio?
Answer: Polio is caused by poliovirus.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is polio transmitted?
Answer: Through the fecal-oral route.
Q4. What are the main symptoms?
Answer: Fever and sometimes paralysis.
Q5. How can polio be prevented?
Answer: Polio vaccination and sanitation.
Q6. How is polio treated?
Answer: Supportive care.
49. Hepatitis D
Q1. What causes hepatitis D?
Answer: Hepatitis D is caused by HDV.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is hepatitis D transmitted?
Answer: Through blood and body fluids; it requires HBV.
Q4. What are the main symptoms?
Answer: Hepatitis.
Q5. How can hepatitis D be prevented?
Answer: Hepatitis B vaccination.
Q6. How is hepatitis D treated?
Answer: Specialist antiviral management.
50. Respiratory Syncytial Virus Disease
Q1. What causes RSV disease?
Answer: RSV disease is caused by respiratory syncytial virus.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is RSV disease transmitted?
Answer: Through respiratory secretions.
Q4. What are the main symptoms?
Answer: Cold-like illness and bronchiolitis.
Q5. How can RSV disease be prevented?
Answer: Hygiene and vaccines or prevention measures for eligible groups.
Q6. How is RSV disease treated?
Answer: Supportive care.
51. Ebola Disease
Q1. What causes Ebola disease?
Answer: Ebola disease is caused by Ebola virus.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is Ebola transmitted?
Answer: Through body fluids and contact.
Q4. What are the main symptoms?
Answer: Fever, vomiting, diarrhea, and bleeding.
Q5. How can Ebola be prevented?
Answer: Infection-control measures.
Q6. How is Ebola treated?
Answer: Specialized supportive care and approved therapies.
52. Marburg Virus Disease
Q1. What causes Marburg virus disease?
Answer: It is caused by Marburg virus.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is it transmitted?
Answer: Through body fluids and contact.
Q4. What are the main symptoms?
Answer: Fever and severe systemic illness.
Q5. How can it be prevented?
Answer: Infection-control measures.
Q6. How is it treated?
Answer: Supportive care.
53. Lassa Fever
Q1. What causes Lassa fever?
Answer: Lassa fever is caused by Lassa virus.
Q2. What is the vector or reservoir?
Answer: Rodent reservoir.
Q3. How is Lassa fever transmitted?
Answer: Through rodent exposure or body fluids.
Q4. What are the main symptoms?
Answer: Fever and weakness; severe disease is possible.
Q5. How can Lassa fever be prevented?
Answer: Rodent control and infection-control measures.
Q6. How is Lassa fever treated?
Answer: Supportive care and selected antiviral use.
54. Mpox
Q1. What causes mpox?
Answer: Mpox is caused by mpox virus.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is mpox transmitted?
Answer: Through skin-to-skin contact, other contact, and respiratory exposure.
Q4. What are the main symptoms?
Answer: Rash, fever, and swollen lymph nodes.
Q5. How can mpox be prevented?
Answer: Vaccination for eligible groups and contact precautions.
Q6. How is mpox treated?
Answer: Supportive care; specific treatment may be used for selected severe cases.
55. Dengue Hemorrhagic / Severe Dengue
Q1. What causes severe dengue?
Answer: Severe dengue is caused by dengue virus.
Q2. What is the vector?
Answer: Aedes mosquitoes.
Q3. How is severe dengue transmitted?
Answer: Through a mosquito bite.
Q4. What are the main symptoms?
Answer: Bleeding, plasma leakage, and shock.
Q5. How can severe dengue be prevented?
Answer: Mosquito control.
Q6. How is severe dengue treated?
Answer: Urgent supportive hospital care.
56. Hand-Foot-and-Mouth Disease
Q1. What causes hand-foot-and-mouth disease?
Answer: It is caused by enteroviruses.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is it transmitted?
Answer: Through respiratory, fecal-oral, and contact routes.
Q4. What are the main symptoms?
Answer: Mouth sores and a rash on the hands and feet.
Q5. How can it be prevented?
Answer: Hand hygiene.
Q6. How is it treated?
Answer: Supportive care.
57. Rotavirus Gastroenteritis
Q1. What causes rotavirus gastroenteritis?
Answer: It is caused by rotavirus.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is it transmitted?
Answer: Through the fecal-oral route.
Q4. What are the main symptoms?
Answer: Severe diarrhea and vomiting in children.
Q5. How can it be prevented?
Answer: Vaccination and hygiene.
Q6. How is it treated?
Answer: Rehydration.
58. Norovirus Gastroenteritis
Q1. What causes norovirus gastroenteritis?
Answer: It is caused by norovirus.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is it transmitted?
Answer: Through food, water, and person-to-person transmission.
Q4. What are the main symptoms?
Answer: Vomiting and diarrhea.
Q5. How can it be prevented?
Answer: Hygiene and food safety.
Q6. How is it treated?
Answer: Rehydration.
59. Viral Gastroenteritis
Q1. What causes viral gastroenteritis?
Answer: It is caused by various viruses.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is it transmitted?
Answer: Through fecal-oral transmission and contact.
Q4. What are the main symptoms?
Answer: Diarrhea and vomiting.
Q5. How can it be prevented?
Answer: Hygiene and safe food and water.
Q6. How is it treated?
Answer: Fluids and electrolytes.
60. Infectious Mononucleosis
Q1. What causes infectious mononucleosis?
Answer: It is caused by Epstein-Barr virus.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is infectious mononucleosis transmitted?
Answer: Through saliva.
Q4. What are the main symptoms?
Answer: Fever, sore throat, and swollen lymph nodes.
Q5. How can it be prevented?
Answer: Avoid sharing saliva.
Q6. How is it treated?
Answer: Supportive care.
61. Amoebiasis
Q1. What causes amoebiasis?
Answer: Amoebiasis is caused by Entamoeba histolytica.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is amoebiasis transmitted?
Answer: Through fecally contaminated food or water.
Q4. What are the main symptoms?
Answer: Diarrhea and abdominal pain.
Q5. How can amoebiasis be prevented?
Answer: Safe water and food.
Q6. How is amoebiasis treated?
Answer: With antiprotozoal medicines.
62. Giardiasis
Q1. What causes giardiasis?
Answer: Giardiasis is caused by Giardia duodenalis.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is giardiasis transmitted?
Answer: Through contaminated water or food.
Q4. What are the main symptoms?
Answer: Diarrhea and bloating.
Q5. How can giardiasis be prevented?
Answer: Safe water.
Q6. How is giardiasis treated?
Answer: With antiprotozoal medicines.
63. Cryptosporidiosis
Q1. What causes cryptosporidiosis?
Answer: Cryptosporidiosis is caused by Cryptosporidium.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is cryptosporidiosis transmitted?
Answer: Through contaminated water or food.
Q4. What is the main symptom?
Answer: Watery diarrhea.
Q5. How can cryptosporidiosis be prevented?
Answer: Safe water and hygiene.
Q6. How is cryptosporidiosis treated?
Answer: Rehydration and selected therapy.
64. Toxoplasmosis
Q1. What causes toxoplasmosis?
Answer: Toxoplasmosis is caused by Toxoplasma gondii.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is toxoplasmosis transmitted?
Answer: Through undercooked meat, cat feces, or congenital transmission.
Q4. What are the main symptoms?
Answer: It is often mild; severe fetal or immune-related disease can occur.
Q5. How can toxoplasmosis be prevented?
Answer: Food precautions and appropriate cat-litter precautions.
Q6. How is toxoplasmosis treated?
Answer: Antiparasitic therapy is used for selected cases.
65. Trichomoniasis
Q1. What causes trichomoniasis?
Answer: Trichomoniasis is caused by Trichomonas vaginalis.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is trichomoniasis transmitted?
Answer: Through sexual contact.
Q4. What are the main symptoms?
Answer: Genital irritation and discharge.
Q5. How can trichomoniasis be prevented?
Answer: Condoms and testing.
Q6. How is trichomoniasis treated?
Answer: With metronidazole or tinidazole.
66. Leishmaniasis
Q1. What causes leishmaniasis?
Answer: Leishmaniasis is caused by Leishmania species.
Q2. What is the vector?
Answer: Sandflies.
Q3. How is leishmaniasis transmitted?
Answer: Through a sandfly bite.
Q4. What are the main symptoms?
Answer: Skin ulcers or systemic disease.
Q5. How can leishmaniasis be prevented?
Answer: Sandfly and vector control.
Q6. How is leishmaniasis treated?
Answer: With antileishmanial drugs.
67. African Trypanosomiasis
Q1. What causes African trypanosomiasis?
Answer: It is caused by Trypanosoma brucei.
Q2. What is the vector?
Answer: Tsetse fly.
Q3. How is it transmitted?
Answer: Through a fly bite.
Q4. What are the main symptoms?
Answer: Fever, sleep disturbance, and neurological disease.
Q5. How can it be prevented?
Answer: Tsetse control.
Q6. How is it treated?
Answer: With stage-specific medicines.
68. Chagas Disease
Q1. What causes Chagas disease?
Answer: Chagas disease is caused by Trypanosoma cruzi.
Q2. What is the vector?
Answer: Triatomine bug.
Q3. How is Chagas disease transmitted?
Answer: Through bug feces; it can also occur through food, congenital transmission, or transfusion.
Q4. What are the main symptoms?
Answer: Fever and later heart or digestive disease.
Q5. How can Chagas disease be prevented?
Answer: Vector control and safe food and blood practices.
Q6. How is Chagas disease treated?
Answer: With antiparasitic drugs.
69. Schistosomiasis
Q1. What causes schistosomiasis?
Answer: Schistosomiasis is caused by Schistosoma species.
Q2. What is the vector?
Answer: Freshwater snails.
Q3. How is schistosomiasis transmitted?
Answer: Through skin contact with contaminated freshwater.
Q4. What are the main symptoms?
Answer: Abdominal or urinary symptoms.
Q5. How can schistosomiasis be prevented?
Answer: Safe water and sanitation.
Q6. How is schistosomiasis treated?
Answer: With praziquantel.
70. Ascariasis
Q1. What causes ascariasis?
Answer: Ascariasis is caused by Ascaris lumbricoides.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is ascariasis transmitted?
Answer: By ingesting eggs from contaminated soil or food.
Q4. What are the main symptoms?
Answer: Abdominal symptoms and worms.
Q5. How can ascariasis be prevented?
Answer: Sanitation and hygiene.
Q6. How is ascariasis treated?
Answer: With anthelmintic drugs.
71. Hookworm Disease
Q1. What causes hookworm disease?
Answer: It is caused by Ancylostoma or Necator species.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is hookworm disease transmitted?
Answer: Larvae penetrate the skin from contaminated soil.
Q4. What are the main symptoms?
Answer: Anemia and abdominal symptoms.
Q5. How can hookworm disease be prevented?
Answer: Wearing footwear and maintaining sanitation.
Q6. How is hookworm disease treated?
Answer: Anthelmintic drugs and iron when needed.
72. Enterobiasis
Q1. What causes enterobiasis?
Answer: Enterobiasis is caused by Enterobius vermicularis.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is enterobiasis transmitted?
Answer: Through ingestion of eggs.
Q4. What is the main symptom?
Answer: Night-time anal itching.
Q5. How can enterobiasis be prevented?
Answer: Hygiene and washing bedding.
Q6. How is enterobiasis treated?
Answer: Anthelmintic treatment.
73. Taeniasis
Q1. What causes taeniasis?
Answer: Taeniasis is caused by Taenia species.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is taeniasis transmitted?
Answer: Through undercooked infected meat.
Q4. What are the main symptoms?
Answer: Abdominal symptoms or no symptoms.
Q5. How can taeniasis be prevented?
Answer: Cook meat thoroughly.
Q6. How is taeniasis treated?
Answer: With anthelmintic drugs.
74. Cysticercosis
Q1. What causes cysticercosis?
Answer: Cysticercosis is caused by Taenia solium larvae.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is cysticercosis transmitted?
Answer: Through ingestion of eggs.
Q4. What are the main symptoms?
Answer: Seizures or neurological disease may occur.
Q5. How can cysticercosis be prevented?
Answer: Sanitation and food hygiene.
Q6. How is cysticercosis treated?
Answer: Antiparasitic and symptom-specific treatment.
75. Strongyloidiasis
Q1. What causes strongyloidiasis?
Answer: Strongyloidiasis is caused by Strongyloides stercoralis.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is strongyloidiasis transmitted?
Answer: Larvae penetrate the skin.
Q4. What are the main symptoms?
Answer: Rash and abdominal symptoms.
Q5. How can strongyloidiasis be prevented?
Answer: Footwear and sanitation.
Q6. How is strongyloidiasis treated?
Answer: With ivermectin.
76. Trichuriasis
Q1. What causes trichuriasis?
Answer: Trichuriasis is caused by Trichuris trichiura.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is trichuriasis transmitted?
Answer: Through ingestion of eggs.
Q4. What are the main symptoms?
Answer: Abdominal symptoms and anemia.
Q5. How can trichuriasis be prevented?
Answer: Sanitation.
Q6. How is trichuriasis treated?
Answer: With anthelmintic drugs.
77. Ringworm
Q1. What causes ringworm?
Answer: Ringworm is caused by dermatophyte fungi.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is ringworm transmitted?
Answer: Through skin contact or contaminated objects.
Q4. What are the main symptoms?
Answer: A ring-shaped itchy rash.
Q5. How can ringworm be prevented?
Answer: Hygiene and avoiding sharing personal items.
Q6. How is ringworm treated?
Answer: With antifungal medicines.
78. Candidiasis
Q1. What causes candidiasis?
Answer: Candidiasis is caused by Candida species.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How does candidiasis occur?
Answer: It usually occurs through overgrowth of normal flora.
Q4. What are the main symptoms?
Answer: Thrush, genital infection, or invasive infection.
Q5. How can candidiasis be prevented?
Answer: Control relevant risk factors.
Q6. How is candidiasis treated?
Answer: With antifungal medicines.
79. Aspergillosis
Q1. What causes aspergillosis?
Answer: Aspergillosis is caused by Aspergillus species.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is aspergillosis transmitted?
Answer: Through inhalation of spores.
Q4. What are the main symptoms?
Answer: Lung disease; invasive disease can occur in high-risk people.
Q5. How can aspergillosis be prevented?
Answer: Reduce exposure in high-risk settings.
Q6. How is aspergillosis treated?
Answer: With antifungal medicines.
80. Histoplasmosis
Q1. What causes histoplasmosis?
Answer: Histoplasmosis is caused by Histoplasma species.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is histoplasmosis transmitted?
Answer: Through inhalation of spores.
Q4. What are the main symptoms?
Answer: Lung disease and sometimes disseminated disease.
Q5. How can histoplasmosis be prevented?
Answer: Avoid heavy exposure to contaminated soil or bird and bat droppings.
Q6. How is histoplasmosis treated?
Answer: With antifungal medicines.
81. Cryptococcosis
Q1. What causes cryptococcosis?
Answer: Cryptococcosis is caused by Cryptococcus species.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is cryptococcosis transmitted?
Answer: Through inhalation of environmental yeast.
Q4. What are the main symptoms?
Answer: Pneumonia and meningitis.
Q5. How can cryptococcosis be prevented?
Answer: Mainly through risk reduction in immunocompromised people.
Q6. How is cryptococcosis treated?
Answer: Antifungal therapy.
82. Scabies
Q1. What causes scabies?
Answer: Scabies is caused by the Sarcoptes scabiei mite.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is scabies transmitted?
Answer: Through prolonged skin contact.
Q4. What are the main symptoms?
Answer: Severe itching and burrows.
Q5. How can scabies be prevented?
Answer: Treat contacts and wash bedding and clothes.
Q6. How is scabies treated?
Answer: With permethrin or other scabicides.
83. Trachoma
Q1. What causes trachoma?
Answer: Trachoma is caused by Chlamydia trachomatis.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is trachoma transmitted?
Answer: Through contact or flies, particularly in association with poor sanitation.
Q4. What are the main symptoms?
Answer: Eye inflammation and scarring.
Q5. How can trachoma be prevented?
Answer: Facial cleanliness and sanitation.
Q6. How is trachoma treated?
Answer: Antibiotics; surgery may be required for advanced disease.
84. Conjunctivitis
Q1. What causes conjunctivitis?
Answer: Conjunctivitis can be caused by viruses or bacteria.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is conjunctivitis transmitted?
Answer: Through contact or respiratory secretions.
Q4. What are the main symptoms?
Answer: A red, watery, or discharging eye.
Q5. How can conjunctivitis be prevented?
Answer: Hand hygiene.
Q6. How is conjunctivitis treated?
Answer: Treatment depends on the cause.
85. Scarlet Fever
Q1. What causes scarlet fever?
Answer: Scarlet fever is caused by Group A Streptococcus.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is scarlet fever transmitted?
Answer: Through respiratory droplets or contact.
Q4. What are the main symptoms?
Answer: Sore throat and a characteristic rash.
Q5. How can scarlet fever be prevented?
Answer: Hygiene and early diagnosis.
Q6. How is scarlet fever treated?
Answer: With antibiotics.
86. Strep Throat
Q1. What causes strep throat?
Answer: Strep throat is caused by Group A Streptococcus.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is strep throat transmitted?
Answer: Through respiratory droplets.
Q4. What are the main symptoms?
Answer: Sore throat and fever.
Q5. How can strep throat be prevented?
Answer: Hygiene.
Q6. How is strep throat treated?
Answer: Antibiotics when confirmed.
87. Rheumatic Fever
Q1. What causes rheumatic fever?
Answer: It is an immune complication of Group A streptococcal infection.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How does rheumatic fever occur?
Answer: It follows untreated strep infection.
Q4. What are the main symptoms?
Answer: Fever and joint or heart inflammation.
Q5. How can rheumatic fever be prevented?
Answer: Prompt treatment of strep infection.
Q6. How is rheumatic fever treated?
Answer: Antibiotics plus anti-inflammatory or supportive treatment.
88. Acute Bacterial Meningitis
Q1. What causes acute bacterial meningitis?
Answer: It can be caused by several bacteria.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is it transmitted?
Answer: Through respiratory or contact routes depending on the organism.
Q4. What are the main symptoms?
Answer: Fever, headache, and stiff neck.
Q5. How can it be prevented?
Answer: Vaccination where available.
Q6. How is it treated?
Answer: Emergency antibiotics.
89. Pneumonia
Q1. What causes pneumonia?
Answer: Pneumonia can be caused by bacteria, viruses, or fungi.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is pneumonia transmitted?
Answer: Through respiratory exposure or aspiration.
Q4. What are the main symptoms?
Answer: Cough, fever, and breathing difficulty.
Q5. How can pneumonia be prevented?
Answer: Vaccination and hygiene.
Q6. How is pneumonia treated?
Answer: Treatment depends on the cause.
90. Otitis Media
Q1. What causes otitis media?
Answer: It is usually caused by bacteria or viruses.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How does otitis media occur?
Answer: It often follows a respiratory infection.
Q4. What are the main symptoms?
Answer: Ear pain and fever.
Q5. How can otitis media be prevented?
Answer: Vaccination and smoke avoidance.
Q6. How is otitis media treated?
Answer: Observation or antibiotics depending on the case.
91. Gastroenteritis
Q1. What causes gastroenteritis?
Answer: Gastroenteritis can be caused by viruses, bacteria, or parasites.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is gastroenteritis transmitted?
Answer: Through food, water, or contact.
Q4. What are the main symptoms?
Answer: Diarrhea and vomiting.
Q5. How can gastroenteritis be prevented?
Answer: Food and water hygiene.
Q6. How is gastroenteritis treated?
Answer: Rehydration and cause-specific treatment.
92. Pelvic Inflammatory Disease
Q1. What causes pelvic inflammatory disease?
Answer: It is usually caused by sexually transmitted bacteria.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How does pelvic inflammatory disease occur?
Answer: Through an ascending genital infection.
Q4. What are the main symptoms?
Answer: Pelvic pain, discharge, and fever.
Q5. How can pelvic inflammatory disease be prevented?
Answer: STI prevention and testing.
Q6. How is pelvic inflammatory disease treated?
Answer: With combination antibiotics.
93. Genital Herpes
Q1. What causes genital herpes?
Answer: Genital herpes is caused by HSV-1 or HSV-2.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is genital herpes transmitted?
Answer: Through skin-to-skin or sexual contact.
Q4. What are the main symptoms?
Answer: Painful blisters or ulcers.
Q5. How can genital herpes be prevented?
Answer: Use condoms and avoid contact during outbreaks.
Q6. How is genital herpes treated?
Answer: With antiviral medicines.
94. HPV Infection
Q1. What causes HPV infection?
Answer: HPV infection is caused by human papillomavirus.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is HPV transmitted?
Answer: Through skin-to-skin or sexual contact.
Q4. What are the main symptoms/features?
Answer: It is often asymptomatic; warts and some cancers can occur.
Q5. How can HPV infection be prevented?
Answer: HPV vaccination and screening.
Q6. How is HPV infection treated?
Answer: There is no treatment for the virus itself; lesions and cancers can be treated.
95. Cervical Cancer
Q1. What causes cervical cancer?
Answer: Cervical cancer is associated with high-risk HPV infection.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is the underlying HPV infection acquired?
Answer: HPV is acquired mainly through sexual contact.
Q4. What are the main symptoms?
Answer: There are often no early symptoms.
Q5. How can cervical cancer be prevented?
Answer: HPV vaccination and cervical screening.
Q6. How is cervical cancer treated?
Answer: Surgery, radiotherapy, or chemotherapy depending on the stage.
96. Viral Encephalitis
Q1. What causes viral encephalitis?
Answer: It can be caused by several viruses.
Q2. What is the vector or origin?
Answer: Sometimes mosquitoes or ticks.
Q3. How is viral encephalitis transmitted?
Answer: Through vector bites or other routes.
Q4. What are the main symptoms?
Answer: Fever, confusion, and seizures.
Q5. How can viral encephalitis be prevented?
Answer: Vaccines and vector control where applicable.
Q6. How is viral encephalitis treated?
Answer: Supportive or ICU care and cause-specific therapy.
97. Hantavirus Disease
Q1. What causes hantavirus disease?
Answer: Hantavirus disease is caused by hantaviruses.
Q2. What is the reservoir?
Answer: Rodents are the reservoir.
Q3. How is hantavirus disease transmitted?
Answer: Through inhalation or contact with rodent excreta.
Q4. What are the main symptoms?
Answer: Fever and severe lung or kidney disease.
Q5. How can hantavirus disease be prevented?
Answer: Rodent control and safe cleaning practices.
Q6. How is hantavirus disease treated?
Answer: Supportive hospital care.
98. Nipah Virus Infection
Q1. What causes Nipah virus infection?
Answer: It is caused by Nipah virus.
Q2. What is the vector or origin?
Answer: No vector is stated in the source.
Q3. How is Nipah virus infection transmitted?
Answer: Through fruit bats or animals and person-to-person transmission.
Q4. What are the main symptoms?
Answer: Fever, encephalitis, and breathing problems.
Q5. How can Nipah virus infection be prevented?
Answer: Avoid exposure to infected animals and their secretions.
Q6. How is Nipah virus infection treated?
Answer: Intensive supportive care.
99. Crimean-Congo Hemorrhagic Fever
Q1. What causes Crimean-Congo hemorrhagic fever?
Answer: It is caused by CCHF virus.
Q2. What is the vector?
Answer: Ticks.
Q3. How is it transmitted?
Answer: Through a tick bite or contact with infected blood.
Q4. What are the main symptoms?
Answer: Fever, bleeding, and severe illness.
Q5. How can it be prevented?
Answer: Tick precautions and infection-control measures.
Q6. How is it treated?
Answer: Intensive supportive care.
100. Yellow Fever
Q1. What causes yellow fever?
Answer: Yellow fever is caused by yellow fever virus.
Q2. What is the vector?
Answer: Mosquitoes.
Q3. How is yellow fever transmitted?
Answer: Through a mosquito bite.
Q4. What are the main symptoms?
Answer: Fever, jaundice, and severe systemic disease.
Q5. How can yellow fever be prevented?
Answer: Vaccination and mosquito control.
Q6. How is yellow fever treated?
Answer: Supportive hospital care.
Diseases and Medical Conditions: Causes, Symptoms, Prevention & Treatment
Pharmaceutical Products, Manufacturing & Global Sourcing Solutions
Nawinza (OPC) Private Limited is engaged in pharmaceutical product sourcing, wholesale supply, export facilitation, contract manufacturing sourcing and private-label opportunities through suitable manufacturers and suppliers in India. We aim to connect international buyers with pharmaceutical products and sourcing solutions according to their business requirements, product specifications and applicable regulatory conditions.
1. Pharmaceutical Medicines Export from India
Nawinza supports international B2B enquiries for pharmaceutical medicines manufactured by eligible and qualified suppliers in India. Product requirements may include generic medicines, branded medicines where authorized, finished pharmaceutical formulations and other eligible healthcare products, subject to availability and applicable regulations.
Our pharmaceutical product categories may include tablets, capsules, syrups, suspensions, injections, creams, ointments, gels, eye drops, ear drops, nasal sprays and other dosage forms.
2. Pharmaceutical Tablets and Capsules
We facilitate sourcing enquiries for pharmaceutical tablets and capsules in different strengths, formulations and pack sizes, depending on supplier availability and regulatory permissions.
Product categories may include:
Antibiotic and antibacterial medicines
Antiallergic and antihistamine medicines
Antidiabetic medicines
Cardiovascular medicines
Gastrointestinal medicines
Pain-relief and anti-inflammatory medicines
Vitamins, minerals and nutritional supplements
Neurology-related medicines
Dermatological medicines
Other eligible therapeutic categories
Product selection, quotations and supply arrangements are subject to product availability, prescription requirements, manufacturer authorization and destination-country regulations.
3. Pharmaceutical Syrups and Oral Suspensions
Nawinza can consider B2B sourcing enquiries for eligible liquid pharmaceutical formulations through qualified suppliers.
These may include oral syrups, suspensions, solutions and other liquid dosage forms, depending on the product, manufacturer capabilities and applicable regulatory requirements.
Buyers can provide the required product name, strength, formulation, pack size, quantity and destination country to help assess sourcing feasibility.
4. Pharmaceutical Injections and Sterile Products
We can evaluate sourcing enquiries for eligible injectable pharmaceutical products through appropriately authorized manufacturers and suppliers.
Depending on availability and regulatory permissions, product requirements may include sterile solutions, injectable formulations and other specialized dosage forms.
Sterile products require suitable manufacturing standards, product-specific documentation, storage conditions and transportation arrangements. Supply is subject to the relevant approvals and legal requirements in the exporting and importing countries.
5. Creams, Ointments, Gels and Topical Medicines
Nawinza can facilitate enquiries for eligible topical pharmaceutical formulations through suitable manufacturers.
Product categories may include dermatological creams, ointments, gels, lotions and other external-use pharmaceutical preparations.
Buyers should specify the product name, active ingredients, strength, formulation, packaging requirements and intended destination to enable a more accurate sourcing assessment.
6. Active Pharmaceutical Ingredients (APIs) and Drug Substances
Active pharmaceutical ingredients are used in the manufacture of pharmaceutical formulations. Nawinza can evaluate B2B sourcing enquiries for APIs and related pharmaceutical raw materials through suitable suppliers, subject to product availability and applicable legal requirements.
Sourcing enquiries may cover:
Active pharmaceutical ingredients
Pharmaceutical-grade raw materials
Selected drug substances and intermediates
Excipients used in pharmaceutical formulations
Product-specific quality and technical documentation
Requirements can be assessed according to the requested specification, quantity, intended use, supplier qualifications and destination-country import rules. API supply is subject to applicable licensing, quality, safety and documentation requirements.
7. Pharmaceutical Third-Party Manufacturing
Nawinza can explore third-party pharmaceutical manufacturing requirements by connecting suitable buyers with qualified manufacturers, where appropriate arrangements are available.
Depending on manufacturer capabilities, enquiries may include tablets, capsules, oral liquids, topical preparations and other permitted pharmaceutical dosage forms.
Buyers can share their product specifications, target quantities, packaging requirements, intended markets and quality documentation requirements for an initial feasibility assessment.
Manufacturing is undertaken by appropriately qualified and authorized facilities. Actual production arrangements depend on manufacturer capacity, regulatory permissions, product suitability and mutually agreed commercial terms.
8. Pharmaceutical Contract Manufacturing and CDMO Sourcing
Contract development and manufacturing services may support pharmaceutical businesses that require external manufacturing capabilities or specialized production services.
Nawinza can assess sourcing requirements for suitable contract manufacturing providers, subject to availability and the scope of services offered by each provider.
Potential enquiries may involve formulation manufacturing, scale-up support, production, filling, packaging and other manufacturing services where offered by qualified facilities.
The availability of development, analytical, sterile manufacturing or specialized biotechnology services must be confirmed separately with the relevant provider.
9. Pharmaceutical OEM and Private-Label Solutions
Nawinza can evaluate OEM and private-label requirements for eligible pharmaceutical products through suitable manufacturers, where permitted by law.
Potential requirements may include:
Product and formulation selection
Manufacturer sourcing
Packaging and labelling requirements
Brand-owner requirements
Product documentation coordination
Export-market suitability assessment
Private-label production is subject to the manufacturer’s capabilities, intellectual property rights, applicable product approvals, labelling rules and the regulatory requirements of the target market.
A private-label or OEM arrangement does not automatically authorize a product for sale in every country.
10. Oncology and Specialized Medicines
Nawinza can assess product-specific sourcing enquiries for eligible oncology and other specialized pharmaceutical medicines through appropriately authorized suppliers.
Requirements may include specific formulations, strengths, packaging and documentation for the intended market.
The sourcing of specialized medicines depends on product authorization, supplier eligibility, applicable restrictions and any special handling or storage requirements. Availability must be confirmed individually for each product.
11. Biologics and Biosimilars
Biologics and biosimilars are specialized pharmaceutical products that may require specific manufacturing, quality assurance, storage and distribution arrangements.
Nawinza can evaluate suitable B2B sourcing enquiries for these products where qualified suppliers and the necessary regulatory arrangements are available.
Potential requirements may include product-specific technical documentation, temperature-controlled logistics, traceability and destination-country approvals.
Supply is subject to applicable product authorization, cold-chain capabilities where required, and the legal requirements governing the particular medicine.
12. Neurology and Central Nervous System (CNS) Medicines
Nawinza can consider sourcing enquiries for eligible medicines used in neurology and other central nervous system-related therapeutic categories.
Requirements may include specific product names, strengths, dosage forms, quantities and packaging configurations.
Certain CNS medicines may be prescription-only, controlled or subject to additional import and export restrictions. Any sourcing or supply arrangement must comply with the applicable requirements of the countries involved.
13. Rare-Disease and Orphan Medicines
Rare-disease medicines are specialized products intended for particular medical conditions and patient populations.
Nawinza can assess specific sourcing enquiries where suitable authorized suppliers, product availability and the required regulatory permissions can be established.
Each enquiry requires an individual assessment of product authorization, availability, documentation, storage conditions and destination-country requirements. No product availability or supply commitment is implied until confirmed.
14. Drug Delivery Systems and Specialized Dosage Forms
Nawinza can evaluate sourcing enquiries for pharmaceutical products incorporating different drug delivery technologies, depending on supplier capabilities and product availability.
Potential product categories may include:
Nasal sprays
Inhalation products and related delivery devices
Transdermal patches
Modified-release pharmaceutical formulations
Selected specialized topical formulations
Other eligible pharmaceutical dosage forms
Requirements are assessed according to product specifications, manufacturer capabilities, applicable approvals and any special storage or handling conditions.
15. Pharmaceutical Quality Documentation and Compliance
Pharmaceutical sourcing and export transactions require appropriate documentation and compliance checks. Documentation requirements vary according to the product, manufacturer, destination country and nature of the transaction.
Depending on the applicable requirements, documents may include:
Manufacturer and product authorization documents
Applicable manufacturing licences
Certificates of Analysis (CoA)
Product specifications and technical documents
Safety Data Sheets (SDS), where applicable
Certificates of Origin, where required
Commercial invoices and packing lists
Export and shipping documentation
Product registration or import authorization documents, where required
Documents are subject to verification and availability from the relevant manufacturer, supplier or competent authority. Requirements must be confirmed for each shipment and destination.
16. Pharmaceutical Wholesale and Bulk Supply
Nawinza can assess wholesale and bulk pharmaceutical enquiries from eligible business buyers, importers, distributors and other authorized customers.
Buyers are encouraged to provide the product name, strength, dosage form, required quantity, packaging details, destination country and preferred delivery terms.
Quotations depend on confirmed supplier pricing, order quantity, product availability, packaging, documentation, freight and applicable commercial conditions. All orders remain subject to regulatory eligibility and supplier confirmation.
17. International Pharmaceutical Sourcing and Export Enquiries
Nawinza welcomes business enquiries from international pharmaceutical buyers seeking to source eligible products from India.
To help assess a requirement, buyers should provide:
Company name and country
Required product or ingredient
Strength and dosage form
Quantity and packaging requirements
Intended use and destination market
Required product documentation
Import licence or other relevant authorization, where applicable
Preferred shipping terms and delivery requirements
Each enquiry is reviewed according to sourcing feasibility, supplier availability, regulatory requirements and commercial suitability. An enquiry does not constitute a confirmed order or guarantee of supply.
18. Pharmaceutical Product Availability and Market-Specific Requirements
Pharmaceutical products differ in their legal status, approved uses, labelling requirements, import eligibility and distribution conditions across countries.
A product that can legally be manufactured or sold in one market may require additional authorization or may not be permitted in another.
Nawinza assesses product enquiries with reference to the intended destination and the information available from relevant suppliers. Buyers remain responsible for meeting their applicable importer, registration, licensing and distribution obligations, with appropriate professional and regulatory guidance.
19. Request a Pharmaceutical Sourcing Quotation
International buyers, importers, wholesalers and eligible business customers may contact Nawinza with their pharmaceutical sourcing requirements.
For a quotation assessment, please include the product name, strength, dosage form, quantity, packaging, destination country and required documentation.
Nawinza (OPC) Private Limited
Website: www.nawinza.com
Email: nawinza2026@gmail.com
Phone / WhatsApp: +91 7709102335
All enquiries are subject to product availability, supplier confirmation, applicable laws, regulatory permissions and mutually agreed commercial terms.
Disclaimer
The information on this page is provided for general B2B sourcing and business enquiry purposes. Product categories described above indicate potential sourcing areas and do not guarantee that every product is currently available or that Nawinza is directly licensed to manufacture, distribute or export every category.
Pharmaceutical manufacturing, procurement, export, import, registration, storage, transportation and sale must comply with the applicable laws and regulatory requirements of the relevant countries. Product licences, registrations, certificates and other documentation must be verified for the specific transaction.
Prescription medicines, controlled substances, sterile products, biologics, oncology medicines and other regulated products may be subject to additional restrictions. No medicine should be supplied or marketed without the necessary authorizations. Buyers and sellers must independently verify the applicable requirements before placing or accepting an order.
Product names and categories are provided for identification and sourcing purposes only. No claim is made that any medicine is suitable for a particular patient, condition or treatment. Medical decisions must be made by appropriately qualified healthcare professionals.
Part 1 — Antibacterial, antifungal and antimicrobial drugs
Drug suffix / stem | Class of drug | Infection / condition | Explanation | Principal therapeutic use |
|---|---|---|---|---|
| Fluoroquinolone antibiotics | Selected UTIs, pyelonephritis, bacterial prostatitis and certain gastrointestinal or respiratory infections | Inhibits bacterial DNA gyrase and/or topoisomerase IV. | Treatment of susceptible bacterial infections when the individual drug is appropriate. |
| Penicillin antibiotics | Strep throat, selected skin infections, susceptible respiratory infections and certain dental infections | Interferes with bacterial cell-wall synthesis. | Treatment of susceptible bacterial infections. |
| Cephalosporin antibiotics | Selected UTIs, pneumonia, skin infections, meningitis and ENT infections | Inhibits bacterial cell-wall synthesis; coverage differs by generation and drug. | Treatment of susceptible bacterial infections. |
| Carbapenem antibiotics | Complicated abdominal infections, complicated UTIs and selected resistant bacterial infections | Inhibits bacterial cell-wall synthesis. | Treatment of serious susceptible bacterial infections. |
| Tetracycline antibiotics | Acne, chlamydial infections, rickettsial infections and selected respiratory infections | Inhibits bacterial protein synthesis. | Treatment of susceptible bacterial infections and selected inflammatory skin conditions. |
| Common pattern among macrolide antibiotics | Selected respiratory and ENT infections, whooping cough and certain chlamydial infections | Inhibits bacterial protein synthesis. | Treatment of selected susceptible bacterial infections. |
| Multiple antibiotic groups | Depends on the individual medicine; may include skin, respiratory or serious systemic infections | This ending occurs in different antibiotic classes and cannot reliably identify the class by itself. | Determined by the complete generic name and its approved indications. |
| Common in certain antibiotic names, including aminoglycosides | Selected serious urinary, bloodstream and other bacterial infections | Certain members inhibit bacterial protein synthesis and may require kidney-function monitoring. | Treatment of susceptible infections with appropriate monitoring. |
| Nitroimidazole antimicrobials | Bacterial vaginosis, trichomoniasis, giardiasis and selected anaerobic infections | Forms reactive metabolites that damage susceptible microorganisms. | Treatment of selected anaerobic bacterial and protozoal infections. |
| Azole antifungals when the complete name identifies this class | Candidiasis, ringworm and selected systemic fungal infections | Many azoles inhibit fungal ergosterol synthesis. | Treatment of susceptible fungal infections, according to the specific agent. |
| Common pattern among azole antifungals | Oral or vaginal candidiasis, dermatophyte infections and selected systemic mycoses | Interferes with fungal membrane sterol synthesis. | Treatment of susceptible fungal infections. |
| Echinocandin antifungals | Invasive candidiasis and selected other serious fungal infections | Inhibits fungal cell-wall glucan synthesis. | Treatment of selected invasive fungal infections. |
| Common pattern among anti-herpesvirus medicines | Cold sores, genital herpes, shingles and chickenpox, depending on the agent | Interferes with viral DNA replication. | Treatment of selected herpesvirus infections. |
| Common pattern among nucleotide/nucleoside antiviral medicines | Hepatitis B and selected HIV treatment regimens, depending on the medicine | Acts on viral nucleic-acid synthesis or related replication processes. | Treatment of specified viral infections. |
| HIV protease inhibitors | HIV infection | Inhibits HIV protease and interferes with viral maturation. | HIV treatment as part of combination antiretroviral therapy. |
| HIV integrase inhibitors | HIV infection; selected agents also have prevention indications | Blocks HIV integrase, preventing integration of viral DNA into host-cell DNA. | Treatment or prevention of HIV, according to the specific medicine. |
| HCV NS5B polymerase inhibitors | Chronic hepatitis C infection | Inhibits viral RNA polymerase. | Hepatitis C treatment as part of an appropriate antiviral regimen. |
| HCV NS5A inhibitors | Chronic hepatitis C infection | Inhibits a viral protein involved in replication and assembly. | Hepatitis C treatment in suitable combination regimens. |
| HCV protease inhibitors | Chronic hepatitis C infection | Inhibits the viral NS3/4A protease. | Hepatitis C treatment according to the selected regimen. |
| Common pattern among influenza neuraminidase inhibitors | Influenza A and B, depending on the agent | Inhibits viral neuraminidase, impairing release of newly formed influenza viruses. | Treatment or prevention of influenza when indicated. |
Part 2 — Cardiovascular and blood-related drugs
Drug suffix / stem | Class of drug | Infection / condition | Explanation | Principal therapeutic use |
|---|---|---|---|---|
| ACE inhibitors | Hypertension, heart failure and selected kidney conditions | Reduces angiotensin II formation and relaxes blood vessels. | Blood-pressure control and selected cardiovascular or renal protection. |
| Angiotensin II receptor blockers (ARBs) | Hypertension, selected heart failure and certain kidney conditions | Blocks angiotensin II receptors. | Management of hypertension and selected cardiovascular or kidney diseases. |
| Beta-adrenergic blockers | Hypertension, angina, selected arrhythmias and certain heart-failure cases | Reduces beta-adrenergic effects on the heart and other tissues. | Management of selected cardiovascular conditions. |
| Dihydropyridine calcium-channel blockers | Hypertension and angina | Relaxes blood vessels by reducing calcium entry into vascular smooth muscle. | Blood-pressure reduction and selected angina treatment. |
| Not a reliable standalone class suffix | Depends on the complete medicine name | Some medicines contain these letters without sharing a pharmacological class. | Determine from the full generic name. |
| HMG-CoA reductase inhibitors | High LDL cholesterol and elevated cardiovascular risk | Reduces hepatic cholesterol synthesis. | Treatment of dyslipidaemia and prevention of cardiovascular events. |
| Direct factor Xa inhibitors | Deep-vein thrombosis (DVT), pulmonary embolism (PE) and eligible patients with atrial fibrillation | Inhibits factor Xa in the coagulation pathway. | Prevention or treatment of selected blood clots and stroke risk associated with atrial fibrillation. |
| Direct thrombin inhibitors | Selected venous thromboembolism and stroke prevention in atrial fibrillation | Inhibits thrombin, reducing clot formation. | Prevention or treatment of specified thromboembolic conditions. |
| Heparin-related anticoagulants | DVT, PE and selected acute cardiovascular conditions | Enhances anticoagulant pathways to reduce clot formation. | Prevention and treatment of blood clots. |
| Common pattern among P2Y12 platelet inhibitors | Selected heart attacks, ischaemic strokes and prevention of stent-related clotting | Inhibits platelet activation through the P2Y12 receptor. | Prevention of selected arterial thrombotic events. |
| Fibrates | High triglycerides and selected mixed lipid disorders | Alters lipid metabolism, particularly triglyceride handling. | Treatment of selected lipid abnormalities. |
| Alpha-1 adrenergic blockers | Hypertension and urinary symptoms of benign prostatic hyperplasia (BPH) | Relaxes vascular and urinary-tract smooth muscle. | Blood-pressure management or relief of selected urinary symptoms. |
| Bisphosphonates | Osteoporosis and selected metabolic bone diseases | Reduces osteoclast-mediated bone resorption. | Prevention or treatment of bone loss and selected bone disorders. |
| Thrombolytic agents | Selected acute ischaemic strokes, myocardial infarction and massive pulmonary embolism | Breaks down fibrin in blood clots. | Emergency clot dissolution in carefully selected patients. |
| PARP inhibitors | Selected ovarian, breast, prostate and other cancers | Inhibits DNA-repair enzymes in susceptible tumour cells. | Targeted treatment of selected cancers. |
| Commonly local anaesthetics; some names have other uses | Procedural pain, dental procedures and regional anaesthesia | Many local anaesthetics block voltage-gated sodium channels in nerves. | Local or regional anaesthesia when the complete drug name confirms this class. |
Part 3 — Diabetes and endocrine drugs
Drug suffix / stem | Class of drug | Infection / condition | Explanation | Principal therapeutic use |
|---|---|---|---|---|
| DPP-4 inhibitors | Type 2 diabetes mellitus | Inhibits DPP-4 and increases incretin activity. | Blood-glucose control in type 2 diabetes. |
| SGLT2 inhibitors | Type 2 diabetes, selected heart failure and chronic kidney disease | Increases urinary glucose excretion and may provide heart and kidney benefits. | Diabetes management and selected cardiovascular and renal indications. |
| Common among GLP-1 receptor agonists | Type 2 diabetes and selected weight-management indications | Activates GLP-1 receptors, affecting glucose regulation, appetite and gastric emptying. | Blood-glucose control and, for selected medicines, chronic weight management. |
| Peptide-drug naming stem, not a single class | Varies by the medicine | Peptides can act on many different receptors and biological pathways. | Determined by the individual drug’s mechanism and approved indications. |
| Biguanide naming pattern | Type 2 diabetes mellitus | Metformin reduces hepatic glucose production and improves insulin sensitivity. | Blood-glucose control. |
| Meglitinide insulin secretagogues | Type 2 diabetes, particularly elevated post-meal glucose | Stimulates pancreatic insulin release. | Improvement of post-meal blood-glucose control. |
| Thiazolidinediones | Type 2 diabetes mellitus | Improves insulin sensitivity in selected tissues. | Blood-glucose control in appropriately selected patients. |
| Common among beta-2 agonist bronchodilators | Asthma and COPD | Relaxes bronchial smooth muscle and opens narrowed airways. | Relief or prevention of bronchospasm, according to the specific agent and regimen. |
| Inhaled antimuscarinic bronchodilators | COPD and selected asthma regimens | Blocks muscarinic receptors in airway smooth muscle. | Bronchodilation and symptom control. |
| Thyroid hormone name, not a general suffix | Hypothyroidism | Levothyroxine replaces deficient thyroid hormone. | Thyroid hormone replacement. |
| Common in GnRH-related drug names | Selected hormone-sensitive cancers, endometriosis and reproductive conditions | Modifies pituitary release of reproductive hormones; effects depend on the agent and regimen. | Treatment of selected endocrine and reproductive disorders. |
| Hormone-related naming pattern | Selected growth-hormone deficiencies and other endocrine disorders | Includes names of hormones or hormone-related medicines; the suffix alone does not identify a unique class. | Hormone replacement or endocrine treatment according to the specific drug. |
Part 4 — Gastrointestinal and digestive-system drugs
Drug suffix / stem | Class of drug | Infection / condition | Explanation | Principal therapeutic use |
|---|---|---|---|---|
| Proton-pump inhibitors (PPIs) | GERD, acid reflux, erosive oesophagitis and peptic ulcers | Suppresses gastric acid secretion by inhibiting the proton pump. | Treatment of acid-related gastrointestinal disorders. |
| Common among histamine H2-receptor antagonists | Heartburn, acid reflux and peptic ulcer disease | Reduces histamine-stimulated gastric acid secretion. | Reduction of gastric acid production. |
| 5-HT3 receptor antagonists | Chemotherapy-associated nausea and postoperative nausea and vomiting | Blocks serotonin receptors involved in the vomiting reflex. | Prevention and treatment of selected forms of nausea and vomiting. |
| Occurs in several unrelated drug names | Depends on the medicine; may include gastrointestinal or neurological conditions | Examples in this family of endings do not all share the same mechanism or indication. | Confirm the complete generic name before assigning a use. |
| GLP-1 receptor agonists among other peptide-name patterns | Type 2 diabetes and approved weight-management indications | Can slow gastric emptying and influence appetite and glucose regulation. | Metabolic treatment, not routine treatment of all digestive complaints. |
| Informal product-name pattern; not a standardized drug suffix | Constipation | Some products bearing this pattern contain laxative ingredients with different mechanisms. | Relief of constipation according to the actual active ingredient. |
| Multiple antibiotic groups | Certain gastrointestinal infections, depending on the medicine | The ending does not uniquely identify an antibiotic class. | Treatment of a specific infection only when the identified drug is appropriate. |
Part 5 — Pain, inflammation, allergy and respiratory drugs
Drug suffix / stem | Class of drug | Infection / condition | Explanation | Principal therapeutic use |
|---|---|---|---|---|
| Common among propionic-acid NSAIDs | Musculoskeletal pain, arthritis, menstrual pain and fever | Reduces prostaglandin synthesis through cyclooxygenase inhibition. | Relief of pain, inflammation and fever. |
| Selective COX-2 inhibitors | Osteoarthritis, rheumatoid arthritis and selected acute pain | Selectively inhibits COX-2-mediated prostaglandin production. | Relief of pain and inflammation in appropriate patients. |
| Pattern found in certain NSAID names | Arthritis, musculoskeletal pain and selected acute pain conditions | Diclofenac is an example; the ending is not a universal class identifier. | Relief of pain and inflammation according to the specific medicine. |
| Common among local anaesthetics | Dental procedures, local pain and regional anaesthesia | Many members block nerve sodium channels and temporarily prevent nerve-signal transmission. | Local or regional anaesthesia. |
| Triptan antimigraine medicines | Acute migraine attacks, with or without aura | Activates specific serotonin receptors involved in migraine pathways. | Acute migraine treatment. |
| Common among benzodiazepines | Anxiety disorders, selected seizures and muscle spasms | Enhances GABA-A receptor-mediated inhibitory signalling. | Anxiolytic, anticonvulsant, muscle-relaxant or sedative treatment, depending on the drug. |
| Common among certain benzodiazepines | Selected anxiety disorders and procedural sedation | Enhances GABA-A receptor activity; duration and clinical role vary by medicine. | Treatment of selected anxiety conditions or sedation when indicated. |
| Occurs in certain antihistamine names | Allergic rhinitis, itching and selected allergic eye conditions | Many members block histamine H1 receptors. | Relief of allergic symptoms, depending on the medicine and route. |
| Common among certain antihistamines | Allergic rhinitis, urticaria and selected motion-related symptoms | Includes medicines with antihistamine effects; some have additional actions. | Treatment of allergies and other drug-specific indications. |
| Occurs in some medicine names but is not a definitive class marker | Depends on the complete drug name | The ending alone cannot reliably identify a pharmacological group. | Determine from the full generic name. |
| Leukotriene receptor antagonists | Asthma control and selected allergic rhinitis cases | Blocks leukotriene-mediated airway inflammation and narrowing. | Long-term control of selected respiratory and allergic conditions; not rescue treatment for acute asthma. |
| Beta-2 agonist bronchodilators | Asthma and COPD | Relaxes airway smooth muscle. | Bronchodilation; the individual agent determines duration and place in therapy. |
| Inhaled antimuscarinic bronchodilators | COPD and selected asthma regimens | Blocks airway muscarinic receptors. | Bronchodilation and respiratory symptom control. |
| Occurs in opioid analgesic names | Moderate to severe pain in selected clinical situations | Opioid-receptor activity alters pain perception and carries dependence and respiratory-depression risks. | Pain relief under appropriate medical supervision. |
| Opioid analgesic name | Severe pain and selected palliative-care situations | Acts primarily at opioid receptors in the central nervous system. | Management of severe pain when indicated. |
Part 6 — Neurology and psychiatric drugs
Drug suffix / stem | Class of drug | Infection / condition | Explanation | Principal therapeutic use |
|---|---|---|---|---|
| Occurs in several antidepressant names | Depression and selected anxiety disorders | Includes different medicines; fluoxetine and paroxetine are SSRIs. The ending itself is not a definitive class marker. | Treatment of the conditions approved for the individual antidepressant. |
| Common among certain antidepressants | Major depressive disorder and selected anxiety disorders | Citalopram and escitalopram inhibit serotonin reuptake. | Treatment of depression and specified anxiety disorders. |
| Common among gabapentinoid names | Neuropathic pain and selected seizure disorders | Pregabalin modulates voltage-gated calcium-channel subunits and reduces certain neuronal signalling. | Treatment of specified neuropathic pain and seizure conditions. |
| Acetylcholinesterase inhibitors | Myasthenia gravis and selected other indications | Inhibits acetylcholinesterase, increasing acetylcholine availability. | Improvement of neuromuscular transmission or other drug-specific effects. |
| Common among certain racetam compounds | Depends on the specific compound and its regulatory status | The suffix does not establish one universal clinical class or approved indication. | Use only according to the identified medicine’s evidence and approved status. |
| Benzodiazepines | Anxiety, selected seizures, muscle spasms and sedation | Enhances GABA-A receptor-mediated inhibition. | Anxiolytic, anticonvulsant or sedative treatment according to the medicine. |
| Benzodiazepines | Selected anxiety disorders and procedural sedation | Enhances GABA-A receptor activity. | Short-term anxiolysis or sedation when clinically indicated. |
| Not a reliable universal drug-class suffix | Depends on the complete drug name | Different drugs with this ending may have unrelated mechanisms and uses. | Must be established from the individual generic name. |
| Appears in several unrelated drug names | Depends on the medicine | This ending can occur in medicines with different pharmacological actions. | Confirm the drug identity and approved indication. |
Part 7 — Antiviral and international medicine stems
Drug suffix / stem | Class of drug | Infection / condition | Explanation | Principal therapeutic use |
|---|---|---|---|---|
| Broad antiviral naming pattern | Depends on the medicine: examples include influenza, herpesvirus infections and chronic viral infections | A broad naming pattern that does not specify a particular virus or mechanism. | Treatment or prevention of specific viral infections when approved. |
| HIV protease inhibitors | HIV infection | Blocks HIV protease and prevents normal viral maturation. | Combination antiretroviral treatment. |
| HIV integrase inhibitors | HIV infection and selected prevention indications | Blocks viral DNA integration. | HIV treatment or prevention according to the specific medicine. |
| HCV NS5B polymerase inhibitors | Chronic hepatitis C | Inhibits hepatitis C RNA replication. | Treatment of hepatitis C in appropriate regimens. |
| HCV NS5A inhibitors | Chronic hepatitis C | Interferes with viral replication and assembly. | Treatment of hepatitis C in combination regimens. |
| HCV protease inhibitors | Chronic hepatitis C | Inhibits the viral NS3/4A protease. | Treatment of hepatitis C according to the appropriate regimen. |
| Common among influenza neuraminidase inhibitors | Influenza A and B, depending on the agent | Inhibits neuraminidase and impairs release of newly formed viruses. | Treatment or prevention of influenza when indicated. |
| Common among anti-herpesvirus medicines | Herpes simplex, shingles and chickenpox, depending on the medicine | Interferes with viral DNA replication. | Treatment of selected herpesvirus infections. |
| Common among nucleotide/nucleoside antiviral names | Hepatitis B and selected HIV treatment regimens, depending on the medicine | Interferes with viral nucleic-acid synthesis or replication. | Treatment of specified viral infections. |
Part 8 — Anticancer and specialist medicines
Drug suffix / stem | Class of drug | Infection / condition | Explanation | Principal therapeutic use |
|---|---|---|---|---|
| Common among targeted kinase inhibitors | Selected cancers and certain specialist diseases | Often inhibits a specific enzyme or cellular signalling pathway. | Targeted treatment according to the drug’s molecular target and approved indications. |
| Common among tyrosine-kinase inhibitors | Certain leukaemias, lung cancers, gastrointestinal stromal tumours and other malignancies | Inhibits specific tyrosine-kinase signalling pathways. | Treatment of selected cancers with the relevant molecular target. |
| Cyclin-dependent kinase 4/6 inhibitors | Selected hormone-receptor-positive breast cancers | Inhibits cell-cycle proteins involved in tumour-cell proliferation. | Treatment of eligible patients with specific breast cancers. |
| PARP inhibitors | Selected ovarian, breast, prostate and other cancers | Interferes with DNA repair in susceptible tumour cells. | Targeted cancer treatment based on tumour type and relevant biomarkers. |
| Common among topoisomerase I inhibitor-related drug names | Selected colorectal, ovarian, lung and other cancers | Interferes with DNA replication in dividing cells. | Chemotherapy for specified malignancies. |
| Platinum-based chemotherapy agents | Selected lung, ovarian, bladder, testicular and other cancers | Forms DNA damage that interferes with cancer-cell replication. | Treatment of selected cancers. |
| Taxane chemotherapy agents | Selected breast, ovarian, lung and other cancers | Disrupts microtubule function during cell division. | Chemotherapy for specified malignancies. |
| Anthracycline-related chemotherapy names | Selected leukaemias, lymphomas and solid tumours | Interferes with DNA-related processes and tumour-cell growth. | Cancer treatment according to the specific medicine and regimen. |
| Alkylating-agent-related drug names | Selected brain tumours, lymphomas and other cancers | Alkylates DNA and disrupts cell replication. | Chemotherapy for specified malignancies. |
| Antifolate chemotherapy drug names | Selected lung cancers and mesothelioma | Interferes with folate-dependent processes needed for DNA synthesis. | Treatment of specified cancers. |
| Established monoclonal-antibody naming stem | Selected cancers, autoimmune diseases and inflammatory conditions | Binds a specific molecular target to alter biological or immune activity. | Targeted biological treatment according to the antibody’s indication. |
Part 9 — Hormones, reproductive health, biologics and advanced medicines
Drug suffix / stem | Class of drug | Infection / condition | Explanation | Principal therapeutic use |
|---|---|---|---|---|
| Occurs in certain steroid-related medicine names | Selected prostate cancers and other hormone-related conditions | Some medicines affect androgen production or steroid-hormone activity. | Hormonal treatment according to the individual medicine. |
| 5-alpha-reductase inhibitors | Benign prostatic hyperplasia and, for selected agents, androgenetic alopecia | Reduces conversion of testosterone to dihydrotestosterone. | Treatment of prostate enlargement or selected hair-loss conditions. |
| Common among prostaglandin-related medicine names | Glaucoma, selected obstetric indications and other specialist conditions | Prostaglandin-related medicines can affect eye pressure, uterine activity and other physiological processes. | Depends on the complete medicine name; examples include latanoprost and misoprostol. |
| Vasopressin-related medicine names | Selected cases of diabetes insipidus and certain bleeding disorders | Some agents act on vasopressin receptors to alter water retention or other physiological responses. | Treatment of specific endocrine, bleeding or fluid-balance conditions. |
| Bisphosphonates | Osteoporosis and selected metabolic bone disorders | Reduces osteoclast-mediated bone resorption. | Prevention or treatment of bone loss and selected bone diseases. |
| Hormone-related naming pattern | Selected growth-hormone deficiencies and endocrine disorders | May occur in hormone names or related medicines; it does not define one universal class. | Hormone replacement or endocrine treatment as indicated. |
| Newer WHO monoclonal-antibody suffix | Selected cancers, immune-mediated diseases and other specialist conditions | Identifies a monoclonal-antibody naming category rather than a specific mechanism. | Determined by the individual antibody’s target and approved indication. |
| Newer WHO monoclonal-antibody suffix | Selected specialist diseases | Represents a category in newer antibody nomenclature. | Targeted biological treatment according to the individual medicine. |
| Newer WHO monoclonal-antibody suffix | Selected cancers and other specialist conditions | Identifies a category of multispecific antibody medicines. | Targeted treatment according to the antibody’s molecular targets. |
| Newer WHO monoclonal-antibody suffix | Selected specialist diseases | Represents a monoclonal-antibody naming category, not one therapeutic class. | Determined by the medicine’s target and approved use. |
| Common among receptor-fusion proteins | Rheumatoid arthritis, psoriasis and selected immune-mediated diseases | Modulates selected immune or inflammatory pathways. | Treatment of specified autoimmune or inflammatory conditions. |
| Erythropoiesis-stimulating agents | Selected anaemias, including certain cases associated with chronic kidney disease | Stimulates red-blood-cell production. | Treatment of specific anaemias when clinically indicated. |
| Thrombolytic agents | Selected acute ischaemic strokes, myocardial infarction and massive pulmonary embolism | Promotes breakdown of fibrin in blood clots. | Emergency clot dissolution in carefully selected patients. |
| Broad enzyme-name ending | Depends on the enzyme; may include certain metabolic disorders or emergency conditions | Enzymes have many unrelated functions, so this ending does not identify one drug class. | Determined by the individual enzyme and its approved indication. |
| Peptide-drug naming stem | Selected diabetes, weight-management, endocrine and other conditions | Peptide medicines act on different receptors and biological pathways. | Treatment of the condition specifically approved for the medicine. |
Complete Guide to Medicine Symbols, Abbreviations and Terms: Rx, XRx, NRx and More
This guide explains the common symbols, prescription markings, dosage abbreviations, medicine forms, packaging terms, and regulatory expressions found on pharmaceutical products. It is written in a professional, educational style that can also be adapted for the Nawinza OPC website.
Important: Medicine markings and legal requirements vary by country. Since the image refers to Indian medicine labels, the regulatory explanations below focus primarily on India. A symbol printed on a medicine pack should not be used as the sole basis for deciding whether a medicine is safe to purchase or use.
1. Prescription and regulatory symbols
Rx
Rx — Prescription medicine
Traditionally derived from the Latin word recipe, meaning “take.” The symbol commonly identifies a medicine supplied on a healthcare professional’s prescription, where required by applicable regulations.
Purpose: Indicates prescription-related status.
Where seen: Medicine cartons, labels and prescriptions.
Important: Rx does not identify the medicine’s strength, safety level or suitability for a particular patient.
XRx
XRx — Schedule X reference in India
XRx is commonly used in educational material to refer to medicines associated with Schedule X controls. However, the symbol alone is not a universal or definitive legal classification.
Purpose: Draws attention to specially regulated medicines.
Regulatory context: Schedule X under India’s Drugs and Cosmetics Rules has specific requirements for covered drugs, including prescription and record-keeping controls.
Important: Do not assume that every medicine displaying XRx is governed by the same restrictions in every country. Verify the actual drug classification and current rules.
NRx
NRx — A prescription-related marking
NRx has been used on Indian pharmaceutical labels in connection with certain medicines subject to additional controls, including medicines covered by relevant provisions for narcotic or psychotropic substances.
Purpose: May indicate a specially controlled prescription category.
Important: NRx is not a universal international symbol and should not automatically be interpreted as meaning every prescription medicine, every narcotic drug or a non-prescription medicine.
Verification: Check the exact medicine, applicable schedule, current legislation and official label.
OTC
OTC — Over the Counter
Refers to medicines that may be sold without a prescription under the applicable rules.
Purpose: Identifies a non-prescription supply category where legally permitted.
Important: OTC status differs between countries and between individual medicines. A product available without a prescription in one country may require one in another.
℞
℞ — Prescription sign
This is the traditional prescription symbol, visually equivalent in meaning to Rx in many contexts. Its presence does not replace the actual prescribing instructions or legal requirements.
2. Other important warnings and medicine-label terms
Term or marking | Full form / meaning | What it tells you |
|---|---|---|
Schedule H | Prescription-controlled category in India | Covered medicines are subject to prescription-related restrictions. |
Schedule H1 | Category under India’s drug rules | Additional controls apply to listed medicines, including specified record-keeping requirements. |
Schedule X | Specially controlled drug category | Specific prescription, storage or record requirements may apply. |
Schedule G | Category under Indian drug rules | Covered medicines carry a caution requiring medical supervision. |
Caution | Safety warning | Read the complete warning and follow professional advice. |
Warning | Risk or restriction notice | May describe side effects, interactions, misuse risks or other hazards. |
For external use only | Not intended to be swallowed | Use only by the route indicated on the label. |
Keep out of reach of children | Child-safety instruction | Store securely to prevent accidental ingestion. |
Not for human use | Not intended for people | May apply to veterinary or other non-human products. |
Veterinary use | Intended for animals | Use according to veterinary directions and the product’s authorised indication. |
Sample / Physician’s sample | Promotional sample designation | Not necessarily intended for ordinary retail sale; follow applicable rules. |
Regulatory note: Schedule classifications are legal categories, not simply marketing labels. A medicine’s actual status must be checked against the current applicable law. Schedule G, H, H1 and X are not interchangeable.
3. Medicine dosage forms and product abbreviations
These abbreviations identify the physical form in which a medicine is manufactured and supplied.
Abbreviation | Full form | Explanation |
|---|---|---|
Tab. | Tablet | Solid dosage form containing a measured amount of medicine. |
Cap. | Capsule | Medicine enclosed in a hard or soft shell. |
Inj. | Injection | Sterile formulation administered by an appropriate injection route. |
Syr. | Syrup | Liquid formulation, often containing dissolved ingredients. |
Susp. | Suspension | Liquid containing dispersed particles that may need shaking. |
Soln. | Solution | Liquid in which the ingredients are dissolved. |
Drops | Drops | Liquid delivered in measured drops, such as eye, ear or oral drops. |
Oint. | Ointment | Semisolid preparation generally intended for application to the skin or another specified site. |
Cream | Cream | Semisolid preparation for a specified application site. |
Gel | Gel | Semisolid formulation with a gel-like consistency. |
Lotion | Lotion | Liquid or fluid preparation for external application. |
Supp. | Suppository | Solid dosage form inserted into the rectum or another specified body cavity. |
Sachet | Sachet | Small packet containing a measured quantity of powder, granules or another formulation. |
SR | Sustained Release | Designed to release the active ingredient over an extended period. |
CR | Controlled Release | Designed to control the release of the active ingredient over time. |
ER / XR | Extended Release | Designed to release the active ingredient over an extended period. |
DR | Delayed Release | Designed to postpone release until a specified point or condition. |
EC | Enteric Coated | Coating designed to resist release in the stomach and allow release farther along the digestive tract. |
DT | Dispersible Tablet | Tablet designed to disperse in liquid before administration, according to its instructions. |
ODT | Orally Disintegrating Tablet | Tablet designed to disintegrate in the mouth. |
Chewable | Chewable Tablet | Tablet intended to be chewed before swallowing. |
Eff. | Effervescent | Formulation designed to dissolve with bubbling in liquid before use. |
MD | Mouth Dissolving | Common descriptive term for a dosage form that dissolves in the mouth; exact meaning depends on the product. |
IV | Intravenous | Administration into a vein. |
IM | Intramuscular | Administration into a muscle. |
SC / SQ | Subcutaneous | Administration beneath the skin. |
ID | Intradermal | Administration into the skin layer. |
Topical | Topical application | Application to the skin or another specified surface. |
Ophthalmic | Eye preparation | Formulation intended for ophthalmic use. |
Otic | Ear preparation | Formulation intended for ear use. |
Inhalation | Inhaled medicine | Medicine delivered through the respiratory tract. |
Important: SR, CR, ER, XR and delayed-release products are not automatically interchangeable. Never crush, split or chew a modified-release tablet unless the product instructions or a qualified healthcare professional specifically permits it.
4. Strength, concentration and quantity terms
mg
Milligram
A unit of mass. For example, 75 mg means 75 milligrams of the stated ingredient per specified unit, as defined by the label.
g
Gram
A unit of mass. One gram equals 1,000 milligrams.
mcg
Microgram
A unit of mass. One milligram equals 1,000 micrograms. Confusing mg with mcg can cause serious dosing errors.
mL
Millilitre
A unit of liquid volume. For example, 5 mL describes a volume, not the amount of active ingredient unless the concentration is also known.
IU
International Unit
A measure of biological activity used for certain substances. Its conversion into mass depends on the particular substance.
%
Percentage concentration
Describes concentration, but the exact interpretation depends on whether it is weight/weight, weight/volume or volume/volume.
Examples of strength and concentration
Paracetamol 500 mg: The label indicates 500 mg of the specified active ingredient per tablet, subject to the product’s labelling convention.
Oral solution 100 mg/5 mL: Each 5 mL contains 100 mg of the stated ingredient.
Cream 1% w/w: One gram of active ingredient per 100 grams of the finished preparation, where the percentage is explicitly weight by weight.
10 mg/mL: Each millilitre contains 10 mg of the stated ingredient.
Strength is not the same as the recommended dose. The dose and frequency must follow the authorised product instructions and the prescriber’s directions.
5. Common abbreviations found on prescriptions
The following are common expressions in clinical and pharmaceutical contexts. They are provided for recognition and education, not as instructions for self-medication.
Abbreviation | Meaning | General interpretation |
|---|---|---|
OD | Once daily in some prescribing contexts; also has other meanings | Must be interpreted in context. |
BD / BID | Twice daily | Two administrations per day when explicitly prescribed. |
TDS / TID | Three times daily | Three administrations per day when prescribed. |
QID | Four times daily | Four administrations per day when prescribed. |
PRN | As needed | Used only under the conditions specified by the prescriber. |
SOS | If required / when necessary | Exact meaning and permitted frequency must be confirmed. |
HS | At bedtime in some contexts | Confirm the intended instruction. |
AC | Before meals in some contexts | Confirm the prescription. |
PC | After meals in some contexts | Confirm the prescription. |
STAT | Immediately | Indicates urgency in certain clinical orders. |
PO | By mouth | Oral administration. |
SL | Sublingual | Under the tongue. |
PR | Per rectum | Rectal route of administration. |
NPO | Nothing by mouth | A clinical instruction that may restrict food and drink. |
No. | Number | May indicate a quantity, depending on the document. |
Sig. | Directions | Instructions for dispensing or using a medicine. |
Rx No. | Prescription number | An identifier used by a healthcare provider or pharmacy. |
Safety note: Some abbreviations have multiple meanings. For example, OD can mean once daily in one context and right eye in ophthalmic terminology. Unclear prescription instructions should always be confirmed with the prescriber or pharmacist rather than guessed.
6. Ingredients and pharmaceutical composition
Term | Full form or meaning | Explanation |
|---|---|---|
API | Active Pharmaceutical Ingredient | The substance responsible for the intended pharmacological action. |
Excipient | Inactive formulation ingredient | Helps manufacture, stabilise, preserve or deliver the medicine. |
IP | Indian Pharmacopoeia | Indicates a connection to Indian Pharmacopoeia standards when used appropriately on a product label. |
BP | British Pharmacopoeia | Refers to the British Pharmacopoeia standard where applicable. |
USP | United States Pharmacopeia | Refers to applicable United States Pharmacopeia standards. |
Ph. Eur. | European Pharmacopoeia | Refers to European Pharmacopoeia standards. |
INN | International Nonproprietary Name | An internationally recognised generic name for a pharmaceutical substance. |
Generic name | Non-brand medicine name | Identifies the active substance rather than a particular brand. |
Brand name | Trade name | The name under which a product is marketed. |
FDC | Fixed-Dose Combination | A formulation containing two or more active ingredients in specified proportions. |
Monograph | Official substance or product specification | Defines applicable quality requirements and tests. |
Bioavailability | Extent and rate of absorption | Describes how much and how quickly the active ingredient reaches systemic circulation. |
Bioequivalence | Comparison of drug exposure | Demonstrates that products meet applicable criteria for comparable drug availability. |
Example: understanding a medicine name
Consider a hypothetical label reading:
Active ingredient 500 mg — Tablets IP
Active ingredient: identifies the substance responsible for the intended effect.
500 mg: states the labelled strength.
Tablets: identifies the dosage form.
IP: indicates the relevant Indian Pharmacopoeia designation or standard, as applicable.
Brand name: identifies the marketed product, if present.
The actual product must still be assessed for its approved composition, manufacturer, quality and authorised use.
7. Batch, manufacturing and expiry information
Term | Meaning | Why it matters |
|---|---|---|
Batch No. / Lot No. | Manufacturing batch identifier | Supports traceability and investigations. |
Mfg. Date / MFD | Manufacturing date | Indicates when the product was manufactured, as labelled. |
Exp. Date / EXP | Expiry date | Indicates the end of the stated shelf life under specified storage conditions. |
MRP | Maximum Retail Price | The maximum retail price where applicable under Indian pricing and labelling rules. |
Net contents | Quantity inside the pack | States the labelled quantity, such as tablets, capsules or millilitres. |
Storage conditions | Required storage environment | Indicates temperature, light, moisture or other storage restrictions. |
Store below 25°C | Temperature instruction | Follow the exact label; this does not mean refrigeration is required. |
Protect from light | Light protection instruction | Store in the recommended protective packaging or environment. |
Refrigerate | Refrigerated storage instruction | Follow the specified temperature range; do not freeze unless explicitly permitted. |
Manufacturer | Manufacturing company | Identifies the company responsible for manufacture as stated on the label. |
Marketed by | Marketing company | Identifies the company marketing or distributing the product, where declared. |
Mfg. Lic. No. | Manufacturing licence number | Identifies a relevant manufacturing licence. |
Batch release | Quality-release decision | Confirms that a batch has passed the applicable release process. |
QR code | Quick Response code | May link to product information, authentication or traceability data. |
GTIN | Global Trade Item Number | Identifies a trade item within a barcode system. |
Barcode | Machine-readable identifier | Helps identify a product or package in supply-chain systems. |
Never use an expired medicine. If the expiry date, batch number or product identity is missing, illegible or suspicious, ask a pharmacist or the relevant manufacturer to verify it.
8. Manufacturing quality and regulatory terms
Abbreviation | Full form | Explanation |
|---|---|---|
GMP | Good Manufacturing Practices | Requirements and principles for consistent pharmaceutical quality. |
cGMP | Current Good Manufacturing Practices | Emphasises applicable current manufacturing requirements. |
GLP | Good Laboratory Practice | Principles for the quality and integrity of certain nonclinical laboratory studies. |
GCP | Good Clinical Practice | Standards for ethical and scientifically sound clinical trials. |
QA | Quality Assurance | Systems designed to ensure quality requirements are met. |
QC | Quality Control | Testing and checks used to assess materials and products. |
COA | Certificate of Analysis | A document reporting specified test results for a batch or material. |
SDS | Safety Data Sheet | Information about chemical hazards, handling, storage and emergency measures. |
MSDS | Material Safety Data Sheet | Older term for the document now generally called an SDS. |
DMF | Drug Master File | A confidential technical submission about manufacturing, facilities, controls or related information, depending on the regulatory system. |
CTD | Common Technical Document | Standardised format for organising pharmaceutical regulatory submissions. |
ANDA | Abbreviated New Drug Application | A US regulatory application pathway for qualifying generic drugs. |
NDA | New Drug Application | A US application seeking approval for a new drug. |
MA / MAH | Marketing Authorisation / Holder | Refers to a product’s marketing authorisation and the entity holding it, where applicable. |
PV | Pharmacovigilance | Monitoring, assessment and prevention of adverse effects and other medicine-related safety problems. |
AE | Adverse Event | An unfavourable medical occurrence after use of a product; causation is not necessarily established. |
ADR | Adverse Drug Reaction | A harmful and unintended response for which a causal relationship with a medicine is suspected or established under the relevant definition. |
CAPA | Corrective and Preventive Action | Measures addressing identified problems and reducing the likelihood of recurrence. |
SOP | Standard Operating Procedure | An approved written procedure for performing a defined activity. |
9. Additional pharmaceutical and medical abbreviations
Abbreviation | Meaning | Application |
|---|---|---|
ATC | Anatomical Therapeutic Chemical classification | Classification system for medicines based on anatomical, therapeutic, pharmacological and chemical characteristics. |
DDD | Defined Daily Dose | Technical drug-utilisation measurement used in research and public health. |
ICD | International Classification of Diseases | Classification used for diseases and health conditions. |
MedDRA | Medical Dictionary for Regulatory Activities | Standardised terminology used in regulatory safety reporting. |
PK | Pharmacokinetics | What the body does to a medicine, including absorption, distribution, metabolism and excretion. |
PD | Pharmacodynamics | What a medicine does to the body. |
ADME | Absorption, Distribution, Metabolism, Excretion | The main processes involved in drug disposition. |
t½ | Half-life | Time required for a measured amount or concentration to decrease by half under the specified conditions. |
Cmax | Maximum observed concentration | Highest measured concentration in a specified pharmacokinetic assessment. |
Tmax | Time to maximum concentration | Time at which Cmax is observed. |
AUC | Area Under the Curve | A measure of drug exposure over time. |
MIC | Minimum Inhibitory Concentration | Lowest concentration of an antimicrobial that prevents visible microbial growth under specified test conditions. |
AMR | Antimicrobial Resistance | Ability of microorganisms to withstand medicines that would ordinarily inhibit or kill them. |
R&D | Research and Development | Activities involved in researching and developing medicines. |
CMO | Contract Manufacturing Organisation | A company providing manufacturing services under contract. |
CDMO | Contract Development and Manufacturing Organisation | A company providing development and manufacturing services. |
OEM | Original Equipment Manufacturer | A manufacturing term whose exact meaning depends on the commercial arrangement. |
PL / Private Label | Private Label | Products marketed under a customer’s or brand owner’s label, subject to applicable manufacturing and regulatory arrangements. |
10. Special markings that require careful interpretation
Red symbol or warning box: May highlight a regulatory category or warning. The colour alone does not determine the medicine’s classification.
Black triangle: In certain jurisdictions and contexts, may identify additional monitoring for medicine safety. It is not a universal symbol.
Pregnancy warning: Indicates a medicine-specific risk or precaution; the exact wording matters.
Driving warning: May indicate possible drowsiness, impaired alertness or another driving-related precaution.
Flammable symbol: Warns of fire risk associated with a product or its contents.
Biohazard symbol: Identifies certain biological hazards, not a general property of all medicines.
Sterile: Indicates a product is labelled as sterile; correct packaging integrity and handling remain important.
Single-dose: Intended for one administration or one use as specified by the product instructions.
Multi-dose: Designed for multiple withdrawals or administrations under the specified conditions.
Cold chain: A temperature-controlled supply and storage system used for products requiring defined temperature conditions.
Tamper-evident seal: Helps reveal whether packaging may have been opened or interfered with.
Counterfeit warning or authentication code: May help identify suspicious products, but a code or QR scan alone does not guarantee authenticity.
11. How to read a medicine pack correctly
Identify the medicine. Read the generic name, brand name and active ingredients.
Check the strength. Confirm the amount of active ingredient and whether it is stated per tablet, capsule, millilitre or another unit.
Check the dosage form. Confirm whether the product is a tablet, capsule, injection, suspension, cream or another formulation.
Read the regulatory warning. Look for Rx, XRx, NRx and the actual Schedule H, H1 or X warning text, where applicable.
Verify the manufacturer and batch. Check batch number, manufacturing details and licence information where required.
Check expiry and storage. Confirm the product is within its shelf life and has been stored correctly.
Follow authorised directions. Use the medicine only according to its approved instructions and the advice of an appropriately qualified healthcare professional.
12. Specific regulatory clarification for India
For an accurate explanation of the symbols in your reference image, the distinctions are important:
Marking | Indian regulatory interpretation |
|---|---|
Rx | Used for Schedule H medicines and also specified for Schedule H1 medicines under the relevant labelling rules. |
NRx | Used for specified Schedule H or H1 medicines that also fall within the scope of the Narcotic Drugs and Psychotropic Substances Act, subject to the applicable rule wording. |
XRx | Used for medicines specified under Schedule X. |
These distinctions follow the labelling provisions in India’s Drugs Rules, 1945. The precise warning text and applicable provisions should be checked in the current consolidated rules and subsequent amendments.
